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Abstract 
Objectives:  
1. To explore visual performance status through a range of psychophysical 
methods beyond corrected distance visual acuity (CDVA), in subjects with age-
related macular degeneration (AMD).  
2. To investigate the effects on these visual performance parameters in subjects 
with neovascular age-related macular degeneration (nv-AMD) and in subjects 
with early AMD undergoing anti-VEGF (vascular endothelial growth factor) 
therapy and macular carotenoid supplementation, respectively.  
3. To understand the role of a supplement containing meso-zeaxanthin (MZ; the 
third, and currently least explored, macular carotenoid) on the augmentation of 
macular pigment (MP), on visual performance and on disease progression 
(graded according to the AREDS [Age-Related Eye Disease Study] criteria), in 
subjects with early AMD.  
4. To explore the impact of macular carotenoid supplementation on vision in 
subjects presenting with atypical macular pigment optical density (MPOD) 
spatial profiles at baseline. 
Outcomes: This study has shown that CDVA is not the most appropriate measure of 
visual function and does not reflect retinal morphology in cases of early AMD or in 
cases of nv-AMD. Retinotopic ocular sensitivity (ROS), however, appears to be a more 
reflective measure of disease severity, where it correlates well with AMD-severity 
grade (in cases of early AMD) and also with mean foveal thickness (MFT; in cases of 
nv-AMD).  
In eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections, 
there have been demonstrable improvements in a range of parameters of visual function, 
namely, contrast sensitivity (CS), glare disability (GD), and ROS but no significant 
change in CDVA, despite a reduction in MFT.  
MP can be augmented, and CS enhanced, in subjects with early AMD who 
receive supplemental macular carotenoids. Subjects with low baseline central MPOD 
had the greatest increases in MPOD and the greatest improvements in CS, when 
compared with subjects with medium or high baseline MPOD, suggesting that the 
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optimisation of CS (and putatively visual performance in general) is somewhat 
dependent on central MP levels. 
The literature review has concluded that supplementation with the macular 
carotenoids offers the best means of fortifying the antioxidant defenses of the macula, 
thus putatively reducing the risk of AMD and/or its progression, and of optimising 
visual performance.  
 
Conclusions: The findings of this work suggest the incorporation of tests, 
complimentary to CDVA, such as CS, GD, and particularly ROS, when attempting to 
understand disease severity in cases of AMD. In terms of monitoring change over time, 
the results of this study do seem to indicate that measures of ROS may be particularly 
useful in monitoring subjects with nv-AMD, while measures of CS and GD may be 
more apt in monitoring change in subjects with early AMD. Macular carotenoid 
supplementation can enhance visual performance in subjects with early AMD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
                     
                     
Analysis and 
Publication 
Exp. 2 (MOST) 
Month:      1        2         3         4         5        6         7         8         9        10      11      12       13      14      15      16      17      18       19       20      21      22 
Ethics approval 
Recruitment  
Data collection 
Ethics approval 
Recruitment  
Data collection 
Analysis and 
Publication 
Exp. 1 (VEGF) 
6 
 
 
 
 
Key findings 
1. CDVA poorly reflects retinal morphology in cases of early AMD and in cases of 
nv-AMD. ROS, however, appears to be a measure which is more reflective of 
disease severity in these conditions, where it correlates well with AMD-severity 
grade (in cases of early AMD) and also with MFT (in cases of nv-AMD). 
2. In eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections, 
there have been demonstrable improvements in a range of parameters of visual 
function, including CS, GD and ROS, but no significant change in CDVA, despite 
a reduction in mean MFT. 
3. Early AMD is visually consequential: while CDVA may not be greatly affected by 
early stages of the condition, it is clear that measures such as CS and GD are 
depressed compared to normal subjects and, therefore, should be considered in the 
diagnosis and monitoring of patients with AMD. 
4. MP can be augmented, and CS enhanced, in subjects with early AMD who receive 
supplemental macular carotenoids. A formulation containing MZ appears to offer 
advantages over a formulation that does not contain MZ, in terms of improvements 
in psychophysical function and in terms of MP augmentation. 
5. Optimisation of CS (and putatively visual performance in general) is influenced by 
central MP levels. Subjects with low baseline central MPOD had the greatest 
increases in MPOD and the greatest improvements in CS, when compared with 
subjects with medium or high baseline MPOD. 
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Chapter 1. Introduction 
 
Age-related macular degeneration (AMD), a degenerative condition of the macula 
typically encountered amongst individuals fifty years or older, is the leading cause of 
blind registration in the developed world
1
 (Figure 1.1). AMD affects an individual’s 
central vision, whilst peripheral vision is preserved. The advanced stages of the 
condition, however, can have a considerable impact on an individual’s quality of life 
and independence, as daily tasks, such as reading, driving, and recognising faces, are 
hampered.  
The measurement of visual performance is a long established practice in the 
assessment and monitoring of ocular disease. It assists clinicians to understand disease 
severity and its corresponding impact on quality of life. It has also been used, in certain 
cases, to determine when to commence, continue or cease treatment, as well as to judge 
the efficacy of intervention, for clinical and research purposes, particularly following 
the introduction of new treatments or new treatment strategies.  
Historically, the quantification of visual performance (in subjects with and 
without AMD) has been, and remains dominated by measures of corrected distance 
visual acuity (CDVA),  a measure of the angular resolution limits of the eye at high 
contrast.
2
  However, there is a general consensus that CDVA is not a true reflection of 
daily visual experience, and research studies have, in more recent times, started to 
incorporate alternative methods of assessing visual performance in clinical trials. Such 
trials have demonstrated the capacity of these additional measures to provide a more 
comprehensive overall assessment of visual performance compared to CDVA alone.
3-13
  
The universality of the measure of CDVA, however, along with other factors such as 
the cost and inconvenience associated with introducing additional methods of visual 
22 
 
assessment, has hindered the translation of these important research findings into 
clinical practice which, for the most part, has not materialised.
14
  This has influenced a 
clinician’s appreciation of disease severity and/or of the efficacy of intervention and 
also potentially influences decisions clinicians make with respect to commencing, 
continuing, or ceasing a given intervention. 
AMD is generally classified as either ‘early’ or ‘late’. The early form involves 
both hypotrophic and hypertrophic changes of the retinal pigment epithelium (RPE) 
underlying the central macula, accompanied by drusen formation beneath the RPE, and 
such changes are, typically at least, of little or moderate visual importance. Late AMD 
is sub-divided into atrophic and neovascular AMD (nv-AMD). The atrophic form 
causes degeneration and thinning of the RPE and choriocapillaris, weakening the RPE’s 
capacity to nourish, and remove waste products from, the retina. Nv-AMD is 
characterised by the growth of abnormal blood vessels from the choroid, which 
penetrate Bruch’s membrane and sometimes the RPE.15  If left untreated, the leakage 
results in subretinal and/or retinal scarring, and associated photoreceptor damage with 
consequential and irreversible loss of central vision.
16
 Nv- AMD can develop very 
rapidly relative to the atrophic form, which typically develops over months or years. 
Approximately 7% of people 75 years and older have progressed to the late stage of this 
disease.
17
  
A global estimate has reported that 8.7% (approximately 14 million cases) of 
visual impairment is attributable to AMD.
18
  It is estimated that the late form of the 
condition affects approximately 1.4 million individuals in the United States, 417,000 
people in the United Kingdom and 70,000 people in the Republic of Ireland,
19
  numbers 
which are likely to increase due to increasing longevity (Figure 1.2). Further, and as a 
result of a continued demographic shift towards an elderly population, the socio-
economic implications of visually consequential AMD is becoming more important.
20
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Figure 1.1 Distribution of the causes of blindness in the developed world. (Data from 
the World Health Organisation: Magnitude and causes of visual impairment. Factsheet 
282. November 2004; image courtesy of the Macular Pigment Research Group 
[MPRG], Waterford). 
 
 
Figure 1.2 European life expectancy (1950 – 2050). (Data from the United Nations, 
World Population prospects [2006] 
http://www.un.org/esa/population/publications/wpp2006/WPP2006_Highlights_rev.pdf
; figure adapted by the MPRG, Waterford) 
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Intravitreal anti-VEGF therapy is now the most commonly used treatment for 
nv-AMD. Studies have conclusively demonstrated the morphological and visual 
benefits of treatment, yet anti-VEGF therapy has cost and logistical implications for the 
healthcare system and for the patient. In addition, there is, as yet, no effective treatment 
for atrophic AMD, which has similarly detrimental effects on a patient’s quality of 
life.
21
 One of the well-established risk factors for developing the late, more debilitating, 
forms of the condition is having early AMD.
22, 23
  There is a clear and urgent need, 
therefore, to understand how the onset of this condition can be prevented, delayed or, at 
least, its progression retarded. 
Macular pigment (MP), a yellow-coloured pigment located in the inner retinal 
layers of the macula, has generated interest in recent years because of its possible 
protective role for AMD, putatively (assumably) attributable to its antioxidant 
properties and/or its pre-receptoral filtration of damaging (short-wavelength) blue light, 
given that (photo)-oxidative retinal injury is known to be important in the pathogenesis 
of this condition.
24, 25
  MP is composed of the two dietary carotenoids, lutein (L) and 
zeaxanthin (Z), and a third carotenoid, meso-zeaxanthin (MZ), which is not found in a 
typical diet.
26, 27
 The anatomical (central retinal), biochemical (anti-oxidant) and optical 
(short-wavelength filtering) properties of MP have generated interest in the biologically 
plausible rationale that MP may confer protection against AMD. 
A study design to conclusively prove MP’s role in disease prevention would 
need to be at least fifteen years in duration, and would involve recruiting subjects who 
are not afflicted with the condition, and evaluating the incidence of AMD with respect 
to dietary intake of the carotenoids and with respect to MP optical density (MPOD). 
Such a study has yet to be undertaken, most likely due to the prohibitive cost and 
methodological difficulties inherent to the required study design. In the interim, the role 
of MP in reducing the risk of progression of the disease can be more readily 
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investigated. Evidence from a large scale clinical trial has shown that supplementation 
with dietary antioxidants can reduce the risk of progression from intermediate to late 
AMD by 25%.
28
  Furthermore, there is now sufficient evidence to suggest that 
supplementation with the macular carotenoids can reduce the risk of disease 
progression, although conclusive evidence from a large scale randomised and placebo-
controlled trial (RCT) is not yet available.  
The influence of MP (and its augmentation) on visual performance has also been 
the focus of scientific investigation. The bulk of the experimental evidence supports the 
concept that MP has a functional influence on visual performance.
29-33
  Supplementation 
with the macular carotenoids has been shown to be related to improvements in visual 
performance amongst subjects with and without AMD,
34-36
  putatively through its 
ability to filter short-wavelength blue light, reducing the effects of chromatic aberration 
(CA) and light scatter, thereby enhancing contrast and reducing glare. A measure as 
crude as CDVA is unlikely to detect the changes in vision that might be attributable to 
MP carotenoid supplementation. Any improvement (or even stabilisation) in vision, 
however, has important implications for patients with or without macular disease. 
Considering the degenerative nature of AMD, it is important to assess visual 
performance as accurately and as comprehensively as possible, for the benefit of the 
patient, clinician and for the betterment of research.  
In addition, the nature of the macular carotenoid formulation that  maximises the 
visual benefit, if any, of MP at the macula has yet to be determined, i.e. the constituent 
carotenoids, individual carotenoid dosage.  
This study was designed to look beyond CDVA in the assessment of visual 
performance, through a range of psychophysical methods, in subjects with AMD, in 
general. Also, this study investigates the effects on these visual performance parameters 
in subjects with nv-AMD and in subjects with early AMD undergoing anti-VEGF 
26 
 
therapy and macular carotenoid supplementation, respectively. This study has also 
sought to investigate the role of a supplement containing MZ (the third, and currently 
least explored, macular carotenoid) on the augmentation of MP, on visual performance 
and on disease progression, in subjects with early AMD.  
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Chapter 2. Age-related macular degeneration 
 
Age-related macular degeneration (AMD) is a degenerative condition of the macula, a 
specialised area of the retina, responsible for central and colour vision.
37
  Whilst 
peripheral (navigational) vision is maintained in cases of AMD (regardless of stage), it 
is central vision that is needed for seeing fine detail and for common daily tasks such as 
reading, driving and face recognition.
38-40
 Therefore, the loss of central vision has a 
significant impact on an individual’s independence and his/her quality of life. 
The retina is a light-sensitive tissue at the back of the eye, which converts light 
images into electrical impulses, which are sent to the brain. The macula, the centre of 
which is the foveola, has a diameter of approximately 5mm at the posterior retina and, 
unlike the rest of the retina, has a particularly high density of cones. Typically, the 
macula has a characteristic yellow colour, which is usually detectable on fundoscopy. 
Its yellow colour attracted the attention of anatomists in the late 18
th
 century, who later 
coined the term “macula lutea” or “yellow spot”. It is now known that the yellow 
colouration is a characteristic of the highly concentrated presence of the macular 
carotenoids, collectively referred to as MP. 
 
2.1 Classification of AMD 
The International age-related maculopathy Epidemiological Study Group delineated the 
parameters of a core grading system to create a universal method with which to classify 
and define AMD for future clinical and epidemiological purposes.
41
  “Age-related 
maculopathy” was the term used to define early stages of the condition and “AMD” was 
used to describe late, more advanced, stages of the disease, namely choroidal 
neovascularisation (CNV; a manifestation of nv-AMD), and geographic atrophy (GA). 
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For the purposes of this thesis, AMD will be used to define the condition in general, 
“early AMD” will be used to describe early manifestations of the disease and “late 
AMD” will be used to denote CNV and/or GA.  
 
2.1.1 Early AMD 
Early AMD is defined as a disorder of the macular area and is apparent clinically in 
subjects typically after the age of fifty. It is characterised by any of the following 
findings, when not associated with another disorder: 
1. Soft drusen ≥ 63µm in diameter. Drusen are focal collections of extracellular 
material that lie external to the neurosensory retina and the RPE and appear as 
whitish-yellow spots on fundoscopy (Figure 2.1). Drusen may be soft and 
confluent, soft distinct, or soft indistinct. Hard drusen appear as small, round, 
discrete, yellow-white spots, while soft drusen are larger and have indistinct 
edges. Soft drusen may enlarge and coalesce (confluent drusen).
42
  Hard drusen, 
alone, does not characterise AMD. 
2. Hyperpigmentation (increased pigment) in the outer retina or choroid, associated 
with drusen (hard or soft). 
3. Hypopigmentation (depigmentation) of the RPE, typically more sharply 
demarcated than drusen, without any visible choroidal vessels, associated with 
drusen (hard or soft). (See Figure 2.2 for hypo- and hyperpigmentation, in 
association with drusen). 
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Figure 2.1 Macular drusen (hard and soft present). (Image obtained from the Institute of 
Eye Surgery, Waterford).  
 
 
Figure 2.2 Macular drusen and pigmentary (hypo and hyper) changes (Image obtained 
from the Institute of Eye Surgery, Waterford). 
 
 
2.1.2 Late AMD 
The presence of early AMD predisposes the individual to late AMD, which is 
subdivided and defined as follows: 
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1. GA is described as any sharply delineated area of hypopigmentation or apparent 
absence of the RPE, in which the choroidal vasculature is more visible that the 
surrounding area. The area of atrophy must be ≥ 175µm in diameter (see 
example Figure 2.3). 
 
Figure 2.3 Geographic atrophy. (Image obtained from the Institute of Eye Surgery, 
Waterford). 
 
2. Nv-AMD, also commonly referred to as “wet AMD” or “exudative AMD”, is 
characterised by any of the following: 
a. RPE detachment(s), which may/may not be associated with neurosensory 
retinal detachment, associated with other signs of early AMD. 
b. Sub-retinal or sub-RPE neovascularisation. 
c. Epiretinal, intraretinal, subretinal, or sub-RPE glial tissue of fibrin-like 
deposits. 
d. Subretinal haemorrhage, unrelated to other retinal vascular disease (Figure 
2.4). 
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e. Hard exudates (lipids) within the macular area, related to any of the above, 
in the absence of other retinal vascular disease. 
 
Figure 2.4 Neovascular AMD, showing subretinal haemorrhage. (Image obtained from 
the Institute of Eye Surgery, Waterford). 
 
2.2 Aetiopathogenesis of AMD 
2.2.1 Oxidative stress 
As AMD is an age-related condition, the free radical theory of ageing is believed to be 
relevant to its aetiopathogenesis. This theory proposes that age-related disorders are the 
result of cumulative tissue damage following interaction with reactive oxygen 
intermediates (ROIs).
43, 44
  ROIs, which include free radicals, hydrogen peroxide and 
singlet oxygen, are unstable by-products of oxygen metabolism. Free radicals, for 
example, lack an electron in their outer orbit (see Figure 2.5), and are therefore 
inherently unstable, causing them to scavenge an electron from another readily available 
source. The membranes of the photoreceptor outer segments have the highest 
concentration of polyunsaturated fatty acids (PUFAs) in the mammalian world.
45
 These 
PUFAs are one such available source of electrons and are readily oxidised by ROIs, 
thus generating a cytotoxic chain reaction of events, thereby producing yet more ROIs 
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and further and consequential oxidative injury
46, 47
 (in this case, impaired photoreceptor 
function and cell death).
48
  The body’s natural defence against ROIs includes their 
neutralisation by enzymes and/or antioxidants.
49
  However, generation of ROIs 
increases in response to environmental stresses, such as atmospheric pollution, asbestos 
exposure, tobacco use, irradiation and alcohol consumption.
47, 50
  Oxidative injury 
occurs, therefore, when the level of oxidants (ROIs) in a system exceeds the detoxifying 
capacity of its antioxidant defence system.
51
  
 
 
Figure 2.5 Schematic representation of the generation of a reactive oxygen intermediate 
(ROI). ‘A’ represents an atom in stable state (full array of electrons in its outer orbit); B 
shows the loss of an electron from the atom’s outer orbit, thus generating a ROI (C), 
which is, as a result, unstable. (Image obtained from 
http://www.health2know.com/2007-03/) 
 
The retina is made up of ten definable layers, nine of which are collectively 
termed the neurosensory retina (containing the photoreceptors and neuron axons), the 
remaining outermost layer being the dark, melanin-rich, RPE. The RPE plays an 
important role in facilitating visual function; not only does it nurture, and remove waste 
products from, the neurosensory retina,
52, 53
 it also protects against photic injury through 
the absorbance of light-induced heat. The melanin pigment of the RPE also allows for 
the absorbance of scattered and excess light, thus providing optical benefits.
54
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AMD is characterised by loss of photoreceptors and by RPE cell dysfunction,
55
  
the latter being largely attributable to an age-related accumulation of lipofuscin (yellow-
brown pigment granules representing lipid-containing residues of lysosomal 
digestion).
56
  Of note, the accumulation of lipofuscin within the RPE cells increases as a 
result of incomplete digestion of oxidatively damaged photoreceptor outer segment 
membranes.
57
  In turn, this yellow age pigment then acts as a chromophore (a 
compound which, when irradiated with light of an appropriate wavelength, emits an 
electron, thereby generating an ROI),
46, 58
  thus provoking further oxidative injury.
57, 59
  
The retina is an ideal tissue for the production of ROIs, because of its high 
oxygen demand and consumption, exposure to visible light, metabolic activities (such 
as RPE phagocytosis) and the presence of photosensitisers (chromophores).
60
 In 
addition, the photoreceptor outer segments contain a high concentration of PUFAs, 
which are readily oxidised by ROIs, thus generating a cytotoxic chain reaction of 
events, thereby producing yet more ROIs and further and consequential oxidative 
injury.
46, 47
  
Light of shorter wavelengths (blue, ultraviolet [UV]) has greater energy than 
that of longer wavelengths (e.g. red, yellow) and is, therefore, more injurious to retinal 
tissue.
61
  In the human eye, the cornea and crystalline lens efficiently filter most of the 
UV light.
62
  However, substantial amounts of damaging, high energy, short-wavelength 
(visible) light is incident upon the retina, even in an ambient setting.
63
  
Damage to the RPE and to the photoreceptors by visible light was first 
demonstrated in 1966.
64
  Later, it was shown that the short-wavelength component of 
the visible spectrum is most injurious.
65
   Of note, it has also been demonstrated that 
such short-wavelength light induced photo-oxidative retinal damage is greater in the 
presence of high oxygen tension.
66
  Lipofuscin also appears to play a decisive role in 
photo-oxidative stress in the retina, inducing the production of ROIs when irradiated 
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with short-wavelength light, as this pigment acts as a chromophore.
67
  Indeed, and 
consistent with this, it has been shown that lipofuscin in RPE cells stimulates cell 
apoptosis when exposed to short wavelength visible light.
68, 69
   
There is a growing consensus that cumulative lifetime exposure to visible light 
increases the risk of AMD,
70, 71
 consistent with the aforementioned findings. AMD-like 
lesions have been demonstrated in laboratory rats reared in ambient levels of light, 
when compared with rats reared in the dark.
72
  Subsequent investigators have 
demonstrated that the generation of AMD-like lesions in monkey retinas, following 
exposure to light of varying wavelengths, requires 70-1000 times less power when 
using short-wavelength light compared to infrared wavelengths.
73
  Furthermore the 
administration of antioxidants to laboratory rats exposed to continuous illumination has 
been shown to confer protection against photoreceptor loss.
74
  A recent analysis by the 
European Eye Study (n=4753) found a significant correlation between cumulative 
exposure to visible light and nv-AMD in those patients with low intake of dietary 
antioxidants, including L and Z.
75
  There is, therefore, a compelling body of evidence to 
suggest that cumulative exposure to visible (short-wavelength) light is an important 
contributor to the development of AMD and that the mechanism of its contribution rests 
on the (photo)-oxidative injury that such short wavelengths of visible light inflict upon 
the retina.  
Of interest, ROI production (and, therefore, oxidative injury) peaks at the 
macula,
76, 77
 where, coincidently, MP peaks, and which is also the site where AMD 
manifests. 
 
2.2.2 Inflammation  
There is a consensus that inflammation also plays a role in the pathogenesis of AMD.
78, 
79
   Inflammation is part of the complex, biological, non-specific, immune response 
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of vascular tissue to harmful stimuli, such as pathogens, damaged cells, or irritants.
80
  It 
is believed that inflammation within the retina is a precursor to the formation of drusen 
and the alteration of the extracellular matrix.
81, 82
  These changes alter the RPE-
choriocapillaris relationship, ultimately causing CNV and other manifestations of 
advanced AMD.
79, 83
  Of note, drusen have been shown to contain proteins associated 
with immune-mediated response and inflammation.
83, 84
  Indeed, histological studies 
have consistently demonstrated the presence of chronic inflammatory cells in retinas 
afflicted with AMD.
85, 86
  It is believed that these inflammatory cells damage tissue by 
releasing proteolytic enzymes and oxidants, thus compounding the effects of oxidative 
stress.  
 The inflammatory hypothesis of AMD has generated a lot of interest, especially 
given the discovery that subjects with a certain gene variant, one which is closely 
connected to the mediation of inflammatory processes, are significantly more at risk of 
developing AMD.
87, 88
   
 It has been shown that oxidative damage-induced inflammation is the initiator of 
AMD.
89
 The investigators demonstrated AMD-like lesions in mice immunized with 
carboxyethylpyrrole, a unique oxidation product of docosahexaenoic acid found in 
drusen from AMD donor eyes. As a result, immunized mice develop antibodies to this 
hapten, fix complement component-3, in Bruch’s membrane (the site of drusen 
formation), accumulate drusen below the RPE during ageing, and develop atrophic 
changes within the RPE. It appears, therefore, that oxidative damage represents the 
trigger for the development of AMD, the pathogenesis of which is mediated by the 
inflammatory response to that insult, which in turn is determined by genetic 
background. It follows, therefore, that prevention or attenuation of the initial oxidative 
injury will reduce the risk of developing AMD, regardless of genetic background.
90
  
 
36 
 
2.3 AMD Risk Factors 
The three undisputed risk factors for AMD are: ageing, genetic pre-disposition (positive 
family history of AMD) and tobacco use.  
 The free radical theory of ageing (discussed above) suggests that the observation 
that advancing age is a strong risk factor in the development of AMD, is attributable 
primarily to increasing levels of oxidative stress. Population-based studies have 
consistently shown that the prevalence, incidence and progression of AMD increase 
exponentially with advancing age.
91-93
   
 The prevalence of AMD among first-degree relatives of subjects with AMD, 
particularly those with nv-AMD, is greater than that of first-degree relatives of subjects 
without disease, suggesting a genetic component may contribute to the development of 
AMD.
94
  A study compared patients with AMD (n = 457) with age- and sex-matched 
controls (n = 1071). Patients who carried the susceptibility alleles for either CFH 
(complement factor H) or LOC387715 were found to have a 3- to 8-fold increased risk 
for developing AMD.
95
 A 50-fold increase in risk was reported in patients who had two 
copies of the susceptibility alleles in both genes. Tobacco use and obesity multiplied the 
risks associated with these variants.
96
 This study (amongst others
97-99
 ) suggests that 
genetic predisposition to AMD is subject to environmental provocation. 
 Tobacco use is the third, and the only environmental (modifiable), established 
risk factor for AMD. Almost all epidemiological studies have shown that tobacco use is 
associated with increased incidence and prevalence of the condition, 
100, 101
 and has been 
confirmed by a number of meta-analyses.
102, 103
  
Other possible risk factors, for which findings have been inconclusive thus far, 
include: obesity, female gender, previous cataract surgery, cardiovascular disease, 
Caucasian race, and lack of physical activity. There is a growing body of evidence that 
cumulative exposure to visible light, in association with a lack of dietary intake of key 
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antioxidants,
104
  also represents an increased risk of AMD.
105
  Of note, an inverse 
association has been shown between risk of AMD and the amounts of L and Z in the 
retina.
106
   
Interestingly, the three established risk factors for AMD (age, genetic 
background and tobacco use) are associated with a relative lack of MP prior to disease 
onset.
107
  Furthermore, obesity (a putative risk factor for AMD), which is known to be 
related to poor diet (and, therefore, consequential low serum and retinal carotenoid 
levels), is associated with increased oxidative stress and inflammation, and has also 
been shown to be inversely and significantly related to MP levels. Moreover, a recent 
study has identified that age and tobacco use are also associated with an atypical, and 
most likely undesirable, central dip in the spatial profile of MP,
108
 which may be 
attributable to a relative lack of the macular carotenoid, MZ (this will be further 
discussed later). 
 
2.4 AMD Treatment 
2.4.1 Previous interventions for nv-AMD 
Nv-AMD is the only form of AMD for which a proven treatment is available. Until 
recently, the available therapeutic interventions for nv-AMD were largely aimed at the 
preservation of the presenting visual acuity (VA). These included: laser 
photocoagulation, photodynamic therapy and submacular surgery, and are summarised 
below. 
  
Laser photocoagulation: Laser was the first treatment introduced to retard the 
progression of nv-AMD and is still used in some cases of well-defined extrafoveal 
CNV. With the advent of newer therapies, however, and the concern for the impact of 
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iatrogenic scotoma in subfoveal CNV, laser photocoagulation of peri- and subfoveal 
CNV is no longer recommended.
109
  
 
Photodynamic therapy (PDT): Choroidal neovascular tissue contains a high 
concentration of low-density lipo-protein (LDL) receptors. Verteporfin, (Visudyne®, 
Novartis, Basel, Switzerland) when infused intravenously complexes with LDLs and 
accumulates in CNV membranes. Non-thermal laser activation (689nm) of verteporfin 
induces endothelial damage with thrombus formation via ROI formation, without 
damage to the overlying retina.
110, 111
 PDT has been effective in reducing the rate of 
vision loss in patients with subfoveal predominantly classic CNV due to AMD.
112
  
However, the VIO (Visudyne In Occult CNV) study failed to show any benefit in cases 
of subfoveal occult CNV.
113
  
 
Surgery: Subretinal removal of CNV by pars plana vitrectomy has been a proposed 
treatment for nv-AMD. The Submacular Surgery Trial
114
 found that submacular surgery 
was not a superior method to (less invasive) laser photocoagulation of subfoveal CNV 
and was abandoned with the advent of PDT and, later, anti-angiogenic therapies. The 
poor results of this particular study are attributed to the collateral damage to the RPE, 
responsible for the nutritional supply of the overlying macula.
115
 Another surgical 
method, macular translocation surgery, has also been used in cases of nv-AMD. The 
procedure involves relocating the fovea to an area where the RPE is healthier than it is 
centrally, the aim allowing for the recovery of some useful vision.
116
   
2.4.2 Anti-VEGF therapy 
Current treatment interventions, specifically anti-VEGF agents, have resulted in better 
visual outcomes for patients with nv-AMD, providing, for the first time, a relatively 
strong probability of visual gain amongst patients with the condition.  
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VEGF, a signal protein (cytokine), is an important regulator of vascular 
permeability and angiogenesis.
117, 118
  The functional role of VEGF is to stimulate new 
blood vessel growth, for example, during embryonic development, after injury, or to by-
pass blocked blood vessels. The production of VEGF significantly increases in hypoxic 
conditions, and VEGF also has a role in tumour-angiogenesis and in other ischaemic 
and inflammatory conditions.
119
  
VEGF encompasses a family of proteins, which include: PGF (Placenta Growth 
Factor), VEGF-A, VEGF-B, VEGF-C, VEGF-D and the viral and snake venom 
homologues, VEGF-E and F, respectively. VEGF-A is most relevant for angiogenesis 
and vascular permeability. Nine human VEGF-A isoforms have been identified to date, 
with varying numbers of amino acids: VEGF121, VEGF145, VEGF148, VEGF162, 
VEGF165b5, VEGF165, VEGF183, VEGF189 and VEGF206. VEGF165 is the most abundant 
isoform.
120, 121
   
VEGF functions by binding to one of three VEGF receptors (VEGFR-1, -2 and -
3) on the cell surface. VEGFR-2 appears to be the receptor that mediates the major 
signalling effects of VEGF-A (angiogenesis and vascular permeability).
122
  The function 
of VEGFR-1 is less clear, although evidence suggests that it functions as a “decoy” 
receptor, thus regulating the activity of VEGF-A by making it less available for binding 
on VEGFR-2. VEGFR-3, on the other hand, does not bind VEGF-A, and is instead, a 
receptor for VEGF-C and -D. 
The two most important forms of ocular angiogenesis are preretinal 
angiogenesis (originating from the retinal vasculature), and subretinal (choroidal) 
angiogenesis. Preretinal angiogensis is associated with capillary non-perfusion and 
neuroretinal ischaemia, which stimulate the growth of new blood vessel along the 
retina-vitreous interface, which can potentially haemorrhage, obscure vision and, in 
addition, increase the risk of retinal detachment. Severe retinal ischaemia can cause new 
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blood vessel formation on the iris, which can block the trabecular meshwork in the 
anterior chamber angle, resulting in neovascular glaucoma. Preretinal angiogenesis is an 
uncommon manifestation of diabetic retinopathy and retinal vein occlusions.
123, 124
  
Subretinal angiogenesis (CNV) is characterised by the growth of abnormal choroidal 
blood vessels, which penetrate Bruch’s membrane and sometimes the RPE,15 and is 
classified according to its appearance on fluorescein angiography. Classic CNV is 
located between the RPE and the neural retina, whereas occult CNV occurs between the 
RPE and Bruch’s membrane. Mixed CNV also exists. If left untreated, the leakage 
results in subretinal and/or retinal scarring, with consequential and irreversible loss of 
central vision.
16
 CNV is a manifestation of nv-AMD as well as other, less common, 
degenerative retinal conditions such as myopic maculopathy and angioid streaks. 
It has been shown that VEGF-A is secreted basally by the RPE towards the 
choriocapillaris, influencing the permeability of its fenestrated capillaries. The secretion 
of VEGF-A increases 10-fold in hypoxic conditions. In addition, VEGF-2 receptors 
were preferentially located at the choriocapillaris endothelium facing the RPE, which is 
suggestive of a paracrine relationship between the RPE and the choriocapillaris 
endothelium. An imbalance in this relationship, which potentially produces an increase 
in VEGF production, or an increase in VEGF secretion simply due to hypoxic 
conditions, are possible contributing factors in the pathogenesis of CNV.
125
  
2.4.2.1 The history of anti-VEGF therapy for nv-AMD 
In 1948, Michaelson suggested that the avascular foetal retina induces vascular 
ingrowth by the release of a diffusible “metabolic” factor, one which also may play a 
role in vascular-related retinal disease, such as diabetic retinopathy.
126
  In 1954, Ashton 
was the first to hypothesise that this factor “X” is stimulated by hypoxia.127  It was not 
until 1983 that VEGF-A was discovered as a protein,
128
  although its angiogenic 
properties were not perceived at this time. It was given the name, Vascular Permeability 
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Factor (VPF), in light of its discovered ability to influence vascular permeability. 
Ferrara et al, in 1992, described VEGF’s major angiogenic role.129  Also, in 1992, and 
thirty-eight years on,  Ashton’s original hypothesis, that VEGF is, indeed, induced by 
hypoxia, was proven.
130
   
Further research in animal models demonstrated that the inhibition of VEGF-A 
prevents the development of CNV, causes regression of existing CNV, reduces 
pathological vascular permeability and prevents the development of iris 
neovascularisation due to retinal ischemia.
131-133
  Important studies were also able to 
show that VEGF-A levels are elevated in the vitreous of subjects with nv-AMD, as well 
as in excised CNV membranes.
134, 135
  
These provocative findings led to the design and the execution of clinical trials 
for the purpose of investigating the effects of anti-VEGF agents in subjects with 
vascular-angiogenic ocular disease. 
2.4.2.2 Ocular anti-VEGF agents 
Pegaptanib (Macugen®; OSI/Eyetech Pharmaceuticals, New York) 
Pegaptanib is an oligonucleotide that binds and inactivates some, but not all, VEGF-A 
isoforms. The VISION trial, a randomised, multicentre study, investigated the effect of 
intravitreal pegaptanib (once every six weeks) in 1186 subjects with nv-AMD over a 
54-week period.  The study demonstrated that pegaptanib could reduce the rate of visual 
loss in patients with subfoveal nv-AMD. Seventy percent of subjects receiving 0.3mg 
pegaptanib lost fewer than 15 letters of VA over the study period, compared with 55% 
of subjects receiving sham treatment.
136
  However, there was no statistically significant 
improvement in vision between the treated and sham groups and 1% of patients 
developed endophthalmitis. Other significant side-effects included retinal detachment 
and traumatic cataract.
136
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Bevacizumab (Avastin®; Genentech, South San Francisco, California) 
Bevacizumab is a humanised full-size antibody that inactivates all isoforms of VEGF-
A, and has been approved for the treatment of metastatic colorectal cancer.
137
  Off-label 
systemically administered bevacizumab was studied in an uncontrolled open label trial 
in 18 patients with CNV attributable to AMD. VA improved in the study eyes within 
the first two weeks of treatment, and by 24 weeks, mean VA increased by 14 letters 
(and was accompanied by a decrease in mean central retinal thickness, determined by 
optical coherence tomography [OCT]). Complications included significant elevations in 
blood pressure in several patients.
138
  Subsequently, intravitreal bevacizumab was 
administered with similar visual outcomes and a very low rate of ocular and systemic 
side-effects.
139-147
  There is a paucity of RCTs investigating the role of intravitreal 
bevacizumab for AMD. One study showed that 1.25 mg of intravitreal bevacizumab, 
given as part of a six-weekly variable retreatment regimen, was superior to standard 
care (intravitreal pegaptanib or verteporfin therapy, depending on lesion type), with low 
rates of serious ocular adverse events.
148
  Mean VA increased by seven letters (from 
baseline) in the bevacizumab group compared with a decrease of 9.4 letters in the 
standard care group (p<0.001) over the 54 week study period. 
 
Ranibizumab (Lucentis®; Genentech, South San Francisco, California) 
Ranibizumab is a humanised antigen-binding fragment of bevacizumab that has a strong 
affinity for all VEGF-A isoforms. The testing of intravitreal ranibizumab in a number of 
large scale clinical trials provided an important breakthrough in the treatment of nv-
AMD.   
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2.4.2.3 Ranibizumab trials 
 
The MARINA study (Minimally Classic/Occult Trial of the Anti-VEGF Antibody 
Ranibizumab in the Treatment of Neovascular AMD)
149
  
The MARINA trial was a randomised, double-blind, controlled, multicentre phase III 
clinical trial, which investigated the response of patients with nv-AMD (either 
minimally classic or occult CNV) to ranibizumab. Seven-hundred and sixteen patients 
were randomly assigned to receive either 0.3mg ranibizumab, 0.5mg ranibizumab or 
sham injections every month for a period of two years. Results at 24 months were as 
follows: 
- 90% of the 0.5mg ranibizumab-treated patients lost fewer than 15 letters 
compared with 53% in control-group (p<0.001). 
- 33.3% and 26.1% of patients being treated with 0.5mg and 0.3mg ranibizumab, 
respectively, gained at least 15 letters of VA, whereas 3.8% had such gains in 
the control-group (p<0.001). 
- Mean VA at 24 months increased by 6.6 lines amongst those receiving 0.5mg 
ranibizumab, compared to a decrease of 14.9 lines in the sham-injection group 
(p<0.001) (Figure 2.6). 
- With similar baseline measurements, approximately 40% of patients treated with 
ranibizumab achieved VA of 20/40 (6/12), compared to 11% in the sham group 
(p<0.001).  
- Approximately 12% of patients in the ranibizumab groups had vision of 20/200 
(6/60; equivalent to legal blindness) or less at 24 months, compared to 43% in 
the control group (p<0.001); both groups were comparable in this respect at 
baseline. 
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- The area of the CNV lesion in the sham group increased by an average of 2.5 
disc diameters in the control group and showed no change in the ranibizumab 
groups, over the course of 24 months (p<0.001).  
- 1% of subjects (n=5) being treated with ranibizumab developed presumed 
endopthalmitis over the course of the study and 1.3% developed uveitis. The 
overall incidence of any serious or non-serious systemic adverse event was 
similar among the groups. 
 
Figure 2.6 MARINA: mean change in visual acuity from baseline over time; from 
Rosenfeld et al.
149
   
 
 
The ANCHOR Study (Anti-VEGF antibody for the treatment of predominantly classic 
choroidal neovascularisation in AMD)
150
  
The ANCHOR trial, another randomised, double-blind, controlled, multicentre phase III 
clincial trial, assessed the effect of ranibizumab in patients with predominantly classic 
CNV. Four-hundred and thirty-two patients were randomly selected to receive PDT 
with verteporfin every three months plus a monthly sham injection, or sham PDT 
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combined with either 0.3 mg or 0.5 mg ranibizumab. The results after 24 months were 
as follows: 
- 90% of both ranibizumab groups lost less than 15 letters compared with 65% in 
PDT group (p<0.001). 
- 41% of those treated with 0.5 mg ranibizumab and 34% treated with 0.3 mg 
ranibizumab gained at least 15 letters, compared with 6% in PDT group 
(p<0.001) (Figure 2.7) 
- Mean VA increased by 11.3 letters in the 0.5 mg ranibizumab-treated/sham PDT 
group whereas it decreased by 10.4 letters in the PDT/sham injection group 
(p<0.001). 
- Changes in lesion anatomic characteristics on fundus fluorescein angiography 
(FFA) favoured ranibizumab (all comparisons p<0.0001 vs. PDT). 
- Similar to the MARINA trial, the risk of presumed endopthalmitis was 1% 
amongst the ranibizumab-treated subjects and there was no imbalance among 
the groups in terms of rates of serious ocular and non-ocular adverse events. 
 
 
Figure 2.7 ANCHOR: Gain ≥15 letters after 1 and 2 years; from Brown et al.150   
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There was no significant evidence of toxicity with either dose of ranibizumab in 
either of the trials. It was suggested that the 0.5 mg dose was superior and has now been 
approved for intravitreal use in patients with nv-AMD. 
 
The PIER study
151
  
The PIER study was designed to evaluate the efficacy and safety of ranibizumab using a 
less frequent injection schedule than that used in MARINA and ANCHOR. One 
hundred and eighty-four patients  were randomised to receive 0.3 mg ranibizumab, 0.5 
ranibizumab or a sham injection every month for three months, followed by injections 
every three months. After one year, there was an observed difference, in terms of VA, 
between the ranibizumab-treated patients and those in the sham group: 
- Mean change in VA between baseline and 12 months were -16.3, -1.6, and -0.2 
letters for the sham, 0.3 mg, and 0.5 mg groups, respectively (p≤0.0001, 
each ranibizumab dose vs. sham) (Figure 2.8).  
- Ranibizumab arrested CNV growth and reduced leakage from CNV compared to 
sham treatement (p<0.001)  
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Figure 2.8 PIER: Mean change from baseline visual acuity at monthly intervals; from 
Regillo et al.
152
  
 
However, in the ranibizumab groups, the treatment effect declined during 
quarterly dosing and the results 12 months showed poorer outcomes compared to those 
observed in the MARINA and ANCHOR trials for the same time period, which used 
monthly dosing. Between month 12 and month 24, changes in protocol meant that 
sham-injection patients crossed over to receive 0.5 mg ranibizumab quarterly after 
completing the month-12 visit. Subsequently, and in light of the 12-month PIER data, 
the protocol was further amended and all patients remaining in the study rolled over to 
receive 0.5 mg ranibizumab monthly for the remainder of the 2-year study. At month 
24: 
- VA decreased an average of 21.4, 2.2, and 2.3 letters from baseline in the sham, 
0.3mg, and 0.5mg groups (p<0.0001 for each ranibizumab group vs. sham). 
- VA of sham patients, who crossed over (and subsequently rolled over) 
to ranibizumab, decreased over time, with an average loss of 3.5 letters 10 
months after crossover. This reduction in VA, in spite of the initiation of 
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treatment, suggests that ranibizumab has limited benefit following 12 months 
without treatment, further emphasising the importance of timely intervention. 
- VA of 0.3 mg and 0.5 mg group patients who rolled over to 
monthly ranibizumab increased for an average gain of 2.2 and 4.1 letters, 
respectively, 4 months after rollover.  
- The ocular safety profile of ranibizumab was favorable and consistent with 
previous reports, with no events of endophthalmitis or serious intraocular 
inflammation.  
After 12 months, subjects in the treatment groups who rolled over to receive monthly 
ranibizumab, had further increases in VA, suggesting that more effective outcomes are 
obtained with a more frequent treatment regimen.  
 
The PrONTO study (Prospective Optical Coherence Tomography Imaging of Patients 
with Neovascular Age-Related Macular Degeneration (AMD) Treated with 
intraOcular Ranibizumab)
153
  
PrONTO investigated the effect of a variable-dosing regimen based on OCT findings 
and other clinical outcomes. Forty patients received three monthly injections of 0.5 mg 
ranibizumab and further injections thereafter, depending on the presence of defined 
criteria, as follows. During the first year, retreatment with ranibizumab was performed 
at each monthly visit if any of the following criteria were met: an increase central retinal 
thickness, as observed by OCT, of at least 100µm, or a loss of five letters or more on 
the acuity chart. The retreatment criteria were amended in the second year of the study 
to include any qualitative increase in the fluid detected using OCT.  
- At month 24, mean VA improved from baseline by 11.1 letters (p<0.001).  
- Central retinal thickness decreased by 212µ (p<0.001).  
- VA improved by 15 letters or more in 43% of patients. 
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In brief, visual outcomes were similar to those acheived in MARINA and ANCHOR 
and were achieved with an average of 9.9 injections over 24 months. In other words, 
fewer intravitreal injections were required. 
 
Other ranibizumab studies 
 
The HORIZON trial was an open-label extension trial (of MARINA and ANCHOR) in 
which re-injections of ranibizumab were given at the clinician’s discretion.154  Half of 
the patients required re-injections within the first six months and the authors report that 
multiple ranibizumab injections were well tolerated for ≥ 4 years. 
 
The EXCITE trial (Efficacy and safety of monthly versus 
quarterly ranibizumab treatment in neovascular age-related macular degeneration) 
compared 0.3mg quarterly, 0.5mg quarterly, and 0.3mg monthly ranibizumab.
155
  
Treatment consisted of a 3-month loading phase, followed by a 9-month maintenence 
phase (injection frequency depending on group). VA increased from baseline to month 
12 by 4.9, 3.8, and 8.3 letters in the 0.3 mg quarterly (n=104), 0.5 mg quarterly (n=88), 
and 0.3 mg monthly (n=101) dosing groups, respectively, confirming the superiority of 
a monthly dosing regimen. The safety profile was similar to that reported in prior 
ranibizumab studies. 
 
The SUSTAIN trial (Safety and efficacy of a flexible dosing regimen of ranibizumab in 
neovascular age-related macular degeneration), undertaken on 513 ranibizumab-naive 
subjects, investigated the efficacy of three initial monthly injections of ranibizumab (0.3 
mg) followed by pro re nata (PRN) retreatment for the remaining nine months of the 
study.
156
  Retreatment was based on the following pre-specified criteria: a) more than 
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five-letter loss in VA from the previous highest VA score during the first three months; 
or b) 100µm increase in central retinal thickness from the previous lowest measurement 
during the first three months. The average number of re-treatments from months three to 
11 was 2.7. Mean VA increased steadily from baseline to month three (reaching +5.8 
letters), decreased slightly from month three to six, and remained stable from month six 
to 12, reaching +3.6 at month 12. Central retinal thickness showed a rapid and 
significant decline in the first three months, which was maintained over the 12-month 
study period. The safety results were comparable to those observed in the previous 
clinical studies. 
 
2.4.2.4 Bevacizumab versus Ranibizumab 
The recently published 24-month results from CATT (Comparisons of Age-Related 
Macular Degeneration Treatments Trial) compared the effiacy and safety of 
bevacizumab and ranibizumab for nv-AMD.
157
  Subjects were randomised to one of 
four groups: ranibizumab or bevacizumab, given either every month or as needed (pro 
re nata; PRN), with monthly review. In brief, the study showed that ranibizumab and 
bevacizumab had similar effects on VA over a 2-year period (p=0.21).  Mean gain in 
VA was greater for monthly rather than for as-needed treatment (difference, -2.4 letters; 
p=0.046). There were no differences between drugs in terms of rates of death or 
arteriothrombotic events (p>0.6). However, the proportion of patients with one or more 
systemic serious adverse events was higher with bevacizumab than ranibizumab (39.9% 
vs. 31.7%; p=0.009). 
 The IVAN trial (A randomised controlled trial of alternative treatments 
to Inhibit VEGF in Age-related choroidal Neovascularisation) also compared the 
efficacy and safety of ranibizumab and bevacizumab in cases of nv-AMD, with the 
same randomisation protocol as CATT (above). Differences in VA at 12 months 
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between bevacizumab and ranibizumab were found to be inconclusive. In contrast to 
CATT, VA outcomes did not differ between monthly and as-needed treatment 
protocols. Drugs and treatment regimens were deemed to have similar efficacy and 
safety (p=0.25). Bevacizumab was less costly for both treatment regimens (p<0.0001). 
A recent safety review and meta-analyses of bevacizumab and ranibizumab has raised 
concern regarding the potentially increased risk of ocular and multiple systemic adverse 
effects with bevacizumab.
158
  The authors also emphasised the need for studies that are 
sufficiently powered for safety outcomes, not just for efficacy. 
 
2.5 Conclusion  
Anti-VEGF therapy may even be termed “revolutionary” in terms of its capability to 
preserve and, indeed, improve vision for subjects with nv-AMD, who, if left untreated, 
would ultimately develop a disciform scar, leading to the irreversible loss of central 
vision. Yet, the current licensed form of anti-VEGF therapy is costly and cumbersome 
to the healthcare provider and to the patient. For example, in Ireland, the cost to the 
healthcare system of a year’s treatment for one eye with (monthly) intravitreal 
injections of Lucentis® (ranibizumab) is in the range of €24,000. In addition, patients 
and their carers have to travel at least once a month (for injections and post-operative 
assessments), which is taxing on their time and finances e.g. travel costs, time off work. 
There is also no effective treatment for atrophic AMD, which has a similarly 
detrimental effect on a patient’s quality of life. The increasing prevalence of AMD, and 
its associated consequences for the patient and the healthcare system, highlight the clear 
need for attention to be directed towards the prevention of AMD and its progression. 
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Chapter 3. Psychophysical assessment of visual performance in 
subjects with AMD 
 
3.1 Introduction 
Psychophysics quantitatively investigates the relationship between physical stimuli and 
the sensations and perceptions they affect in the observer. Psychophysics, described by 
Gescheider as "the scientific study of the relation between stimulus and sensation",
159
  
provides valuable information about the functional status of the visual system, which 
includes the status of the retina, the visual pathways and the visual cortex. 
Psychophysical assessment can, therefore, reflect, compliment, and even inform 
physiological assessment. 
AMD is the advanced stage of a degenerative process that occurs in all eyes. The 
presence of excessive lipofuscin in RPE cells (typically increases with age) is associated 
with RPE dysfunction and also with drusen formation (between Bruch’s membrane and 
the RPE), causing further RPE damage. Loss of vision occurs due to the degeneration of 
RPE cells, which no longer facilitate the absorbance of excess light necessary for 
optimal visual function, nor provide nourishment to the overlying photoreceptors, 
leading to photoreceptor cell death. Visual loss can also be caused by leakage from 
neovascular membranes that invade the retina, disrupting its normal architecture, and 
which, if left untreated, results in scar formation and irreversible visual loss. 
Considering the delicate and precise nature of visual perception (in particular, that of 
central vision), and the fact that the optimum perception of an image relies on the 
intactness and health of a complete array of photoreceptors at the macula, a reduction in 
psychophysical function would, therefore, be expected in the presence of AMD. 
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An excellent review summarises psychophysical function in AMD;
160
  (a) 
Spatial vision refers to our ability to resolve or discriminate spatially defined features 
and includes: (high contrast) VA, hyperacuity, reading speed and CS. (b) Visual field 
testing (perimetry): the systematic measurement of differential light sensitivity at 
topographically defined loci in the visual field. (c) Temporal vision represents how we 
perceive changes in luminance over time, e.g. the response of an eye to a flickering 
stimulus. (d) Visual adaptation describes the processes by which the visual system alters 
its functioning in response to changes in the environment. The human eye can function 
over a remarkably wide range of luminances (a range of greater than eight log units). 
The integrity of these visual processes can be assessed using tests, such as dark 
adaptation of both rods and cones and, also, the photostress recovery test. (e) Chromatic 
function (colour vision) represents the ability to discriminate between stimuli that differ 
with respect to their spectral composition, regardless of other parameters, such as 
intensity. 
The assessment of psychophysical function is largely based on the concept of 
threshold testing, the threshold being defined as the point of intensity at which the 
presence of a stimulus, or the difference between two stimuli, is either just detectable or 
just undetectable. There are two types of thresholds, absolute thresholds and difference 
thresholds. An absolute threshold is the level of intensity of a stimulus at which it can 
be detected. A difference threshold is the magnitude of the smallest detectable 
difference between two stimuli of differing intensities. Humans, however, are not 
perfect observers, rendering the acquisition of precise thresholds challenging. The most 
common means of assessing thresholds are: the method of adjustment, the method of 
limits, the modified (staircase) methods of limits, and the method of constant stimuli. 
For the purpose of this publication, I will review those measures of 
psychophysical function relevant to studies carried out as part of this PhD, and 
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comment on some of the studies germane to the impact of AMD on these particular 
measures of visual performance, where available. 
 
3.2 Corrected distance visual acuity 
Currently, CDVA a measure of the angular resolution limits of the eye at high contrast 
i.e. the smallest discernible black letter on a white chart,
2
  represents the standard 
vision-related outcome measure for the management of AMD (and for vision in general, 
in subjects with and without ocular disease).
14
  The inherent weaknesses of the 150 
year-old, and still widely used, Snellen chart have been largely overcome with the 
introduction of the Bailey-Lovie and ETDRS (Early Treatment Diabetic Retinopathy 
Study) logMAR charts, which allows for a more standardised measure of high contrast 
acuity. These alterations, which are the novel features of the logMAR chart, include: 
equal numbers of letters per line, equal (logarithmic) graduations from line to line, the 
use of letters of equal legibility and the uniformity between-letter and between-row 
spacing.
161
  However, and in spite of these important advances, there is a general 
consensus that CDVA is not a true reflection of daily visual experience in a world with 
few visual stimuli at such high levels of contrast, suggesting that perhaps other 
measures of visual function may be more appropriate in assessing visual performance 
and experience in patients with AMD.
162
   
 
CDVA and AMD: Lesions associated with early AMD are associated with a decrease 
in CDVA of up to two letters or fewer when compared with eyes without such 
lesions,
163
 which is neither clinically meaningful nor reliably detectable, considering 
that the test-retest variability can be up to two lines of letters on a logMAR chart.
164
  
Also, a report has shown no statistical difference in acuity between subjects with nv-
AMD and subjects with GA.
163
 CDVA is, therefore, unlikely to be a sensitive 
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psychophysical measure with the capacity to (a) detect the presence of early AMD, (b) 
detect change in visual function e.g. following intervention, or (c) provide a useful 
prognostic indicator of disease progression. Late AMD is associated with a more 
significant decrease in CDVA (approximately seven lines of letters), but only when 
signs of advanced AMD involved the central subfields of the macula.
163
  CDVA is a 
poor indicator of disease severity. Acuity levels can vary dramatically despite similar 
areas of atrophy, although foveal involvement is a key predictor of VA.
165
  Similarly, 
lesion size in subfoveal nv-AMD cannot explain the wide variations in VA.
166
  Another 
study has shown that for the same level of VA, eyes with GA have worse function, 
particularly for dark-adapted vision tests and reading speed, than eyes with drusen (≥ 
6/15).
167
   
 
CDVA in response to anti-VEGF therapy: The large scale clinical trials (discussed in 
section 2.4.2.3) have demonstrated that CDVA improved significantly following 
ranibizumab therapy. Optimum visual outcomes are observed with monthly or criteria-
based dosing regimens, compared to less-frequent dosing schedules. 
 
CDVA in response to macular carotenoid supplementation: Various studies have 
also reported improvements in CDVA following macular carotenoid supplementation, 
in both normal and AMD-afflicted subjects.
168-171
  However, there have been studies 
that have not reported such changes
35, 172
  whilst reporting improvements in other 
parameters of visual function. It is generally accepted that CDVA is not a sensitive 
enough measure to detect subtle (but yet important) changes in visual performance. In 
this respect, other measures of psychophysical visual function, that might better reflect 
the functional status of the macula, should be considered in assessment and 
management of subjects with AMD.  
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3.3 Contrast sensitivity 
Contrast threshold is the least amount of contrast required for an observer to discern a 
target, and is typically expressed as CS, its reciprocal. A graph, plotting CS as a 
function of spatial frequency, is known as the CS function (CSF) curve, which 
represents the minimum contrast required to detect a grating at varying spatial 
frequencies. In fact, losses in CS are associated with much smaller losses of VA (spatial 
resolution).
173
  In normal subjects, under normal (photopic) viewing conditions, CS 
function peaks at 3-6 cycles per degree (cpd), with a steep reduction in CS approaching 
higher spatial frequencies and a more gradual decline in CS towards lower spatial 
frequencies.
174
  A review has concluded that CS is an important measure of visual 
function in patients with AMD,
175
  based on studies that have shown that, when 
compared with VA, CS better relates to the ability to perform tasks accurately and 
efficiently (including computer task accuracy),
176
  to discriminate between objects
177
  
and to judge distances.
178
   
 
CS and AMD: The aforementioned review (on psychophysical function), concluded 
that the available data indicates an observed loss in CS across all spatial frequencies in 
subjects with AMD. In normal subjects, reduction in CS is typically related to a 
reduction in CDVA. Importantly, however, patients with AMD may present with good 
CS (at low spatial frequencies) and poor CDVA (or vice versa),
179
 suggesting that 
CDVA alone cannot account for the visual experience in subjects with AMD. In fact, a 
significant association has been observed between the loss of CS at high spatial 
frequencies and a number of AMD lesions including drusen confluence, focal 
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hyperpigmentation of the RPE, and RPE atrophy, whereas lesion size/type (in cases of 
late AMD) was not associated with CDVA (previously discussed).
180
  
 
CS in response to anti-VEGF therapy: In light of the usefulness of CS as a measure 
of visual function in AMD, it is interesting to note that there is a paucity of studies that 
have investigated the impact of anti-VEGF therapy on CS, in cases of nv-AMD. An 
unpublished report reviewing the three large scale, Phase III clinical trials, namely, 
MARINA, ANCHOR and PIER, showed that, from the total of 1,323 enrolled 
participants in these studies, there was a significant improvement in CS at 12 months 
for all CNV lesion types, following intravitreal ranibizumab (0.3mg or 0.5mg).
181
  
Another much smaller-scaled study of three subjects with AMD,  reported improvement 
in CS in one and stabilisation in two (subjects), following three consecutive 
ranibizumab injections.
182
 The IVAN trial reported improvements in CS in subjects 
being treated with either intravitreal ranibizumab or intravitreal bevacizumab (with no 
significant difference reported between the two drugs).
183
  Another study, investigating 
the impact of one injection of intravitreal ranibizumab, in combination with one PDT 
treatment, observed an improvement in CS in approximately 82% of subjects (n =17).
184
 
Also, improvements in CS scores were observed following one year of either 
intravitreal ranibizumab or intravitreal bevacizumab in eyes with CNV due to myopic 
maculopathy.
185
   
 
CS in response to macular carotenoid supplementation: A statistically significant 
improvement in contrast acuity thresholds (the contrast threshold needed to detect and 
correctly identify the orientation of the gap in a Landolt ring) has been reported in 
normal subjects supplemented with L under mesopic conditions.
186
  The MOST Vision 
trial (normal subjects; discussed in detail in section 4.4.3.2) also reported improvements 
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in CS following supplementation with a formulation containing all three macular 
carotenoids, an improvement which was not observed either amongst subjects taking 
placebo, or amongst subjects taking a supplement containing L primarily.
170
 In 2004, 
the LAST study (Lutein Antioxidant Supplementation Trial) was carried out in an 
attempt to evaluate the effect of L, either alone or in combination with co-antioxidants, 
vitamins and minerals, on the progression of atrophic AMD.
187
  In brief, results showed 
that the subjects taking MP carotenoid supplements (whether alone or in combination) 
demonstrated an improvement in VA, CS, glare recovery and visual distortion.  
 
3.4 Glare disability 
Glare can be categorized as (a) discomfort glare: the discomfort caused when the overall 
illumination is greater than the luminance to which the eyes are adapted, and can be 
caused by both direct and indirect light sources e.g. car headlights at night, reflections 
from water surfaces, snow, and (b) glare disability (GD): causes a reduction in target 
visibility against its background. Discomfort glare typically produces visual fatigue or 
annoyance, without necessarily reducing visual performance or visibility. It is thought 
to be related to neuronal interactions similar to that of the pupillary response to light.
188
  
GD, on the other hand, is caused by straylight (forward light scatter) either exterior to 
and/or within the eye, impairing visual performance and visibility. GD typically 
increases with age and/or ocular disease and can be used synonymously with straylight 
according to the definition by the CIE (Commission International d’Eclairage, or the 
International Committee on Illumination).
189
   
Light travels in straight lines unless it is either absorbed, reflected or scattered 
by obstructing particles. The physics of light scatter has been eloquently described as 
follows: “Scattering is the process by which a particle – any bit of matter – in the path 
59 
 
of an electromagnetic wave continuously 1) abstracts energy from the incident wave, 
and 2) reradiates that energy into the total solid angle centered at the particle. 
Scattering only occurs when the particle’s refractive index differs from the surrounding 
medium.”190  
 The impact of light scatter on CS and visibility has been eloquently described in 
a review
33
  where the effects of scatter by air particles are explored, in particular scatter 
caused by haze aerosols (a dispersed system of small particles suspended in a gas,
190
 the 
most common component of the atmosphere), on visibility i.e. “how far one can see and 
how well details can be resolved.”  Light scatter is wavelength-dependent for small 
particles (e.g. 0.2µm), such as those found in haze aerosols. As light passes through the 
atmosphere, shorter wavelengths are more prone to scatter than longer wavelengths. The 
scattering of short-wavelength light creates a bluish veiling luminance, often termed 
“blue haze”, which, when superimposed on the retinal image, reduces the contrast of 
targets being observed. 
 
GD and AMD: The effect of straylight is exacerbated in the presence of retinal disease, 
such as AMD. AMD is associated with RPE dysfunction (discussed above), which in 
turn increases the effects of straylight. In addition, the orientation of photoreceptors is 
an important anatomical consideration with respect to glare. In a normal, healthy eye, 
photoreceptors are orientated in such a way that light entering the eye (though the pupil 
centre) is incident on the “top” of the photoreceptors. This limits the response to light 
scatter in the healthy eye (the Stiles-Crawford effect), particularly in the case of 
cones.
191
 Photoreceptors that are irregularly oriented are less likely to respond to light 
than normally oriented receptors. In AMD, for example, the presence of drusen, retinal 
cysts, fluid, pigment epithelial detachments, alter the normal architecture (orientation) 
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of the photoreceptors, causing them to be less responsive to incoming light and more 
responsive to scattered light within the eye, exacerbated by an ageing RPE.  
 
GD in response to anti-VEGF therapy: To my knowledge, no study has investigated 
the impact of anti-VEGF therapy in cases of nv-AMD on a subject’s vision measured in 
the presence of glare.  
 
GD in response to macular carotenoid supplementation: MP’s short-wavelength 
filtering properties render it capable, in theory at least, of attenuating straylight incident 
upon the retina, reducing GD. Wooten and Hammond have proposed that having 
MPOD of e.g. 0.5 OD units (compared with having little or no MPOD) can attenuate 
the veiling luminance of a short-wavelength dominant background by 17%, thereby 
increasing the visibility and discriminability of objects in natural viewing conditions.
33
 
Studies have shown the inverse relationship between levels of MP and GD.
32
 A study 
has shown that supplementation with 10mg of L and 2mg of Z for a period of 4-6 
months significantly increases MPOD and improves visual performance in the presence 
of glare in normal healthy subjects.
36
 Similarly, demonstrable improvements in mesopic 
and photopic GD for a range of spatial frequencies amongst normal healthy subjects 
supplementing with 10mg MZ, 10mg L and 2mg Z over a six-month period, have been 
observed. Of note, there were no statistically significant improvements in these 
parameters of visual performance amongst subjects supplementing with either placebo 
or L and Z alone.
170
   
Improvements in GD have been reported in AMD subjects following 
supplementation with 15mg dietary L, improvements which were not observed amongst 
those supplementing with placebo, albeit in a small sample (n=5). To the best of my 
knowledge, no other study has looked at the impact of macular carotenoid 
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supplementation on GD in subjects with AMD. Of note, GD has also been shown to 
improve amongst subjects with cataract taking dietary supplementation of 15mg L three 
times a week, compared with subjects on placebo.
192
 However, the presence of AMD 
was not an exclusion criterion in this study. Therefore, ascertaining whether or not the 
observed visual benefits of supplementation were related to regression in macular 
disease is not possible. 
 
3.5 Reading speed 
Word reading is a complex task comprising of a combination of visual, neural, motor 
and cognitive processes, and is influenced by stimulus conditions such as size of print, 
contrast, colour, and optical defocus.
193
  Reading speed is also strongly associated with 
vision-related quality of life.
194
 Reading speed is measured in words per minute (wpm) 
and is reported to have a mean (range) of 215 (169-273) wpm in subjects with normal 
vision.
38
   
 
Reading speed and AMD: The intactness of the central field is one of the most 
important factors for accurate reading,
195
 and is likely, therefore, to be of primary 
concern to subjects with late stages of AMD. Differences in maximum reading speed 
have been observed between subjects with nv-AMD and subjects with GA, with 
significantly higher reading speeds achieved by subjects with macular scotomas due to 
nv-AMD compared to those due to GA.
196
 The authors postulate that this difference 
might be as a result of the different time-courses of the two conditions, which involve 
different types of visuo-motor and adaptation processes. The loss of central field elicits 
the use of eccentric viewing, thus impacting the size of the visual span (the number of 
letters recognised with each glance, which shrinks in peripheral compared to central 
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vision
197
 ) and, consequently, reading speed. Central field loss also impacts fixation 
ability, which is an important contributing factor to comfortable reading.
198
  Bullimore 
et al reported that subjects with AMD (not defined by the authors as early or late) show 
similar fixation rates to normals, but they average fewer letters per forward saccade and 
make more frequent regressions.
199
   
 
Reading speed and anti-VEGF therapy: There are very few studies that have 
investigated the impact of anti-VEGF therapy on reading speed. Two are of particular 
interest. A statistically significant improvement was reported in mean[±sd] reading 
speed (59[±40] to 85[±50] wpm; p < 0.0001) over a three month period in a group of 
thirty subjects being treated with ranibizumab for nv-AMD.
200
  This study also showed 
that there was no significant relationship between change in CDVA and change in 
reading speed following intervention, indicating that change in CDVA alone cannot 
predict a change in reading speed, which was shown to relate more strongly to patient 
quality of life than CDVA. Another study has shown a shift in the critical print size 
towards smaller print sizes after three intravitreal injections of ranibizumab, i.e. subjects 
reached their maximum reading speed for smaller print sizes than those achieved at 
baseline, requiring less magnification for effortless reading following treatment.
201
  
 
Reading speed and macular carotenoid supplementation: There is little information 
known about the relationship between MP and reading speed, or on the influence of 
macular carotenoid supplementation on this measure of visual function over time. 
Further research in this area is required. It has been reported, however, that the use of 
yellow filters (similar to MP) improve magnocellular function, which has been shown 
to enhance reading performance in children with reading difficulties.
202
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Another study investigated the effects of four different light filters (the yellow 
Corning Photochromic Filter [CPF] 450 [absorbing wavelengths below 450 nm], a grey 
neural density filter, an individualised filter obtained using the Intuitive Colorimeter®, 
and a clear filter) on reading speed in normal subjects and in subjects with (non-
neovascular) AMD associated with central field loss. There was no statistically 
significant light filter effect on reading speed for normal subjects. However, the AMD 
group demonstrated a statistically significant (mean = 5%) improvement 
in reading speed with the CPF450 compared with the other filters, and some subjects 
had improvements of 10-15%. This suggests that the filtration of short-wavelength light 
may be of greater visual benefit for subjects with AMD than for normal subjects.
203
   
 
3.6 Retinotopic ocular sensitivity  
Retinotopic ocular sensitivity (ROS), as determined using Microperimetry (devices such 
as the Microperimeter (MP 1)®, Nidek Technologies, Padova, Italy), provides 
information regarding ocular functional performance by examining the differential light 
threshold at specific points on the retina, under direct visualisation of the fundus. It 
allows a point-to-point correlation between fundus lesions and functional defects and 
simultaneously corrects for eye movements. Other important features of the technique 
include real-time automated fundus tracking, the automatic, accurate mapping of the 
location and quality of fixation, and the facility to analyse eyes over time, using point to 
point comparisons from visit to visit. ROS uses a more sophisticated method of 
psychophysical assessment (compared to CDVA) and is, therefore, inherently more 
sensitive to subtle changes in retinal physiology. 
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ROS and AMD: ROS overlying areas of drusen and pigment abnormalities, using the 
MP 1, was examined in 13 patients with early AMD and good VA (6/6).
204
 The results 
showed that, in subjects with early AMD, ROS diminishes in areas overlying drusen 
and/or pigment abnormalities, despite good VA. The reduction in sensitivity was greater 
when both types of lesion were present. These findings suggest that microperimetry 
provides additional and possibly more useful information than CDVA with respect to 
visual function in cases of AMD. 
 
ROS and anti-VEGF therapy: Microperimetry has been shown to provide additional 
and valuable information in cases of nv-AMD undergoing anti-VEGF therapy. A study 
has demonstrated a progressive improvement of ROS, in response to ranibizumab 
therapy, as far as 24 months following the initiation of treatment, despite stabilisation of 
VA after six months.
7
  Changes in macular morphology following anti-VEGF therapy 
have been shown to correlate with changes in central ROS, as measured by 
microperimetry.
205
  Changes in microperimetry have also been shown to reflect changes 
in macular thickness for other eye conditions, such as diabetic macular oedema.
206, 207
  
A study has shown that, compared with microperimetry, CDVA seems to significantly 
underestimate the change in visual function experienced by patients following treatment 
(three consecutive monthly intravitreal ranibizumab injections) for nv-AMD. In that 
particular study, one patient exhibited a significant improvement in CDVA compared 
with eight patients who exhibited a significant improvement in mean ROS (but not 
CDVA).
208
  This difference in the proportion of patients who had improved visual 
function as assessed by microperimetry compared with CDVA was statistically 
significant. 
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ROS and macular carotenoid supplementation: The first study that investigated the 
impact of macular carotenoid supplementation on macular function as examined by 
microperimetry in subjects with early AMD reported a tendency towards improvement 
following supplementation with L for six months (20mg for first three months and 
10mg for the remaining three months), although the observed improvement did not 
reach statistical significance.
35
  However, the authors report a significant correlation 
between the increase in MPOD and the increase in ROS over the study period. No other 
studies to date have investigated the impact of macular carotenoid supplementation on 
ROS. 
 
3.7. Preferential Hyperacuity Perimetry 
Preferential Hyperacuity Perimetry (PHP) is based on the phenomenon of vernier 
acuity, which reflects the ability to discern a subtle misalignment of an object. Vernier 
acuity, a form of hyperacuity, has a resolution threshold of three to six seconds of arc at 
the fovea, which is approximately 10-fold lower than that required for optimal 
resolution of an object on, for example, a letter chart (30 to 60 seconds of arc).
209
  It is 
unaffected by patient age or physical condition,
210
  as well as being quite resistant to 
image degradation e.g. as a result of lens opacities, when compared to resolution 
acuity.
211
  
 
PHP and AMD:  It has been suggested that measures of hyperacuity (such as vernier 
acuity) may better detect early loss of visual function in patients with age-related retinal 
disease, such as AMD.
212
  The Foresee PHP® has demonstrated high sensitivity and 
specificity in differentiating between patients with intermediate AMD and recent-onset 
CNV,
213
 and also greater sensitivity in detecting macular changes and AMD when 
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compared to the Amsler grid.
214
  The PHP has, however, demonstrated a higher number 
of false-positive results amongst healthy individuals, compared with the Amsler grid.
215
  
 
PHP and anti-VEGF therapy: A study has shown that improvements in the PHP 
metamorphopsia test score correlated closely with improvements in several OCT 
parameters, following a single intravitreal ranibizumab injection, amongst 14 subjects 
with nv-AMD.
216
  A longer prospective study (by the same authors) in a similar group 
of subjects, over a period of six months has shown that improvements in OCT 
parameters correlated with functional improvements as evaluated by PHP (r = 0.9; p < 
0.05), following intravitreal ranibizumab therapy. In addition, the PHP could predict the 
need for further injections with an accuracy of 75% (sensitivity, 83±12%; specificity, 
67±15%), whereas a combination of all the measurements (PHP, CDVA, and OCT) 
yielded a higher accuracy of 87% (sensitivity, 83±12%; specificity, 90±10%),217 
rendering it a potentially useful tool for monitoring patients undergoing treatment for 
nv-AMD.  
 
PHP and macular carotenoid supplementation: To date, PHP has not been assessed 
in conjunction with macular carotenoid supplementation. 
 
3.8 Subjective Experience and Quality of Life. 
Quantification of disease severity or any observed improvement or deterioration in a 
given patient’s condition, judged by a clinician according to defined morphological or 
even psychophysical criteria, in many ways falls below the importance of subjective 
experience i.e. how the patient experiences the world as a result of the condition and/or 
its treatment. Whether or not the patient notices appreciable change in vision or in their 
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quality of life (QoL) is central to understanding the impact of any disease or resulting 
treatment strategy. This is interesting considering that ophthalmologists often 
underestimate the impact of AMD on a patient’s QoL.218  In addition, patient-reported 
outcomes are now part of US FDA guidelines for the design of clinical trials.
219
   
There is considerable evidence to highlight the significantly negative impact of 
AMD on QoL.
220-223
  Compared to age-matched normals, subjects with AMD are eight 
times more likely to report difficulty shopping, 13 times more likely to have difficulty 
managing finances, four times more likely to experience difficulty with meal 
preparation, 12 times more likely to have problems using a telephone, and nine times 
more likely to have difficulty carrying out housework.
223
  
A number of studies have looked at the impact of AMD on psychological well-
being.  Patients with AMD and VA of 6/60 or worse in at least one eye are more likely 
to experience emotional distress than age-matched normals (from the Profile of Mood 
States).
224
  However, QoL scores are dependent on stage, where late stages of the 
condition have a more profound impact.
39
  Longer duration of the condition was 
associated with reduced levels of distress, most probably due to adaptation. However, 
poor adaptation was shown to be associated with depression.
225
 A US-based cross-
sectional study found that rates of depression amongst patients with advanced visual 
loss attributable to AMD were twice those found among a general sample of 
community-dwelling elderly subjects.
226
   
There are obvious limitations to measuring QoL using standard questionnaires. 
As is implied, QoL is a subjective perception and will have a different meaning to 
different people. Many QoL measures, although obtaining a score or quantifying the 
degree of difficulty with respect to a given task, do not necessarily take into 
consideration the relevance of that particular task or aspect of daily life for the patient in 
question. For example, two patients with similar deterioration in reading speed may 
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exhibit vastly different QoL scores, depending on whether or not reading is an 
important part of their daily lives. The availability of support and rehabilitation may 
also contribute to variations in QoL scores. Patient to patient variability in QoL scores 
are further confounded when one considers the influence of the presence or absence of 
disease in the fellow eye.  
Vision-related QoL questionnaires that have been validated for use amongst 
subjects with AMD include: the National Eye Institute Visual-Function Questionnaire 
(NEI-VFQ), the Visual Function-14 (VF-14) questionnaire, Daily Living Tasks 
dependent on Vision (DLTV) questionnaire and the Activities of Daily Vision (ADV) 
scale. Of these, NEI-VFQ
227
  is the only questionnaire that investigates psychological 
aspects of visual impairment (social functioning, mental health, dependency), in 
addition to items specifically related to vision-related tasks.  
A study investigating the responsiveness of the NEI-VFQ to changes in VA, 
using data from the MARINA and ANCHOR trials, has shown that the NEI-VFQ was a 
responsive and sensitive measure of vision-related function amongst patients with nv-
AMD receiving anti-VEGF therapy.
228
  However, it must be borne in mind that the 
criterion for change in VA in these studies was defined as >15 letters (three lines of a 
logMAR chart), which is a change of relatively large magnitude. The sensitivity of the 
NEI-VFQ to smaller changes, e.g. one or two lines, has yet to be ascertained.  
NEI-VFQ has been critiqued with respect to its unidimensionality, a 
characteristic essential for a valid questionnaire. The overall composite score (a score 
between 0 and 100), which combines the scores of 11 subscales encompassing items 
related to socio-emotional state, and items related to visual functioning, should be 
interpreted with caution, considering the differing nature of these two concepts. 
Although there is overlap between the two, simply combining them in one common 
score will not accurately reflect the contribution of each to the overall output measure. 
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This has largely been remedied through recently derived scales (socioemotional and 
visual functioning scales) in combination with Rasch analysis.
229
  Rasch analysis 
transforms raw nominal numeric questionnaire values into a continuous scale, reducing 
noise and allowing for parametric statistical analyses of the data.
230
 Rasch analysis is 
now widely recognised as a valuable measure in the revalidation of questionnaires, 
including within the area of ophthalmology.
231-233
  
All things considered, and in spite of limitations, a measurement designed to 
quantify a patient’s QoL, either as a result of a condition such as AMD or following 
therapeutic intervention for the condition, should be given due consideration in studies 
investigating visual performance. 
 
3.9 Conclusion  
Considering the wide range and scope of psychophysical visual function and the 
importance of the information yielded with respect to assessment of subjective visual 
function, it would seem unwise to rely solely on one measure of visual performance 
when attempting to quantify disease severity, or when assessing the need for 
intervention, or when evaluating functional outcomes of intervention, both clinically 
and in research studies. 
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Chapter 4. The evidence germane to the role of macular pigment for 
the enhancement of vision, and its putative protective function against 
age-related macular degeneration 
 
4.1 Study rationale, aims and objectives 
There is a consensus that AMD is the result of (photo)-oxidative-induced retinal injury 
and its inflammatory sequelae, the latter being influenced by genetic background.  
MP is a yellow-coloured pigment which accumulates primarily within the inner 
retinal layers at the macula,
234
 and is optically undetectable beyond 7° eccentricity.
235
  
MP is composed of two dietary carotenoids, L and Z, and a third carotenoid, MZ, which 
is not found in a typical diet
26, 27
 (chemical structure given in Figure 4.1) MP has 
generated interest in recent years because of its (now generally accepted) role in the 
enhancement of visual performance and its possible protective role for AMD, putatively 
attributable to its antioxidant properties and/or its pre-receptoral filtration of damaging 
short-wavelength visible light, given that photo-oxidative retinal injury is known to be 
important in the pathogenesis of this condition.
24, 25
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Figure 4.1 Chemical strutures of zeaxanthin ([3R,3’R]-β,β-Carotene-3,3’-diol), meso-
zeaxanthin ([3R,3’S]-β,β-Carotene-3,3’-diol), and lutein ([3R,3’R,6R]-β,ε-Carotene-
3,3’-diol). Image obtained from the MPRG, Waterford. 
 
Evidence quality is typically graded on the basis of study design, where 
systematic reviews or meta-analyses of RCTs are widely accepted as providing the best 
evidence (Level 1) on the effects of preventative, as well as other, interventions in 
medicine.
236
  (see Table 4.1) 
RCTs are regarded as the “gold standard” in clinical research, yet they have 
certain limitations
237
  such as inappropriate outcome measures and/or biased sample 
recruitment. Given that studies involving humans are laden with ethical issues and, in 
many cases, may not be feasible, practical or indeed appropriate,
237, 238
  many important 
epidemiologic findings have been the result of observational studies. The weight 
accorded to RCTs can, in some instances, result in the exclusion of evidence arising 
from other valid study designs. In other words, studies with alternative designs should 
be seen as complementary, rather than an alternative, to RCTs. 
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Table 4.1 Levels of evidence for therapy or prevention 
Level  Type of study 
1a Systematic review (homogeneous) of RCTs  
1b Individual RCT (with narrow confidence interval) 
2a Systematic review of (homogeneous) cohort studies 
2b Individual cohort study / Low quality RCT 
3a Systematic review of (homogeneous) case-control studies 
3b Individual case-control studies 
4 Case series, low-quality cohort or case-control studies 
5 
Expert opinions without explicit critical appraisal, or based 
on physiology, bench research or “first principles” 
Abbreviations: RCT=randomised control trial 
Material adapted from the recommendations for evidence-based medicine in Oxford.
239
   
 
Level 1 evidence has shown that dietary supplementation with broad-spectrum 
antioxidants results in risk reduction for AMD progression. Studies have demonstrated 
that MP rises in response to supplementation with the macular carotenoids, although 
Level 1 evidence that such supplementation results in risk reduction of AMD and/or its 
progression is still lacking. Although appropriately weighted attention should be 
accorded to higher levels of evidence, the totality of available data should be appraised 
in an attempt to inform clinical practice. In this context, I have reviewed the literature 
with respect to macular carotenoid supplementation and its putative protective role in 
the onset/progression of AMD and also its impact on visual performance, in subjects 
with and without the condition. 
 
4.2 The Origins of Macular Pigment 
The macula lutea (“yellow spot”) was first identified more than two centuries ago 
(1792) by a Milanese ophthalmologist, Francesco Buzzi (1751-1805). Whilst dissecting 
and analysing eyes, he noticed a constant finding in the retina: the existence of a small 
area of yellowish colour lateral to the optic disc. He reported this finding in his famous 
work “Nuovo sperienze fatte sull' occhio umano” – new experiments on the human 
eye.
240
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Buzzi’s finding was independently confirmed in 1795 by the German physician, 
Samuel Thomas von Soemmering (1775-1830), who observed yellow pigment at the 
macula during dissection of the eyes of a young man who had drowned. He described it 
as a “yellow round spot, and a small hole in the middle.”  Soemmering did, in fact, 
believe it to be a hole at the centre of the retina and named it (in Italian), 
foramine centrali limbo luteo - the central yellow-edged hole. He published his finding 
in a communication in 1799.
241
   
Sir Everard Home, a British physician, took great interest in the discovery and 
carried out further research to investigate the presence of the pigment in human eyes, as 
well as those of other species, such as monkeys, cows and sheep. He concluded that 
only human and monkey eyes had the pigment. In 1798, he published the first review on 
the “macular yellow”,242  beginning an era of investigation into the composition, and 
function, of what has become known as macular pigment,
243
  a term first coined in 1933 
by Walls et al.
244
   
The visual performance and protective hypotheses of MP was first discussed by 
Schultze in 1866 where, in his paper, “The retina’s yellow spot – it’s influence on vision 
and on colour-blindness”, he concluded, “Therefore, under an otherwise equal 
organisation, a retina without a yellow spot would see more blue light than one with 
such a spot.” He believed that absorption of the “most refractable violet” reduced CA, 
but also hypothesised that macular yellow might provide some protection against the 
hazards of short-wavelength visible light.
245
  MP’s function was further discussed in a 
series of studies in the early 20
th
 century.
246-249
  
In 1945, Wald demonstrated the spectral sensitivity of MP (using a spectral 
adaptometer), indicating that it had a characteristic carotenoid absorption spectrum and 
belonged to a family of xanthophylls found in green leaves. Extraction of pigment 
yielded a hydroxy-carotenoid that Wald believed to be L.
250
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However, it was not until 1985 that Bone and Landrum first reported that the 
pigment was composed of the carotenoids L and Z,
251
  and this was later confirmed in 
1993, at which point the authors also identified MZ as being the third carotenoid present 
in the central retina, where it is the dominant carotenoid at the epicentre of the 
macula.
252
  Bone et al proposed that MZ was primarily formed at the macula following 
conversion from retinal L,
253
  and this has subsequently been confirmed.
254-256
  
 
4.3 The Functions of Macular Pigment  
The putative protective role of MP for AMD derives from its anatomical position in the 
retina (central and pre-receptoral), and from two functional properties of this pigment: 
its absorbance spectrum (peak absorption of this pigment is 460nm), and its ability to 
quench ROIs, referred to as antioxidant capacity (see Figure 4.2).  
 
 
 
Figure 4.2 The antioxidant and blue-light filtering properties of macular pigment. 
Image obtained from the Macular Pigment Research Group, Waterford, Ireland. 
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4.3.1 Short wavelength light filtration 
Although almost all UV-B (320-290nm) and UV-A (320-400nm) light is absorbed by 
the cornea and lens, light of slightly longer wavelength (400-520nm) passes through the 
anterior media, and irradiates the retina.
257
  Given that the peak absorption of MP is at 
460nm,
250
  it has the ideal light filtration properties to screen short-wavelength light pre-
receptorally. This allows MP to attenuate the amount of short-wavelength light incident 
upon the central retina.  
L is reported to be a superior filter of short-wavelength light when compared to 
Z, due to its orientation with respect to the plane of the phospholipid bilayer of the cell 
membrane (see Figure 4.3),
258
  which is both parallel and perpendicular. In contrast, Z 
and MZ only exhibit perpendicular orientation to this layer. However, it is important to 
note that the different absorption spectra of these pigments (L, Z and MZ) result in a 
collective optimal filtration of short-wave light at the macula, which would not be 
achieved by any of these carotenoids in isolation.
258-260
  
 
 
 
Figure 4.3 Lutein and zeaxanthin within the cell membrane. Image obtained from 
Krinsky et al.
261
  
A recent analysis by the European Eye Study (n=4753) found a significant 
correlation between cumulative exposure to visible light and nv-AMD in those patients 
with low intake of dietary antioxidants, including L and Z.
75
 A further study has 
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recently reported the effect of low-power laser light (476nm [blue]) on the retinae of 
eight rhesus monkeys who had lifelong deprivation of the dietary xanthophylls, and 
therefore no detectable MP. A further four monkeys (controls) had a typical dietary 
intake of L and Z from birth. The retinae of primates deprived of dietary xanthophylls 
until exposed to the low-power laser light, but then supplemented with either L or Z, 
were then exposed once again to the same laser light six months later. The relationship 
between lesion size and exposure energy was then analysed. The controls (primates with 
typical dietary intake of L and Z from birth) exhibited less severe short-wavelength light 
induced lesions in the foveal region of the retina when compared to the parafoveal 
region (where there is no MP), whereas those with lifetime deprivation of xanthophylls, 
and no measurable MP, exhibited no difference between the fovea and parafovea in 
terms of blue light induced retinal damage prior to supplementation, thus supporting the 
hypothesis that foveal photo-protection is indeed attributable to MP. This was further 
confirmed by the observation that, following either L or Z supplementation, relative 
foveal protection was restored, and those animals with prior lifelong deprivation of 
dietary xanthophylls no longer exhibited greater relative vulnerability of the fovea when 
compared with the parafovea, and were, therefore, similar to the control group in this 
respect following supplementation.
262
  
 
4.3.2 Antioxidant Properties 
L, Z and MZ are structural isomers of one another and are characterised, biochemically, 
by their high number of double-bonds.
253
  Their supply of readily available electrons 
enables these carotenoids to quench ROIs, thus limiting membrane phospholipid 
peroxidation and attenuating oxidative injury.
258, 263, 264
  Kirschfeld was the first to 
propose the idea that carotenoids protect the macula against oxidative stress.
265
   
However, it was not until 1997 that  the presence of direct oxidation products of L and 
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Z in human retinal tissue was confirmed, supporting the hypothesis that MP does indeed 
protect against oxidative damage in this tissue.
266
    
The antioxidant capacity of Z (and other carotenoids), however, has been shown 
to decrease with increasing oxygen tensions in tissue.
267
  Of note, MP is at its highest 
concentration in the receptor axon layer of the foveola and in the inner plexiform 
layer.
268, 269
   Also, the concentration of the carotenoids within each retinal layer peaks 
at the foveola. Importantly, it is at this central retinal location where ROI production is 
greatest.
270
  
In vitro studies of human RPE cells, subjected to oxidative stress, have shown 
enhanced survival of these cells in the presence of Z and other antioxidants, when 
compared with controls.
271
  Furthermore, L and Z are also more resistant to degradation 
than other carotenoids when subjected to oxidative stress.
272
  Z appears to be a more 
potent antioxidant than L
273
  and MZ is yet more efficacious, but only in conjunction 
with its binding protein
274
 (binding proteins are likely to mediate the uptake of the 
carotenoids at the macula
275
 ). Another study has demonstrated that light-induced 
photoreceptor apoptosis is limited in response to supplemental Z in quail (the retinae of 
which, like those of primates, selectively accumulate L and Z).
276
  Chucair et al 
provided the first evidence of direct neuroprotection of photoreceptors by the macular 
carotenoids,
277
  by demonstrating that the retinal neurons of rats in culture were 
protected from oxidative stress when pre-treated with L and Z, compared to those not 
pre-treated with these carotenoids. Recently, it has been demonstrated that a mixture of 
L, Z and MZ (in a ratio of 1:1:1) quenches more singlet oxygen than any of these 
carotenoids individually at the same total concentration.
278
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4.3.3 MP for vision 
The optical properties of MP, and its selective accumulation at the macula, prompted 
the original hypothesis that MP is important for visual performance and comfort. 
Indeed, the evidence-based consensus is that the principal function of MP at the central 
retina relates to its contribution to visual performance and experience. MP contributes in 
this respect through its short-wavelength light-filtering properties at a pre-receptoral 
level, thereby attenuating CA and light scatter (which are the result of defocus and 
scatter, primarily of short-wavelength visible light), with consequentially enhanced CS 
and reduced GD, respectively. The dichroic properties of MP may further contribute to 
glare reduction due to the preferential absorption of plane-polarised light.
279
  
Furthermore, MP’s antioxidant properties may also contribute to the enhancement of 
visual function by neutralising damaging ROIs, which would otherwise, over time, 
impair the physiological functionality of the photoreceptors, and this putative 
contribution of MP to visual performance has been termed “neural efficiency”.170  
Many cross-sectional studies have shown a positive association between MP and 
measures of visual performance, including VA, CS, photostress recovery and GD 
(amongst others).
29-33
  Early AMD is associated with the loss of psychophysical 
function,
160
 and it has been shown that supplementation with the macular carotenoids 
improves parameters of visual function in patients afflicted with the early form of this 
condition.
34, 169, 171, 280
  However, no study has yet investigated the impact of a 
formulation containing MZ on visual function in subjects with early AMD, or on the 
natural course of this condition. 
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4.4 The Source of the Macular Carotenoids  
An average western diet contains 1.3-3 mg/day of L and Z combined, with significantly 
more L than Z (represented by an estimated ratio of circa 7:1).
281
  It has been reported 
that approximately 78% of dietary L and Z is sourced from vegetables, with L found in 
highest concentrations in dark green leafy vegetables (including spinach, broccoli, kale, 
and collard greens).
282
  However, as most current dietary databases report intakes of L 
and Z combined, it has been difficult to assess the respective and relative intakes of the 
individual macular carotenoids. However, a recent study reported concentrations of L 
and Z separately within the major food sources, as determined by the National Health 
and Nutrition Examination Survey (NHANES).
283
  The authors confirmed that green 
leafy vegetables were the richest source of L (e.g. cooked spinach and kale), whereas 
corn and corn products were confirmed as being a major source of Z. Eggs are also a 
good source of L and Z, especially given the enhanced bioavailability of these 
carotenoids in this form because of co-ingestion of fat.
284
   
It appears that humans ingest relatively low concentrations of MZ (if any). Eggs 
from hens fed MZ are known to be a rich human dietary source of this carotenoid.
285
  
Also, in 1986 a study reported that MZ and Z are present in twenty-one species of 
edible fish, shrimp, and sea turtles.
286
 However, it should be noted that there is a paucity 
of studies conducted to test foods for the presence of MZ, and further study is this area 
is needed. The presence of MZ in the serum of unsupplemented individuals has never 
been unambiguously demonstrated, although efforts to extract and quantify MZ in 
human blood have demonstrated that, if it is present, the concentrations of this 
carotenoid are low.
287
 
 
Interestingly, and in spite of its absence or low concentration in a 
normal diet, MZ accounts for about one third of total MP at the macula, consistent with 
the finding that retinal MZ is produced primarily by isomerisation of retinal L at the 
macula.
253, 256
  L differs from MZ (structurally) with respect to the location of the 
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double bond in one of the end rings (see Figure 4.1). The conversion of L into MZ 
requires a shift in this carbon-carbon double bond. The exact mechanism of the 
conversion, however, remains unknown. 
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4.5 The Evidence 
4.5.1 Types of Evidence 
There is the notable challenge of fitting carotenoid research into the, sometimes rigid, 
paradigm of evidence-based medicine.  
A systematic review is a thorough, comprehensive, and explicit means by which 
to identify, critically appraise and evaluate medical literature related to a specific 
research question. A meta-analysis is a statistical approach to combine and analyse the 
data derived from a systematic-review. RCTs are studies in which participants are 
allocated at random, rather than by conscious decision of clinician or patient (which is 
the case in non-randomised trials), to receive one of several clinical interventions, one 
of which typically acts as a control (placebo). The greater the sample size, the reduced 
likelihood of bias. In contrast, an observational study is one in which conclusions are 
drawn by observation alone, examples of which may include case-control and cohort 
studies.  
AMD is a slow, complex disorder, and the carotenoids under review, 
particularly L and Z, are already commonly found in the daily diet and are easily 
available in supplement form on the open market. This makes the conduct of gold 
standard RCTs particularly difficult. What is important to acknowledge is that all study 
designs contribute to an ever-growing body of knowledge in a given area. This point has 
been eloquently made by Hennekens:“Every research strategy within a discipline, 
contributes importantly relevant and complimentary information to a totality of 
evidence upon which rational clinical decision making and public policy can be reliably 
based. In this context, observational evidence has provided and will continue to make 
unique and important contributions to this totality of evidence upon which to support a 
judgment of proof beyond a reasonable doubt in the evaluation of interventions.”288  
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While recognising the importance of study design in public health research, we 
are encouraged to give adequate attention to the completeness and transferability of 
evidence when interpreting the results of such studies. This has been eloquently 
articulated, as follows: “Care is needed that the use of evidence hierarchies to compare 
the potential for bias between study designs does not translate into unrealistic or overly 
expensive demands for level 1 or 2 evidence, particularly if there is a good or adequate 
level 3 evidence to inform a decision.”289   
The reader should also be aware that the capacity and resources of competing 
stakeholders (e.g. pharmaceutical companies, academic institutions) to generate and 
disseminate evidence has a profound influence on the prestige and volume of available 
and published literature on a given subject.
289
  
 
4.5.2 Clinical trials investigating the macular carotenoids in subjects with AMD  
4.5.2.1 Proof of Principle 
In 2001, the Age-Related Eye Disease Study (AREDS) was published, having been 
conducted by the National Eye Institute (NEI). This was a double-masked, randomised, 
placebo-controlled trial of 4757 subjects over a period of 5 years. In brief, it was shown 
that supplementation with vitamins C and E, beta carotene, and zinc, in combination, 
resulted in a 25% risk reduction of progression from intermediate to advanced AMD.
28
  
Of note, the AREDS formulation did not contain any of the macular carotenoids, 
primarily because these compounds were not available in supplement form at the 
inception of that study. This landmark work did, however, provide Level 1 evidence 
that supplemental dietary antioxidants were of benefit to patients with AMD.  
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4.5.2.2 Interventional studies 
Following AREDS, and in consideration of the possible protective role that MP plays in 
AMD, given its anatomical, antioxidant and optical properties, investigators began to 
direct their attention towards studies designed to explore the possible benefits of 
supplementation with MP’s constiuent carotenoids. There now exists a plethora of 
published interventional studies reporting on supplementation with macular carotenoids 
and its impact on AMD (Table 4.2), ranging from case series to RCTs.
35, 168, 169, 171, 187, 
280, 290-293
   
 In 2004, the LAST study was carried out in an attempt to evaluate the effect of 
L, either alone or in combination with co-antioxidants, vitamins and minerals, on the 
progression of atrophic AMD.
187
 This study was a prospective, 12-month, randomised, 
double-masked, placebo-controlled trial, involving 90 subjects with atrophic (dry) 
AMD. The subjects were assigned to one of three groups: group 1 received L (10mg) 
only; group 2 received a broad-spectrum supplementation formula containing L (10mg) 
as well as co-antioxidants, vitamins and minerals; group 3 received a placebo. Results 
showed that the subjects in groups 1 and 2 demonstrated an increase in mean MP optical 
density as well as an improvement in VA, CS, glare recovery and visual distortion. This 
study, therefore, demonstrated that visual function is improved in patients with atrophic 
AMD following supplementation with either L alone or L in combination with co-
antioxidants, vitamins and minerals. However, the LAST study is open to legitimate 
criticism on the basis of the small number of patients recruited into each arm of the 
investigation, and the short follow-up i.e. only 12 months (compared to e.g. AREDS).  
 The Carotenoids in Age-Related Maculopathy (CARMA) study was a 
randomised, double blind, placebo controlled clinical trial of L (12mg) and Z (0.6mg) 
supplementation with co-antioxidants versus placebo in patients with AMD.
294
  This 
study included 433 subjects, who were recruited and randomly assigned to the treatment 
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or the placebo arms of the study. Although the primary outcome measure (CDVA at one 
year) did not differ between the placebo and the intervention arms of the study, it was 
noted that CDVA was significantly better in the intervention arm of the study at 36 
months follow-up. In addition, an increase in serum L was associated with significantly 
improved CDVA and slowing of progression along the AMD severity scale.
171
  It is 
important, however, to note there are several limitations in the CARMA study design, 
despite it being an RCT. These limitations include a relatively small sample size, 
particularly at 36 months (n = 41, 20 in the intervention group and 21 in the placebo 
group), and the questionable appropriateness of its primary outcome measure (CDVA at 
12 months), given the chronic nature of AMD. 
  
Carotenoids = Macular carotenoids assessed in the study; L = Lutein; Z = Zeaxanthin; VP = Visual Performance; n = 
number of subjects participating in study; Age = Age range (years) of subjects in study; RCT = Randomised control 
trial; LAST = Lutein Antioxidant Supplementation Trial; CARMA = Carotenoids in Age-Related Maculopathy; LISA 
= Lutein Intervention Study Austria; ZVF = Zeaxanthin Visual Function; CARMIS = Carotenoids in Age-related 
Maculopathy Italian Study; PRS = prospective randomised study; - = data unavailable. 
*20mg taken for first 3 months and 10mg taken for remaining 3 months 
†mean(±sd) 
¹macular pigment measurements were obtained in the study 
 
The optical, anatomical and antioxidant properties of MP have generated a 
consensus that MP plays an important role in vision. Many studies have already 
demonstrated the positive cross-sectional association between measures of MPOD and 
measures of visual performance, including: CDVA, CS, GD, photostress recovery, 
Table 4.2 Interventional studies investigating the effect of supplementation with the macular 
carortenoids in subjects with AMD 
Principal Author Study Year n Study Design Age Carotenoids Finding 
Richer et al - 1999 14 Case Series 61-79 L (14mg) Improved VP 
Olmedilla et al - 2001 5 Case Series 69-75 L (15mg) Improved VP 
Richer et al LAST 2004 90 RCT 68-82 L (10mg) Improved VP¹ 
Bartlett et al - 2007 25 RCT 55-82 L (6mg) No benefit 
Beatty et al CARMA 2007 433 RCT 50+ L (12mg) & Z (0.6mg) Improved VP¹ 
Weigart et al LISA 2011 126 RCT 50-90 L (20mg/10mg)* Improved VP¹ 
Richer et al ZVF 2011 60 RCT 75(±10)† Z (8mg) & L (9mg) Improved VP¹ 
Sasamoto et al - 2011 33 Case Series 65(±9)† L (6mg) Improved VP¹ 
Piermarocchi et al CARMIS 2011 145 PRS - L (10mg) & Z (1mg) Improved VP 
Jentsch et al Lutega 2011 172 RCT 50+ L (10mg/20mg) & Z (1mg/2mg) Improved VP¹ 
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critical flicker fusion frequency, colour vision (amongst others).
29-33, 295, 296
  One might 
hypothesise, therefore, that an increase in MPOD will be paralleled by an improvement 
in vision. Indeed, increases in MPOD correlated significantly with decreases in mean 
differential light threshold (assessed by microperimetry), suggesting that augmentation 
of MPOD enhances ROS.
35
  It is important to note that psychophysical function is 
adversely affected in AMD,
160
  and this is confounded by age-related decline in many 
aspects of visual function in the absence of macular pathology.
297-299
  Therefore, a 
demonstrable improvement (or even stabilisation) in visual function in response to 
supplemental macular carotenoids in an older population with a known degenerative 
disease should be deemed beneficial. In this context, it is interesting to note that nine of 
the ten studies investigating changes in visual performance following supplementation 
with macular carotenoids in AMD subjects have demonstrated an improvement in visual 
function, and the remaining study consisted of only 25 subjects supplemented with only 
6mg L (alone), and even here vision did not deteriorate.  
 
Trials awaiting completion 
There are a number of trials underway investigating the putative protective role of L and 
Z in individuals with AMD. The AREDS 2 is an on-going multi-centre RCT (n=circa. 
4000) evaluating the impact of supplemental L and Z (and/or omega-3) on the 
progression of intermediate to advanced AMD and the influence of these supplements 
on VA. Additionally, it seeks to assess whether modified forms of the original AREDS 
supplement, with reduced zinc and no beta-carotene, work as effectively as the original 
supplement in reducing the risk of progression to advanced AMD. 
AREDS 2 is expected to be completed in December 2012 
(http://clinicaltrials.gov/ct2/show/NCT00345176?term=AREDS2&rank=1). The results 
of AREDS 2 will provide valuable and timely data on the potential role of antioxidants, 
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including L and Z, in delaying AMD progression, and will inform current professional 
practice with respect to the role of dietary modification and/or supplementation in 
patients with AMD. A limitation of the trial, however, rests on the fact that MP is not 
being measured. Therefore, a finding that supplemental L and Z in AREDS 2 are not 
beneficial cannot be interpreted to mean that MP augmentation is not beneficial, as the 
latter will not have been demonstrated. Further, it is likely that a very high proportion of 
participants in the US-based AREDS 2 will have been supplementing with dietary 
antioxidants for many years, thereby contaminating the baseline findings for all study 
groups (further hindered by a short wash-out period of only thirty days in subjects who 
may have been supplementing for many years), and, therefore, compromising the trial’s 
capacity to demonstrate a beneficial effect of supplementation. In fact, a recent baseline 
analysis on AREDS 2 subjects from one AREDS 2 centre that is assessing MP levels 
has reported unusually high baseline MPOD levels relative to an age-matched control 
group which did not regularly consume carotenoid supplements.
300
  Also, since AREDS 
2 is only investigating rates of progression among high risk patients (for advanced 
AMD), it therefore, cannot answer one of the most crucial questions with respect to 
carotenoid supplementation – does it prevent/delay AMD onset, or does it reduce 
progression in earlier stages of the condition? 
4.5.2.3 Observational studies 
A large number of studies have investigated the relationship between dietary intake of 
the macular carotenoids and AMD.
104, 301-307
  Of these ten published observational 
studies, six reported that a high dietary intake of the carotenoids was associated with a 
reduced risk of AMD. The relationship between AMD and serum concentration of the 
macular carotenoids has also been investigated,
75, 303, 308-315
  and of the ten published 
studies in this respect, seven have shown that low serum concentrations of the macular 
carotenoids are associated with increased risk of this condition. (Table 4.3) 
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Table 4.3. Observational studies investigating the relationship between the macular carotenoids and age-related macular degeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: carotenoids = macular carotenoids assessed in the study; L = lutein; Z = zeaxanthin; n = number of subjects; Age = age range (years) of subjects in 
study; EDCCS = Eye Disease Case Control Study; BDES = Beaver Dam Eye Study; NHANES = National Health and Nutrition Examination Survey; BMES = Blue 
Mountains Eye Study; CAREDS = Carotenoids in Age-Related Eye Disease Study; AREDS = Age-Related Eye Disease Study; POLA = Pathologies Oculaires Liées à 
l'Age; EES = European Eye Study; - = data unavailable. 
*cases/controls 
‡for late stages of AMD
Observational Dietary Studies      
Principal Author Study Year n Study Design Age Carotenoids 
Nutrient/AMD 
relationship 
Seddon et al EDCCS 1994 356/520* Case Control 55-80 L&Z Inverse 
VandenLangenberg et al BDES 1996 1968 Cohort 45-86 L&Z None 
Mares-Perlman et al NHANES III 2001 8222 Cross-sectional 40+ L&Z Inverse 
Flood et al BMES 2002 2335 Cohort 49+ L&Z None 
Snellen et al - 2002 72/66* Case Control 60+ L Inverse 
Moeller et al CAREDS 2006 1787 Cross-sectional 50-79 L&Z None 
San Giovanni et al AREDS 2007 4519 Case Control 60-80 L&Z Inverse 
Tan et al BMES 2008 2454 Cohort 49+ L&Z Inverse 
Cho et al  2008 66,993 Cohort 50+ L&Z None 
Olea et al - 2012 52 Cross-sectional mean=79 L&Z Inverse‡ 
Observational Serum Studies        
- EDCCS 1993 421/615* Case Control - L&Z Inverse 
Mares-Perlman et al BDES 1995 167/167* Case Control 43-86 L&Z None 
Mares-Perlman et al NHANES III 2001 8222 Cross-sectional 40+ L&Z Inverse 
Simonelli et al - 2002 48/46* Case Control mean=67 L&Z None 
Gale et al - 2003 380 Cross-sectional 66-75 L&Z; L; Z Inverse (Z only) 
Cardinault et al - 2005 34/21* Case Control 72-74 L; Z None 
Delcourt et al POLA 2006 899 Cohort 60+ L&Z Inverse (esp. Z) 
Fletcher et al EES 2008 2283/2117* Cross-sectional 65+ L; Z Inverse (esp. Z) 
Michikawa et al - 2009 722 Cross-sectional 65+ L&Z Inverse‡ 
Zhao et al - 2011 263 Cross-sectional 50-88 L&Z Inverse‡ 
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4.5.3 Clinical trials investigating the macular carotenoids in normal subjects 
Many studies have reported on the cross-sectional relationship between MP and a 
plethora of visual performance parameters, and a number of trials have investigated the 
impact of supplementation with the macular carotenoids on visual performance in 
subjects without disease (see Table 4.4)
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Table 4.4 Interventional studies investigating the impact of the macular carotenoids on visual performance in normal subjects. 
Principal author(s) Year n 
Placebo-
control 
Carotenoids Visual performance tests 
Study duration 
(months) 
Observed visual benefit 
following supplementation 
Monje
a
 1948 14 No L dipalmitate 
Dark adaptation & 
scotopic VA 
2-6 Yes‡ 
Wustenberg
a
 1951 7 No L dipalmitate Dark adaptation - No 
Klaes & Riegel 1951 - No L dipalmitate Dark adaptation - Yes 
Andreani & Volpi
a
 1956 10 No L dipalmitate Dark adaptation - Yes 
Mosci
a
 1956 - No L dipalmitate Light sensitivity - Yes 
Hayano
a
 1959 - No L dipalmitate Dark adaptation - Yes† 
Wenzel 2006 10 Yes 30mg L + 2.7mg Z Photophobia 3 Yes 
Rodriguez-Carmona 2006 24 Yes* 
10mg/20mg of 
L/Z/L+Z 
B/Y colour discrimination 12 No 
Kvansakul 2006 34 Yes 
10mg L/10mg 
Z/combination 
Mesopic CS 6 Yes 
Barlett & Eperjesi 2008 29 Yes 6mg L 
VA (dist.&near), CS, 
photostress recovery 
18 No 
Stringham & 
Hammond 
2008 40 No 10mg L + 2mg Z 
Photostress recovery & 
grating visibility 
6 Yes; both 
Nolan 2010 121 Yes 12mg L + 1mg Z 
VA, CS, GD, photostress 
recovery 
12 Yes; CS, GD 
Loughman 2012 36 Yes 
10mg L+2mg Z+10mg 
MZ/20mg L+2mg Z 
VA, CS, GD, photostress 
recovery 
6 Yes; VA, CS, GD 
Abbreviations: carotenoids=macular carotenoids investigated; L=lutein; VA=visual acuity; Z=zeaxanthin; B/Y=blue/yellow; CS=contrast sensitivity; GD=glare 
disability; MZ=meso-zeaxanthin; - =data not available. 
a 
data obtained from Nussbaum
316
  
*for second 6 months of the study 
†proportional to serum L 
‡described as having a “transient” benefit 
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4.5.3.1 COMPASS 
The Collaborative Optical Macular Pigment ASsessment Study (COMPASS) was a 
RCT designed to investigate the impact of supplementation with macular carotenoids 
versus placebo, on MPOD and visual performance. One hundred and twenty-one normal 
subjects were recruited (age range: 18 - 41 years) to COMPASS. The active group 
consumed 12mg of L and 1mg of Z (but no MZ) every day for 12 months (n=61), while 
the remaining subjects were assigned to placebo. A range of psychophysical tests were 
used to assess visual performance, including: CDVA, CS, GD and photostress recovery. 
Subjective visual function was determined by questionnaire and MPOD was measured 
using customized heterochromatic flicker photometry (cHFP). The results of this study 
showed that central MPOD increased significantly in the active group (but only at the 
12 month time point), whereas no such augmentation was demonstrable in the placebo 
group. Although this observed increase in MPOD did not result, generally, in a 
demonstrable improvement in visual performance, statistically significant differences in 
mesopic CS (with and without glare) were observed between those who had high 
MPOD and those who had low MPOD at 12 months, whereas this was not the case at 
baseline.
172
   
  
4.5.3.2 MOST Vision 
The widest range of short-wavelength light filtration is achieved in the presence of all 
three macular carotenoids (L, Z and MZ).
317, 318
  Emerging data further indicates that 
supplementation with all three macular carotenoids increases MPOD faster and to a 
greater extent when compared to a formulation that does not contain MZ. In vitro 
studies have also shown that maximum anti-oxidant capacity of the pigment is 
dependent upon the presence of all three macular carotenoids.
319
  Investigators, 
91 
 
therefore, have begun to study the impact of supplementation with a formulation 
containing L, Z and MZ on MPOD and on visual performance. 
 The Meso-zeaxanthin Ocular Supplementation Vision Trial (MOST Vision) 
investigated the effect of supplementation of different carotenoid dose combinations, on 
visual performance in normal subjects.
170
 The 36 recruited subjects were assigned to 
one of three groups, as follows: the first was given a high dose (20mg) of L and 2mg Z 
(Group 1); the second group was given 10mg L, 10mg MZ and 2mg Z (Group 2); and 
the third group was given placebo (Group 3), every day for six months. A statistically 
significant rise in MP was observed (notably, three months following commencement of 
supplementation) only among subjects supplemented with a formulation containing all 
three macular carotenoids, including MZ (Group 2). Statistically significant 
improvements in CDVA were observed at six months, but only for subjects in Group 2. 
Statistically significant improvements in CS were noted across a range of spatial 
frequencies, under photopic (3, 12 and 18cpd) and mesopic conditions (1.5, 3, 12 and 
18cpd), again only among subjects in Group 2 (with a single exception of improved CS 
at a single spatial frequency [6cpd] in the high L group [Group 1]). There were no 
statistically significant improvements in mesopic or photopic GD between baseline and 
six months in Groups 1 and 3. However, there was a demonstrable improvement in 
mesopic and photopic GD for subjects in Group 2 for all spatial frequencies tested (with 
the exception of 18cpd).  
 
4.5.3.3 Supplementation with the macular carotenoids in subjects with an atypical 
MPOD spatial profile 
A study investigated the relationship between MP and known risk factors for 
developing AMD amongst 828 normal subjects between the ages of 18 and 55. The 
study demonstrated a relative lack of MP in association with tobacco use and with a 
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family history of AMD. Also, the authors report an age-related decline in MP, 
suggesting that the risk that such variables represent for AMD may be attributable, at 
least in part, to a parallel lack of MP. It appears, therefore, that, prior to disease onset, 
known risk factors for AMD are independently associated with a relative lack of MP.
320
  
 Of the 828 subjects, a proportion (12%) exhibited a “central dip” (i.e. they did 
not exhibit the typical central peak that declines in from the foveal centre) in their 
MPOD spatial profile. Interestingly, this central dip was associated with tobacco use 
and increasing age,
321
  suggesting that such atypical spatial profiles of MP may 
(independently) represent risk for AMD. Given that MZ is the dominant carotenoid in 
the foveal centre, it has been hypothesised that the observed central dip in the MP 
spatial profile (found in 12% of the study population) is attributable to a relative lack of 
this carotenoid. Further, and since retinal MZ is formed from retinal L (but not retinal 
Z), the observed central dip in the MP spatial profile may be the result of an inability 
among these subjects to convert retinal L to MZ, and therefore such subjects may 
require this carotenoid in supplement form if they are to achieve a typical and desirable 
spatial profile characterised by a central peak and an associated decline from the foveal 
centre. 
 The effect of supplementation on a group of subjects that exhibited a central dip 
in their MP spatial profile has also been investigated.
322
  Thirty-one subjects were 
assigned to one of three intervention groups, as follows: one given a 20mg of L and 
2mg of Z (Group 1); the second group was given 10mg L, 10mg MZ and 2mg Z (Group 
2); and the third group was supplemented 17mg MZ and 3mg L (Group 3). Subjects 
took one capsule a day for eight weeks. A significant increase in MPOD was not 
demonstrable among subjects supplemented with high doses of L (Group 1), at any 
eccentricity. Subjects supplemented with high doses of MZ (Group 3) exhibited 
significant increases in MPOD at the centre of the MP spatial profile, but at no other 
93 
 
eccentricity. Subjects in the combined carotenoid group (Group 2, containing L, Z and 
MZ) exhibited a significant augmentation of MPOD at 0.25° and at 0.5° eccentricity, 
and a trend towards a rise in MP approaching statistical significance at all other 
eccentricities. The authors concluded that these atypical spatial profiles of MP, 
characterised by central dips, which have been shown to be associated with risk for 
AMD,
321
 can be normalised following supplementation with a formulation containing 
MZ, but not with a formulation that is lacking this carotenoid, at least not over an eight-
week study period. Augmentation of MPOD across its spatial profile was best achieved 
with a formulation containing all three macular carotenoids during the study period. 
Further trials, of longer duration and that explore different supplement 
doses/combinations, are required to support this finding. 
 
4.5.4 Serum and retinal response to supplementation with the macular carotenoids 
 
There have been many published studies on serum (Table 4.5) and retinal response (i.e. 
MPOD; Table 4.6) to supplementation with the macular carotenoids, in normal and in 
AMD subjects, and it is clear that serum carotenoid levels and MPOD rise in response 
to supplementation with MP’s constituent carotenoids. However, it is important to point 
out that the magnitude of response is influenced by many factors, including the type of 
carotenoid used (i.e. L, Z, MZ, independently or in combination), the concentration of 
carotenoid present in the supplement (dose), the duration of supplementation (time), 
individual characteristics (e.g. adiposity), and baseline MP levels.
323
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Table 4.5 Serum carotenoid response per milligram of supplemental carotenoid, following supplementation with the macular carotenoids. 
Principal Author Journal Year n Age L(mg) Z(mg) MZ(mg) 
L Response 
(µmol/L/mg) 
Z Response 
(µmol/L/mg) 
MZ Response 
(µmol/L/mg) 
Duration 
Normal Subjects            
Bone et al. JN 2003 21 19-59 2.4 - - 0.100 (p <0.05) - - 24 
Bone et al. ABB 2010 17 18-30 5 - - 0.035 (p<0.0001) - - 20 
   22 18-30 10 - - 0.071 (p<0.0001) - - 20 
   24 18-30 20 - - 0.053 (p<0.0001) - - 20 
   14 51-64 20 - - 0.071 (p<0.0001) - - 20 
Koh et al. EER 2004 6 58-72 10 - - 0.168 (p n/a) - - 19 
Berendschot et al. IOVS 2000 8 18-50 10 - - 0.072 (p<0.001) - - 12 
Zhao et al. AJCN 2006 8 50-70 12 - - 0.116 (p<0.01) - - 8 
Hughes et al. JID 2000 21 26–56 15 - - 0.092 (p<0.01) - - 4 
Hartmann et al. AJCN 2004 10 28-38 - 1 - - 0.152 (p n/a) - 42 
   10 28-43 - 10 - - 0.087 (p n/a) - 42 
Schalch et al. ABB 2007* 16 18-45 - 12.6 - - 0.064 (p n/a) - 24 
Bone et al. JN 2003 2 21-53 - 30 - - 0.014 (p n/a) - 12 
Thürmann et al. AJCN 2005 8 21-37 4.1 0.58  0.093 (p n/a) - - 42 
 AJCN 2005 8 24-34 20.5 2.9  0.064 (p n/a) - - 42 
Schalch et al. ABB 2007* 18 18-45 10.7 0.8 - 0.078 (p n/a) 0.063 (p n/a) - 24 
   19 18-45 10.2 11.9 - 0.037 (p n/a) 0.046 (p n/a) - 24 
Huang et al. IOVS 2008 40 64-86 10 2 - 0.041 (p n/a) 0.046 (p n/a) - 24 
Johnson et al. AJCN 2008 11 60-80 12 0.5 - 0.022 (p<0.001) 0.030 (p n/a) - 16 
Nolan et al. VR 2011 61 18-41 12 1 -  0.053 (p<0.001) -0.003 (p>0.05) - 48 
Johnson et al. AJCN 2000 7 33–54 19.7 1 - 0.018 (p<0.05) 0.016 (p<0.003) - 15 
Bone et al. JN 2003 2 42-53 30 1.5 - 0.063 (p n/a) 0 (p n/a) - 20 
Connolly et al. CER 2010 5 18-60 3.7 0.8 7.3 0.019 (p<0.05) -0.028 (p>0.05) 0.006 (p<0.05) 8 
Thurnham et al. BJN 2008 19 21-46 10.8 1.2 8 0.056 (p<0.01) 0.088 (p<0.001) 0.026 (p=0.004) 3 
Bone et al. NM 2007* 10 21-58 5.5 1.4 14.9 0.014 (p n/a) 0.121^ (p n/a) - 17 
Loughman et al.‡  2012 12 56±8 20 1 - 0.014 (p=0.139) 0.010 (p=0.045) - 24 
   12 51±13 10 2 10 0.066 (p=0.001) 0.015 (p=0.023) 0.009 (p=0.001) 24 
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AMD Subjects            
Connolly et al. CER 2010 5 18-60 3.7 0.8 7.3 0.012 (p<0.05) 0.035 (p>0.05) 0.004 (p<0.05) 8 
Koh et al. EER 2004 7 60-81 10 - - 0.157 (p n/a) - - 19 
Khachik et al. IOVS 2006 15 60+ 10 0.5 - 0.079 (p<0.0001) 0.076 (p<0.0001) - 24 
Trieschmann et al. EER 2007 97 51-87 12 1 - 0.036 (p<0.001) 0.004 (p=0.007) - 36 
Abbreviations: L=lutein; Z=zeaxanthin; MZ=meso-zeaxanthin; n=number of subjects participating in study; Age=age range (years) of subjects in study; duration=duration of 
supplementation (weeks); ABB=Archives of Biochemistry and Biophysics; BJN=British Journal of Nutrition; IOVS=Investigative Ophthalmology and Visual Science; 
AJCN=American Journal of Clinical Nutrition; JN=Journal of Nutrition; JID=Journal of Infectious Diseases; VR=Vision Research; EER=Experimental Eye Research; 
CER=Current Eye Research; NM=Nutrition and Metabolism; OPO=Ophthalmic and Physiological Optics; (-)=data unavailable; n/a=not available. 
*free (un-esterified) carotenoid supplement  
†includes MZ supplementation 
^refers to total Z+MZ 
‡ARVO abstract 
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Table 4.6 Studies reporting on macular pigment optical density response to supplementation with the macular carotenoids. 
Principal Author Year n Age L 
mg/d  
Z 
mg/d  
MZ  
mg/d 
Duration 
(weeks) 
Tec Retinal  
ecc 
PF MP 
 rise 
Sig. 
NORMAL subjects - dietary modification          
Hammond et al.324  1997 10 30-65 11.2 0.6 0 15 HFP 0.5° 5.5° ~ 0.05 p < 0.05 
  2 30-65 0.4 0.3 0 15 HFP 0.5° 5.5° ~ 0.05  - 
  1 30-65 10.8 0.3 0 15 HFP 0.5° 5.5° ~ 0.05 p < 0.05 
Johnson et al.325  2000 7 33-54 11.2 0.57 0 15 HFP 0.5° 5.5° ~ 0.07 p < 0.05 
NORMAL subjects - supplement modification          
Landrum et al.326  1997 2 42-51 30 0 0 20 HFP 0.75° 8° ~ 0.20  - 
Berendschot et al.327  2000 8 18-50 10 0 0 12 SLO  0.75° 14° ~ 0.05  p = 0.022 
  8 18-50 10 0 0 12 SA 0.75°  -  ~ 0.04  p < 0.001 
Aleman et al.328  2001 8 11-59 20 0 0 24 HFP 0.17° 5-7° 0.07 p = 0.04 
  8 11-59 20 0 0 24 HFP 0.5° 5-7° 0.07  - 
  8 11-59 20 0 0 24 HFP 1° 5-7° 0.08  - 
  8 11-59 20 0 0 24 HFP 2° 5-7° 0.04  - 
Bone et al.329  2003 2 19-59 30 1.5 0 20 HFP 0.75° 8° ~ 0.20  - 
  1 53 0 30 0 17 HFP 0.75° 8° ~ 0.07  - 
  21 19-59 2.4 0 0 17 HFP 0.75° 8° ~ 0.04  - 
  12 19-60 20 0 0 17 HFP 0.75° 8° ~ 0.06 p < 0.05 
  2 26-27 5 0 0 17 HFP 0.75° 8° ~ 0.03  - 
Koh et al.330  2004 6 64-81 20 0 0 20 HFP 0.5° 6° 0.07 p > 0.05 
Bernstein et al.331  2004 8 <61 20 0 0 16 HFP 0.75° 8° 0.04  - 
  8 <61 20 0 0 16 RRS  -  - 76RC  - 
Bone et al.332  2007 10 21-58 5.5 1.4 15 17 HFP 0.75° 8° ~ 0.07 p < 0.05 
Wenzel et al.333  2007 3 24-52 30 2.7 0 17 HFP 0.33° 7° 0.07 p < 0.001 
  3 24-52 30 2.7 0 17 HFP 0.5° 7° 0.07 p < 0.002 
  3 24-52 30 2.7 0 17 HFP 1° 7° 0.046 p< 0.002 
  3 24-52 30 2.7 0 17 HFP 2° 7° 0  - 
Schalch et al.334  2007 23 18-45 10.7 0.8 0 17 HFP 0.5° 5.5° 0.06 p = 0.04 
  23 18-45 0 12.6 0 17 HFP 0.5° 5.5° 0.01 p > 0.1 
  23 18-45 10.2 11.9 0 17 HFP 0.5° 5.5° 0.06 p = 0.04 
Johnson et al.335   2008 11 60-80 12 0.5 0 16 HFP 1.5° 7°  - p < 0.05 
  11 60-80 12 0.5 0 16 HFP 3° 7°  - p < 0.01 
Stringham et al.336  2008 40 17-41 10 2 0 24 HFP 0.25° 10° 0.19  - 
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  40 17-41 10 2 0 24 HFP 0.5° 10° 0.16  - 
  40 17-41 10 2 0 24 HFP 1° 10° 0.1  - 
  40 17-41 10 2 0 24 HFP 3° 10° 0.07  - 
  40 17-41 10 2 0 24 HFP 7° 10° 0.03  - 
Connolly et al.287  2010 5 30-85 3.7 0.8 7.3 8 HFP 0.25° 7° 0.16 p < 0.05 
  5 30-85 3.7 0.8 7.3 8 HFP 0.5° 7° 0.16 p < 0.05 
Nolan et al.337  2011 61 18-41 12 1 0 52 HFP 0.25° 7° 0.12 p = 0.001 
  62 18-42 12 1 0 52 HFP 0.5° 7° 0.11 p = 0.001 
Loughman et al.170  2012 12 56±8 20 2 0 24 HFP 0.25° 7° 0.09 p = 0.092 
 2012 12 51±13 10 2 10 24 HFP 0.25° 7° 0.13 p = 0.002 
             
AMD subjects              
Principal Author Year n Age L 
mg/d  
Z 
mg/d  
MZ  
mg/d 
Duration 
(weeks) 
Tech Retinal 
ecc. 
PF MP  
rise  
Sig. 
Koh et al.330  2004 7 64-81 20 0 0 20 HFP 1° 6° 0.07 p > 0.05 
Trieschmann et al.338  2007 108 51-87 12 1 0 24 AF 1° 6° 0.1 p < 0.001 
Richer et al.339  2007 76  - 10 0 0 52 HFP 1° 7° 0.25 p < 0.05 
Connolly et al.287  2010 5 30-85 3.7 0.8 7.3 8 HFP 0.25° 7° 1.6 p < 0.05 
  5 30-85 3.7 0.8 7.3 8 HFP 0.5° 7° 1.6 p < 0.05 
Weigert35  2011 84 72±9 15 0 0 24 HFP 0.25° 7° 0.08 p <0.001 
Richer280  2011 25 76±9 0 8 0 52 HFP* 1° 7° 0.13† p = 0.03 
  25 74±11 9 8 0 52 HFP 1° 7° 0.20† p = 0.06 
  10 74±9 9 0 0 52 HFP 1° 7° 0.18† p = 0.03 
Beatty et al. 2012 246/63‡ 55+ 12 0.6 0 104 RRS central 3° - 61 (RC) p < 0.001 
Abbreviations:  L = Lutein (mg/day); Z = Zeaxanthin (mg/day); MZ = Meso-zeaxanthin (mg/day); Tec = technique used to measure MPOD (macular pigment optical density); 
n = Number of subjects participating in study; Age = Age range (years) of subjects in study; Retinal ecc.= retinal eccentricity; PF = Parafovea stimulus; AJCN = American 
Journal of Clinical Nutrition; IOVS = Investigative Ophthalmology and Visual Science; ABB = Archives of Biochemistry and Biophysics; OPO = Ophthalmic and 
Physiological Optics; EER = Experimental Eye Research; NM = Nutrition and Metabolism; OPT = Optometry; JN = Journal of Nutrition; OVS = Optometry and Vision 
Science; RC = Raman counts; ODU = Optical density units; HFP = Heterochromatic flicker photometry; AF = Autofluorescence; SLO = Scanning Laser ophthalmoscope; SA 
= Spectral Analysis; AMD = Age related Macular Degeneration; RRS = Resonance Raman Spectroscopy; RC = raman count- = data unavailable. 
*modified HFP technique (QuantifEYE®) 
†measurements from right eyes in the study 
‡246 at baseline, 63 at year 2 
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The data suggest that supplementation with all three macular carotenoids results 
in the greatest and broadest response in terms of MP augmentation and changes in its 
spatial profile. Therefore, and given that the antioxidant capacity of MP is maximised in 
the presence of all three macular carotenoids,
319
  and where the objective is to augment 
MP and to thereby putatively confer protection against AMD, current evidence suggests 
that supplementation with all three macular carotenoids is most likely to (1) limit 
(photo)-oxidative retinal injury with a consequential reduction in risk of AMD 
development or progression and (2) maximally enhance visual performance and 
ameliorate GD.  
Interestingly, a study by Bone and Landrum has shown that serum levels of L 
and Z rise and fall rapidly following commencement and discontinuation of 
supplementation with the macular carotenoids, respectively. In contrast, MP optical 
density increases more slowly from baseline following commencement of 
supplementation with the macular carotenoids, and returns to baseline levels more 
slowly following discontinuation of supplementation, reflecting a slow biological 
turnover or these carotenoids at the macula.
326
  A recent study investigated the impact of 
dietary deprivation of all L- and Z-containing foodstuffs on serum carotenoid levels and 
on MPOD, over a period of six weeks. In brief, a rapid decline in serum levels of L and 
Z, and also in MPOD, was observed in response to this dramatic dietary change by 
week three. The resumption of a normal diet resulted in a 40% recovery in MPOD 
levels within two weeks.
340
   
 
4.5.5 Conclusion 
In summary, the properties of MP, namely its central retinal location, its pre-receptoral 
filtration of damaging short-wavelength light and its ability to quench free radicals, 
suggest that it plays a key role in the aetiopathogenesis of AMD and its progression, in 
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addition to contributing to the optimisation of visual performance (in subjects with and 
without disease). Level 1 evidence has demonstrated that supplemental dietary 
antioxidants reduce the risk of vision loss in AMD, although evidence of this quality for 
supplementation with the macular carotenoids is still lacking. The visual performance 
hypothesis of MP, on the other hand, is now accepted, with many clinical trials 
reporting that macular carotenoid supplementation demonstrably enhances visual 
performance in subjects with and without disease. Clinical trials have repeatedly shown 
that dietary supplementation with the macular carotenoids (L, Z and/or MZ) results in 
augmentation of MP, and the best response in terms of augmentation, changes in spatial 
profile of the pigment, global fortification of the antioxidant defenses of the tissue to be 
protected and in terms of visual performance, appears to be a supplement containing all 
three macular carotenoids. These trials (involving all three macular carotenoids), 
however, have been limited by several factors, including small numbers of subjects and 
inadequate masking, such that definitive conclusions cannot yet be drawn. 
To effectively investigate the putative protective role of carotenoid supplements 
in AMD, including a possible role in prevention of this condition, an RCT of 
considerable length (at least a decade) would be required. As a consequence, it is 
important that we appraise the totality of currently available evidence in order to assist 
eyecare professionals to make well-informed decisions with respect to the prevention 
and/or delay of AMD onset and/or its progression. In this context, it would appear that 
supplementation with the macular carotenoids offers the best means of fortifying the 
antioxidant defenses of the macula, thus putatively reducing the risk of AMD and/or its 
progression, and of optimising visual performance. 
 
This work is divided into four principal areas; the rationale, methods, results and 
discussion of each is contained within its own chapter (Chapters 5-8).  
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Chapter 5. Visual performance in patients undergoing intravitreal 
ranibizumab for neovascular AMD. 
5.1 Study rationale, aims and objectives. 
Considering the emergence of new therapies and treatment regimens for subjects with 
nv-AMD, and considering the complex nature of the visual experience, it is essential 
that visual performance is not judged solely on the outcomes of one visual task (most 
often, CDVA), either in clinical or research settings. This study was designed to assess 
the effect of anti-VEGF therapy in cases of nv-AMD on a subject’s visual performance 
and experience, through a range of psychophysical tests, which take into greater 
consideration the complexity of the visual environment. 
There is a strong rationale to support the administration of anti-VEGF therapy in 
spite of good presenting CDVA,
341
  as early treatment is essential in terms of preventing 
visual loss. However, it is well documented that the extent of visual improvement 
following anti-VEGF therapy is inversely dependent upon presenting CDVA, i.e. 
presenting CDVA is a prognostic indicator for improvement in CDVA following 
treatment, with greater acuity benefits accruing in those with poorest baseline 
CDVA.
342, 343
   Therefore, a patient who presents for anti-VEGF therapy with relatively 
good CDVA e.g. 6/7.5, will not exhibit the same level of improvement as a patient who 
presents with CDVA of 6/30, for example, purely due to ceiling effects. This finding 
may lead one to believe that the treatment is not having a functional benefit in the case 
of the high acuity patient, whereas there may be important parameters of visual function 
that are improving/changing but that are not being detected by a measure as crude as 
CDVA. In addition, if other measures of vision are depleted (and CDVA preserved), 
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then CDVA is also not detecting a certain amount of functional loss, which is important 
with respect to (re)treatment strategies. 
The vast majority of studies investigating visual function in subjects with nv-
AMD (i.e. assessing disease severity, determining when to commence, cease or 
recommence treatment), have depended, for the most part, on the measurement of 
CDVA. Considering the complexity of visual experience, and the known range of 
methods available to ascertain a more realistic and thorough appreciation of visual 
function, it would seem reasonable to conclude that the full extent of the effect of anti-
VEGF therapy on visual function has yet to be elucidated. The current study has sought 
to more deeply probe and investigate visual performance beyond CDVA, both in terms 
of understanding how to evaluate disease severity, and also in terms of assessing 
functional outcomes of visual performance following intravitreal anti-VEGF therapy in 
subjects with nv-AMD. 
 
5.2 Methods 
5.2.1 Study design 
Suitability for inclusion in this prospective study was confirmed by an ophthalmologist, 
in compliance with the following inclusion criteria: the study eye must be suffering 
from active nv-AMD, and be scheduled to commence, recommence or continue a 
course of intravitreal ranibizumab and have a baseline CDVA of logMAR 0.7 or better. 
Exclusion criteria included a history of diabetes mellitus, the presence of physical or 
mental impairment, or any visually important ocular comorbidity. All patients were 
recruited from the Institute of Eye Surgery, Whitfield Clinic, Waterford. In cases where 
both eyes were being treated, the eye with the better CDVA was selected for the study. 
Ethics approval was granted by the Dublin Institute of Techonology Ethics Committee 
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(Appendix 1), and informed consent was secured from each subject (Appendix 2). The 
research was conducted in accordance with the principles of the Declaration of Helsinki.  
  A diagnosis of nv-AMD was made by a retinal specialist on the basis of clinical 
examination, OCT and FFA. The standard regime of treatment (following initial 
diagnosis) included three consecutive monthly injections, followed by monthly 
evaluation for further treatment. Subsequent injections were administered based on 
signs of lesion activity on OCT and FFA, as per previously described protocol,
344
  and 
typically upon resolution of fluid and/or cysts (determined by OCT), one more 
intravitreal injection of ranibizumab was administered. Two weeks following that 
intraocular injection, FFA was repeated. Where lesion inactivity was angiographically 
confirmed, treatment was discontinued. 
Data were collected at baseline, and at monthly intervals (midway between 
monthly ranibizumab injections) within the 11 month study period. An exit visit was 
defined as the patient’s final study visit (two weeks after the preceding and final 
intravitreal injection in the study). Subjects exited the study either when the study 
period came to an end (n=20; after a maximum follow-up of 11 months; some of these 
patients may have continued with further intravitreal injections of ranibizumab 
following closure of the study), when treatment was discontinued on clinical grounds 
(n=23; in these cases it was deemed, clinically, that maximum realisable benefits of 
treatment had been achieved i.e. fluid/cysts resolution and absence of leakage on FFA), 
when the patient was unable to continue in the study for unrelated health reasons (n=2) 
or when the patient elected to discontinue his/her participation in the study (n=2).  
Patients were naïve to all the tests involved, with the exception of CDVA. 
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5.2.2 The technique for the administration of an intravitreal injection of a 
pharmacological agent (ranibizumab 0.5mg) 
Valid and informed consent was obtained prior to the procedure, which included 
informing the patient of all risks inherent in the procedure. Patients were instructed to 
instill prophylactic antibiotics drops (chloramphenicol or exocin [ofloxacin]) into the 
conjunctival sac four times daily for three days prior to the date of each injection.  
On the day of injection, the following steps were taken: the pupil was 
pharmacologically dilated (tropicamide); povodine iodine was instilled into the 
conjunctival sac ten minutes prior to the injection; anesthetic (proxymethacaine) was 
instilled into the conjunctival sac five minutes prior to the injection; povodine iodine 
was once again instilled into the conjunctival sac approximately two minutes prior to 
the injection. 
The technique of intravitreal injection. Patient was supine. A sterile drape was 
used to cover the eye, and a speculum was used keep the eye open during the procedure. 
The intravitreal pharmocological agent (ranibizumab 0.5mg) was drawn up in a sterile 
syringe. Using a callipers, the intravitreal pharmocological agent was then injected (at 
90 degrees to the sclera), through the pars plana into the vitreous cavity (3.5mm and 
4mm from the limbus in pseudophakic and phakic eyes, respectively; Figure 5.1). Using 
the indirect ophthalmoscope, the central retinal artery was examined (the central retinal 
artery should be either pulsatile and/or pink in colour, and if pale in colour and non-
pulsatile, paracentesis should be considered). A topical antibiotic was then instilled, the 
lid speculum removed, and the eye and lid margins rinsed with sterile saline. Following 
the procedure, the patient was told to continue the antibiotic drops for five or six days, 
and to contact the eye clinic should any problems arise (a detailed information leaflet 
with contact numbers, was furnished to the patient with respect to such a need). 
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Figure 5.1 Left: The administration of intravitreal ranibizumab. Image courtesy of the 
Institute of Eye Surgery, Waterford, Ireland. Right: Schematic representation of an 
intravitreal injection through the pars plana. Image obtained from My Vision Test - 
www.myvisiontest.com/newsarchive.php?id=1321 
 
5.2.3 Visual acuity 
CDVA was measured for the study eye monocularly using the logMAR chart provided 
by Test Chart 2000 PRO® (Thomson Software Solutions, Herts, UK) at a test distance 
of 4m. The logMAR form of the ETDRS letterset were selected due to the benefits of 
regular logarithmic progression and equal legibility of letters.
345, 346
  CDVA was 
determined with the patient’s best subjective (distance) refraction. All tests were 
performed at a constant room illuminance of 870 lux. The patients were told that the 
charts have letters only, that they are allowed to guess, and that they should read slowly 
to achieve the best identification of each letter. The letters were presented in one 
isolated row at a time. The testing did not proceed until the patient had given a definite 
response. A visual acuity rating (VAR) was calculated for each patient (see below).
29
  
Points were awarded for all fully read lines. At the first incompletely read line, the 
letters of the line were changed using the software’s randomisation function and the 
patient was encouraged to attempt to read the new line. This process was repeated 
resulting in the patient being shown three different lines of letters of equal size. Each 
time, the score was recorded (each correctly identified letter was awarded one point, and 
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a full line of five correctly identified letters was awarded five points) and an average of 
the three scores was taken as the score of the line with the smallest legible letters read. 
After that, the next (smaller) line was presented and the patient was encouraged to read 
it. If any of the letters were identified correctly, one point per letter was added to the 
previous score and that was the VAR for the eye of that patient. For example, a patient 
achieving CDVA of logMAR 0.0 would receive a VAR of 100, and all additional letters 
identified would be added, so that logMAR -0.1, for example, would be recorded as 
105, while logMAR 0.1 would be recorded as 95. 
 
5.2.4 Contrast sensitivity and glare disability (Functional Vision Analyzer™) 
CS was measured using the Functional Vision Analyser™ (FVA; Stereo Optical Co., 
Inc – Chicago, USA), a sine wave grating contrast test system. CS was measured for the 
study eye, monocularly, at a constant room illuminance of 1.5 lux, with distance 
correction. Each patient was asked to look at five linear sine-wave grating charts of 1.5, 
3, 6, 12 and 18 cpd, respectively. Each chart consisted of nine circular patches 
containing gratings of decreasing contrast. The background of each patch tapered into a 
grey field (i.e. Gabor patch) to maintain the retinal illumination and avoid ghost images. 
The nine patches were arranged in two rows (five patches above, four patches below). 
The contrast step between each patch was 0.15 log units i.e. there was a 50% loss of 
contrast between consecutive patches. The patch subtended an angle of approximately 
1.7 degrees. Patients were instructed to identify the orientation of the gratings by 
choosing one of three options: gratings tilted left (+15°), gratings upright (0°) or 
gratings tilted right (-15°). Patients were instructed not to guess the orientation of the 
gratings (in order to optimize the accuracy of the measurement, as guessing would yield 
a 33% chance of a correct response). In cases of uncertainty, patients were advised to 
report that they were unable to determine the orientation of the gratings. The three-
106 
 
alternative forced-choice method was stopped after the first incorrect or “don’t know” 
response, and the last correct answer was recorded. The CS corresponding to that 
grating was taken as the CS score for that spatial frequency. The test was then repeated 
for the other spatial frequencies (increasing while testing), with the grating charts 
mounted as slides on a rotatable drum. 
Testing was performed under: mesopic (3 cd/m
2
) and photopic (85 cd/m
2
) 
background illumination conditions, in that order. Each patient was tested at a 
maximum of nine contrast levels at five spatial frequencies. If a subject could not 
determine the orientation of the highest contrast stimulus at any particular spatial 
frequency, they were given a nominal baseline value, which was chosen as half of the 
lowest CS value achievable for the particular spatial frequency. 
The procedure was repeated in a similar manner for GD, but with an additional 
glare light; 1 Lux for mesopic conditions, and 10 Lux for photopic conditions, inducing 
an estimated luminance increase of 30% and 12%, respectively. Glare light was 
achieved by 12 inbuilt white light emitting diodes (LEDs) arranged circumferentially in 
an oval pattern surrounding the gratings (ranging from 4.5° to 6° from central 
fixation).
347
  The LED glare source rendered a daylight simulating colour temperature of 
6500°K, and a spectral emission profile with a single large peak at 453 nm (close to 
peak MP spectral absorbance). 
 
5.2.5 Retinotopic ocular sensitivity 
ROS was measured by performing microperimetry, using the Microperimeter MP 1® 
(Nidek Technologies Srl, 6/A - 35020 Albignasego, Padova, Italy). ROS performs a 
similar function to visual field analysis, but has the added advantage of being able to 
test at the site of a lesion. 
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ROS was measured monocularly and without correction, at a constant room 
illuminance of 1.5 lux. The study eye was pharmacologically dilated with one drop of 
guttae Tropicamide BP 1% w/v minims® (Chauvin Pharmaceuticals Ltd, Ashton Road, 
Harold Hill, Routond, Essex, RM3 8SL, UK) fifteen minutes prior to the test. The other 
eye was covered for the duration of the test. The patient was given a hand-button, and 
was instructed to fixate at the presented fixation target, a red cross spanning three 
degrees from fixation. They were informed that they will see small lights appear, either 
on the fixation target or close to it, and were instructed to press the hand-button every 
time they see such a light, no matter how dim or bright it may appear. 
The central 16 degrees of fixation were examined. The examination pattern 
comprised 21 stimuli, presented under mesopic background illumination of 1.27 cd/m2 
(4 asb). The stimulus size was Goldmann III (26 minutes of arc), of white colour and of 
200 msec presentation duration. Stimulus intensity ranged from 20 dB (dimmest [4 
asb]) to 0 dB (brightest [400 asb]); an increase of 1 dB equates to 0.1 log reduction in 
stimulus intensity (asb). In order to reduce testing time, the threshold values were 
determined for four paracentral loci (one in each quadrant of the visual field being 
examined); the initial attenuation of the stimulus was set at 10 dB, in this case. The 
thresholds for these four test loci were then used as the starting intensities for testing 
sensitivities of the remaining loci in each of the corresponding quadrants. This protocol 
has been previously utilised.
348
  Thresholds were determined using a 4-2 linear staircase 
strategy (which uses one reversal to determine threshold). At any given locus, the initial 
(pre-test) intensity value was presented, and depending on whether this stimulus was 
seen or not seen, the intensity of the stimulus was then either decreased or increased by 
4 dB, respectively. At reversal, the intensity of the stimulus then increased/decreased in 
increments corresponding to 2dB, until such a point as the stimulus was no longer 
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detectable. The eye tracking function was used for the duration of the test. Once all 21 
stimuli had been presented, a fundus colour photograph of 45 degrees of the field of 
view was taken using the built-in colour camera (resolution 1392x1038) using a flash 
intensity of 10 W/second. ROS was calculated for three areas: fixation (one stimulus); 
within central 5 degrees (including fixation) using an average of nine stimuli; and 
within 16 degrees of fixation (average of 21 stimuli).  
 
5.2.6 Reading performance 
Reading speed and near VA were measured with an English version of the standardised 
Radner Reading Chart (can assess both reading acuity and reading speed), the reliability 
and reproducibility of which have been established, both for subjects with normal 
vision, and for those with visual impairment.
349
 The reading chart consists of "sentence 
optotypes” that are highly comparable in terms of number of words (14 words), word 
length, position of words, lexical difficulty and syntactical complexity. Language 
specific characteristics were taken into account as were the number of letters and 
syllables per word, line, and sentence. Reading ability was tested monocularly with the 
patient’s reading correction on. The patient was instructed to hold the chart at a distance 
of 40cm, which was measured by the examiner, advised not to alter it during the 
examination, and was monitored for compliance by the examiner throughout the 
procedure. The sentences were covered with a piece of paper, and the patient was asked 
to uncover sentence after sentence, reading each one aloud as quickly and as accurately 
as possible. Reading acuity (the sentence of smallest print that was read with a fluency 
i.e. in less than 20 seconds) was expressed in logRAD (logarithm of the reading acuity; 
the angular subtense of these letters at the fixation distance used; the reading equivalent 
of logMAR). Reading errors were calculated by noting the number of missed or 
misspoken word(s) in the sentence. Errors were counted, even when immediately 
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corrected, and those of the last sentence were then included in the calculation of the 
reading acuity score (logRAD score = logRAD + 0.005, for each incorrectly read word 
of a subject’s last sentence). For example, a subject reads the 0.3 logRAD line and 
incorrectly reads two words, his/her score is 0.3 + (2 x 0.005) = 0.310. 
Reading speed was measured in seconds using a stopwatch (www.online-
stopwatch.com). Reading speed (wpm) was calculated for each sentence (acuity level) 
based on the number of words in a sentence and the time required to read the sentence 
(14 words x 60 seconds divided by the reading time in seconds). Reading speed was 
calculated at each visit based on the highest level of logRAD acuity achieved at baseline 
i.e. even if the logRAD value improved at the following visit, the best baseline logRAD 
value was used to calculate the reading speed to maintain continuity. Mean reading 
speed was calculated using the reading speed of each of the sentences read (across the 
range of print sizes) at any given study visit. 
 
5.2.7 Preferential hyperacuity 
Preferential Hyperacuity was measured using the Reichert Foresee PHP® Preferential 
Hyperacuity Perimeter (Figure 5.2). The PHP exploits the principle of visual attention 
being attracted to a more prominent stimulus
350
 and uses this to determine the size of 
any pathological distortion (PD) that may be present. The stimulus generated is a linear 
series of horizontal or vertical white dots (on a black background), and utilises the 
technique of dot misalignment to create a discontinuity, or artificial distortion (AD), in 
the line contour (see example on monitor in Figure 5.2). Depending on the size of the 
AD the patient may see one of four things: only the AD (if there is no PD or the PD is 
small), only the PD (if the AD is small), both the AD and the PD (if the two are of 
similar size), or neither (if the AD falls on a region of scotoma).
351
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Figure 5.2 The Reichert Foresee Preferential Hyperacuity Perimeter®. Image obtained 
from Grafton Optical. 
 
An explanatory tutorial and trial run were performed before each test (according 
to the standardized protocol) and the patients were supervised for the duration of the 
test. The patient’s chin was placed on an adjustable rest at a fixed distance from the 
screen (50cm), so that the patient’s line of sight was perpendicular to the centre of the 
screen. The normal reading correction was worn and the fellow eye was occluded. A 
trial frame was also available to provide the appropriate refractive correction, if required 
i.e. in cases where the subject presented with bifocals or multifocals, or without his/her 
reading spectacles.  
The device assesses approximately a total of 500 data points within the central 
14° of the subject’s visual field, each data point at a spatial resolution of 0.75°. Each 
stimulus was flashed (for 160ms) and the patient was asked to identify the location of 
perceived misalignments at each stimulus presentation, using a pen, on the touch-
sensitive screen. The technique relies on the presumption that when photoreceptors are 
anatomically undisturbed, no extra misalignment is perceived, other than the AD 
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presented. However, if the subject’s photoreceptors are slightly misaligned due to, for 
example, the presence of fluid as a result of CNV, or due to the elevation of the RPE as 
a result of drusen, additional pathological misalignments can be perceived by the patient 
and recorded by the PHP.  
 
The PHP output is presented in Figure 5.3 and its features are described, as follows: 
- Within/Outside normal limits: Within normal limits means that similar visual 
field findings are found in the normal population of intermediate AMD patients 
(dry AMD) in the normative database. Outside normal limits means that similar 
visual field findings are found in the population of CNV patients in the 
normative database. If the deviation is outside normal limits, a “p” value is 
given. For example, p < 1% means that the visual field defect in this test is 
found among 1% of the intermediate AMD population. Categories for p values 
are: p < 10%, p < 5%, p < 1%. 
- Reliability is determined by two indices, 1) False negative errors: the frequency 
with which the patient failed to respond to stimuli expected to be visible and 2) 
False positive errors: the frequency with which the patient responded to stimuli 
that could not have been seen. The test is reliable only if both reliability indices 
are reliable, which is reflected in an overall reliability result (“Yes” or “No”).  
- Hyperacuity deviation map: displays a spatial representation of the patient’s 
metamorphopsia (compiled using all the test parameters). The cross in the centre 
represents fixation. Each point in the map has a colour corresponding to the 
level of disturbance at this point. A metamorphopsia scale legend is provided, 
where darker colours correspond to larger disturbances. 
- A test score: an arbitrary score generated by the algorithm used to compare the 
presenting results to the normative database of intermediate and CNV patients. 
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The score is interpreted by looking at the p-value, which gives an indication of 
the chance of a test with this score of being an intermediate AMD (non-CNV) 
patient. In the example below (Figure 5.3), there is a 0.93% chance that this 
subject does not have intermediate AMD and is, therefore, very (99.07%) likely 
to have CNV. Of note, more recent versions of the PHP have removed the test 
score, which was deemed to be causing confusion. 
- Numbers of clusters: the number of detected metamorphopsia clusters in the 
data. 
- Total Integrated Intensity: Displays the progression in time of the integrated 
intensity of the distortion detected over all clusters in the test. 
- Total Area: Displays the progression in time of the total areas of distortion (area 
of all clusters in the test) in square degrees. 
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Figure 5.3 The Reichert Foresee Preferential Hyperacuity Perimeter® output. 
 
5.2.8 Assessment of retinal thickness 
Optical Coherence Topography (OCT) was performed using a Topcon 3D OCT-1000® 
(version 3.01, Mark I; Topcon Corporation, Tokyo, Japan) on each patient at each visit, 
as part of their normal pre- and post-injection assessment.  
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OCT is a non-invasive, cross sectional imaging technique, which uses low-
coherence interferometry to produce a high resolution, two-dimensional image of 
optical scattering from the internal microstructure of the eye.
352
  Image resolutions of 1–
15 µm (twice the magnitude of conventional ultrasound) can be achieved. 
Approximately twenty minutes following pupil dilation with Tropicamide (as 
described in ROS section, above), OCT was performed on each eye, separately. The 
patient placed his/her chin on a chinrest, was asked to look ahead at the centre of a large 
cross and keep their eyes open for five seconds. 
The central 1 mm mean foveal thickness (MFT), which has also been described 
as central subfield thickness in previous studies, was obtained from typical ETDRS 
macular thickness maps.
353-356
  Foveal thickness was defined as the distance between the 
inner and outer boundaries of the scanned image, identified using a validated internal 
algorithm, and did not include any fluid under the RPE. 
 
5.2.9 Subjective Visual Function (NEI VFQ) 
Subjectively perceived visual impairment in everyday life was evaluated using the NEI 
VFQ-25, Version 2000 (Appendix 3). The NEI VFQ-25 was developed to measure 
patients’ perception of vision-related function357-359  and is a reliable and valid vision-
specific quality-of-life instrument.
358, 360
  It is also the most frequently used measure of 
patient-reported, vision-related function in studies of nv-AMD.
359, 361, 362
  It has been 
validated by a study which confirms the responsiveness of the NEI VFQ-25 to changes 
in VA over time and the benefit of using it for a nv-AMD population receiving 
pharmacologic therapy.
363
  Further studies have shown its effectiveness in detecting 
differences in patients’ reading speed and CS.364, 365  
The NEI VFQ-25 contains 25 questions that measure different components of 
visual function, with thirteen additional optional items that enhance the reliability of 
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certain activities, all grouped within subscales. The 38-question version was used in this 
study. Scores range from 0 (worst) to 100 (best, perfect vision-related function). The 38 
questions fall within 12 subscales: one general health subscale and eleven related to 
vision including: general vision, near- and distance-vision activities, driving, vision-
specific dependency, social functioning, role difficulties, peripheral and colour vision, 
ocular pain, and mental health issues related to vision. The overall composite score (a 
number between 0 and 100) is calculated by taking the mean of all the subscales, 
excluding the general health subscale (see 
www.nei.nih.gov/resources/visionfunction/manual_cm2000.pdf).  
Two versions of the questionnaire are available; one, a self-administered 
version, the other, examiner administered (used in this study). The questions, and the 
possible answers, were read aloud by the examiner, and the patient was required to 
verbally indicate their choice. The questionnaire was administered at baseline, six 
months, and at the final study visit (either when their treatment concluded or the study 
period ended). In cases where a patient had less than six study visits, the questionnaire 
was administered at baseline and when the treatment concluded. Rasch analysis was 
applied to the questionnaire data, according to a recently developed protocol,
366
  using 
commercial software (WINSTEPS Rasch measurement computer program, version 
3.70.0.2; Beaverton, Oregon [http://www.Winsteps.com]), thus calibrating item 
difficulty and patient ability on the same scale. Values for the long-form visual function 
score (LFVFS), near vision score (NVS) and overall composite score are reported in 
this study. The overall composite score (a score between 0 and 100) combines the 
scores of 11 subscales encompassing items related to socio-emotional state, and items 
related to visual functioning. However, simply combining them in one common score 
will not accurately reflect the contribution of each to this overall score. This has largely 
been remedied through recently derived scales (socioemotional and visual functioning 
116 
 
scales) in combination with Rasch analysis.
229
  Rasch analysis transforms raw nominal 
numeric questionnaire values into a continuous scale, reducing noise and allowing for 
parametric statistical analyses of the data.
230
  
Since a clinically meaningful change in NEI VFQ is difficult to quantify, a 
additional supplementary question was asked at every visit (excluding baseline), where 
the patients were simply asked if their vision had “improved”, “deteriorated” or 
exhibited “no change” since their most recent injection (supplementary questionnaire; 
see Appendix 4). These results were used to generate an individual’s overall description 
of his/her experience over the course of the study period. Eligibility for inclusion in this 
aspect of the analysis required that an individual did not report both improvement and 
deterioration over the course of the study.   
 
5.2.10 Statistical Analysis 
Descriptive statistics were calculated for all measured variables, including demographic, 
ocular, psychophysical and morphological data, as well as data on subjective visual 
functioning (the questionnaire). VAR scores were used for the statistical analysis of 
CDVA data. Statistical analysis was performed using the software package PASW 
Statistics 18.0 (IBM Corp., Somers, NY, USA). 
Baseline and exit visit measures were compared using the paired-samples t test. 
Correlations between observed changes in MFT (and MFV) and observed changes in 
psychophysical measures following serial anti-VEGF therapy were investigated using 
Pearson correlations. Power analysis, for the sample size of 43 subjects (following 
dropouts), yielded the following results: for detecting a correlation of 0.5, the power of 
a sample of this size is 0.94; for detecting a change of half a standard deviation on a 
paired t test, the power is 0.89. Tests were 2-sided in all analyses and the 5% level of 
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significance was used throughout. Bonferroni adjustment was incorporated when 
multiple tests were performed. 
 
5.3 Results 
5.3.1 Baseline data 
Forty-seven patients (47 study eyes) met the inclusion criteria and were recruited into 
this study. Of the study eyes, 26 (55%) where pseudophakic and 21 (45%) were phakic, 
with no eyes with visually important lens opacities included. Baseline data were 
typically collected one or two days prior to intravitreal injection of ranibizumab in those 
cases where a course of anti-VEGF therapy was commencing or recommencing. The 
demographic, ocular, psychophysical and morphological data, as well as data on 
subjective visual difficulty, are given in Table 5.1. Of the 47 eyes, it was possible to 
obtain baseline measurements prior to the first injection (of that course of injections) in 
16 participants who were commencing or recommencing treatment, one of whom did 
not continue beyond baseline. It was hypothesised that data from the subgroup might 
differ from study eyes where serial intravitreal treatment was already underway, 
because of the recent (re)activation of nv-AMD in this subgroup, and therefore 
warranted separate analyses. The remaining 31 study eyes were already undergoing 
treatment when recruited into the study (mean [±sd] and range of duration of prior 
treatment: 7 [±5] and 1-20 months, respectively). Eight of the 47 study patients were 
concurrently undergoing serial intravitreal ranibizumab treatment in their fellow eye, at 
enrolment. A total of 248 injections of ranibizumab were administered to the study eyes 
over the course of the investigation. The mean (±sd) and range number of injections per 
patient was 5.4 (±2.8) and 1-10, respectively, over the course of the study period. 
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Table 5.1 Baseline demographic, ocular, psychophysical, morphological and subjective 
visual difficulty data, in subjects with nv-AMD. 
Variable n (%) Mean (±sd) Range 
Demographic    
Age (years) 47 (100%) 72.02 (9.61) 53 – 97 
    
Gender    
Male 11 (23.4%)  
Female 36 (76.6%)   
    
Ocular    
Eye    
Right 24 (51.1%)   
Left 23 (48.9%)  
    
Psychophysical    
CDVA    
Study eye 47 (100%) 87.64 (9.04) 64 – 104 
Fellow eye 47 (100%) 74.57 (31.15) 2 – 103 
    
Reading performance    
LogRad 47 (100%) 0.320 (0.2) 0.005 – 0.905 
Reading speed (wpm) 47 (100%) 85 (27) 31 – 142 
Mean reading speed (wpm) 47 (100%) 136 (35) 32 – 216 
    
PHP    
Total area 35 (74.5%)† 54.53 (44.60) 0.00 –  166.4 
Total integrated intensity 35 (74.5%)† 11.10 (14.16) 0.00 – 54.60 
    
CS (mesopic conditions)    
Frequency (cpd)    
1.5 46 (97.9%)† 20.43 (9.68) 3.50 – 36.00 
3 46 (97.9%)† 29.28(18.81) 5.00 – 80.00 
6 46 (97.9%)† 11.24 (9.45) 6.00 – 45.00 
12 46 (97.9%)† 4.15 (1.03) 4.00 – 11.00 
18 46 (97.9%)† 2.00 (0.00) 2.00 – 2.00 
    
CS (photopic conditions)    
Frequency (cpd)    
1.5 46 (97.9%)† 22.10 (13.24) 3.50 – 71.00 
3 46 (97.9%)† 35.74 (22.35) 10.00 – 114.00 
6 46 (97.9%)† 20.59 (18.80) 6.00 – 64.00 
12 46 (97.9%)† 5.67 (4.22) 4.00 – 22.00 
18 46 (97.9%)† 2.48 (2.50) 2.00 – 18.00 
    
GD (mesopic conditions)    
Frequency (cpd)     
1.5 46 (97.9%)† 11.46 (7.83) 3.50 – 36.00 
3 46 (97.9%)† 16.54 (12.32) 5.00 – 57.00 
6 46 (97.9%)† 7.65 (5.78) 6.00 – 33.00 
12 46 (97.9%)† 4.09 (0.59) 4.00 – 8.00 
18 46 (97.9%)† 2.00 (0.00) 2.00 – 2.00 
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GD (photopic conditions)    
Frequency (cpd)    
1.5 46 (97.9%)† 20.31 (12.09) 3.50 – 71.00 
3 46 (97.9%)† 35.98 (24.67) 5.00 – 114.00 
6 46 (97.9%)† 19.28 (19.23) 6.00 – 90.00 
12 46 (97.9%)† 5.78 (5.73) 4.00 – 30.00 
18 46 (97.9%)† 2.39 (1.61) 2.00 – 12.00 
    
Mean retinotopic ocular sensitivity (dB)   
Fixation 45 (95.7%)† 8.71 (5.92) 0.00 – 20 
Central 5° 45 (95.7%)† 9.70 (4.85) 0.44 – 19.56 
Central 16° 45 (95.7%)† 11.02 (4.53) 1.40 – 19.10 
     
Morphological (OCT)    
MFT (µm) 47 (100%) 232 (57) 126 – 403 
MFV (µm) 47 (100%) 0.18 (0.05) 0.10 – 0.32 
    
Subjective visual disability  
(questionnaire) 
  
Composite score 47 (100%) 89.92 (8.12) 65.91 – 100.00 
Rasch-scaled LFVFS 47 (100%) -1.71 (1.37) -6.07 – -0.07 
Rasch-scaled NVS 47 (100%) -2.19 (1.29) -4.38 – 0.10 
Abbreviations: nv-AMD=neovascular age-related macular degeneration; n=number of subjects; 
CDVA=corrected-distance visual acuity; LogRad=log reading acuity; Reading speed (at best baseline 
LogRad value); mean reading speed (for range of LogRad values); wpm=words per minute; 
PHP=preferential hyperacuity perimeter; CS=contrast sensitivity; cpd=cycles per degree; GD=glare 
disability; dB=decibel; OCT=optical coherence tomography; MFT=mean foveal thickness; MFV=mean 
foveal volume; LFVFS=long-form visual functioning score;  
†n≠47 as certain tests/measures could not be obtained or were unreliable 
 
5.3.2 Follow-up data 
Of the 47 patients recruited at baseline, four did not participate further. Of these, two 
fell ill (one patient was immobile due to a car accident, the other [aged 97] was not well 
enough to attend for further injections, and clinical review deemed that these events 
were unrelated to intravitreal injections of ranibizumab). A further two withdrew from 
the study for personal reasons. The mean (±sd) number of visits for the remaining 43 
subjects was 6 (±2.6), with a range of 2-10 study visits. Patients were assessed, and data 
collected, approximately two weeks following each monthly injection of ranibizumab.  
An analysis (2-tailed paired t test) was performed to investigate which, if any, of 
the measured parameters exhibited significant change over the course of the study 
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period (Table 5.2). The two time points chosen for this purpose were baseline and exit 
visits, respectively. An exit visit was defined as the patient’s final study visit (two 
weeks after the preceding and final intravitreal injection in the study period). Therefore, 
in some cases, the exit visit was associated with cessation of treatment (n=23) as it was 
deemed, clinically, that maximum realisable benefits of treatment had been reached i.e. 
no evidence of active CNV (on FFA). The remainder (n=20) coincided with the 
termination of the study period (11 months; and these patients may have, therefore, 
continued with further intravitreal injections of ranibizumab following closure of the 
study). 
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Table 5.2 Baseline and exit data for study eyes in the entire study group and subgroup, between baseline and exit study visits. 
 Entire group  Subgroup  
 Baseline Exit   Baseline Exit   
Variable Mean (±sd) Mean (±sd) p Bon.? Mean (±sd) Mean (±sd) p Bon.? 
CDVA study eye 87.9 (9.3) 88.7 (10.3) 0.480 N 89.1 (12.1) 91.3 (13.1) 0.387 N 
CDVA non-study eye 74.7 (30.2) 75.6 (30.1) 0.419 N 80.8 (23.3) 84.3 (21.9) 0.134 N 
Reading performance        
logRAD 0.33 (0.20) 0.28 (0.22) 0.032† N 0.25 (0.18) 0.19 (0.19) 0.139 N 
Reading speed 85 (28) 103 (46) 0.019 N 85 (26) 118 (56) 0.037 N 
Mean reading speed 136 (36) 146 (42) 0.005 N 148 (28) 166 (36) 0.005 N 
Preferential Hyperacuity Perimetry        
Ta 51.2 (41.5) 60.3 (45.4) 0.165 N 45.1 (32.8) 48.7 (46.0) 0.810 N 
Tii 9.8 (12.4) 11.9 (14.0) 0.250† N 6.9 (6.2) 9.6 (11.4) 0.674† N 
CS (mesopic)*         
Frequency (cpd)         
1.5 19.47 (10.1) 30.22 (21.00) 0.003 N 20.30 (12.15) 39.43 (26.12) 0.008 N 
3 28.93 (19.72) 42.02 (34.04) 0.004† N 32.47 (24.01) 53.13 (33.87) 0.036 N 
6 11.26 (9.78) 15.91 (17.32) 0.002† Y 12.80 (11.19) 26.67 (25.14) 0.070 N 
12 4.09 (1.17) 4.88 (2.27) p<0.001† Y 3.80 (0.77) 6.27 (3.35) 0.001† Y 
18 1.98 (0.15) 2.37 (1.25) p<0.001† Y 1.93 (0.26) 3.07 (1.98) 0.001† Y 
CS (photopic)*         
Frequency (cpd)         
1.5 21.50 (14.03) 27.22 (18.69) 0.163† N 25.20 (18.18) 34.50 (23.06) 0.347 N 
3 35.05 (23.68) 47.63 (30.12) 0.005† N 40.00 (30.72 61.07 (32.54) 0.020 N 
6 19.56 (19.28) 28.44 (30.98) 0.001† Y 25.93 (22.52) 47.13 (42.60) 0.221 N 
12 5.72 (4.00) 10.16 (15.29) p<0.001† Y 7.40 (6.53) 19.47 (23.08) 0.025 N 
18 2.49 (2.59) 3.58 (4.01) p<0.001† Y 2.33 (1.59) 6.53 (5.82) 0.016 N 
GD (mesopic)*         
Frequency (cpd)         
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1.5 11.10 (7.88) 18.76 (15.03) 0.002† Y 12.40 (9.79) 27.87 (17.80) 0.019† N 
3 16.47 (12.63) 29.28 (23.67) p<0.001 Y 17.93 (14.80) 42.13 (30.51) 0.001 Y 
6 7.51 (6.02) 11.49 (11.71) p<0.001† Y 10.33 (9.77) 19.87 (16.83) 0.134 N 
12 4.02 (0.77) 4.70 (2.89) p<0.001† Y 3.80 (0.77) 6.00 (4.72) 0.001† Y 
18 1.98 (0.15) 2.09 (0.43) p<0.001† Y 1.93 (0.26) 2.27 (0.70) p<0.001† Y 
GD (photopic)*         
Frequency (cpd)         
1.5 19.50 (12.57) 24.77 (14.71) 0.081† N 20.40 (11.44) 30.80 (15.82) 0.220† N 
3 35.16 (25.82) 47.33 (33.20) p<0.001† Y 43.13 (30.86) 67.67 (39.65) 0.039 N 
6 19.04 (19.46) 28.42 (31.20) 0.001† Y 26.13 (25.76) 46.93 (40.53) 0.069 N 
12 5.84 (5.96) 7.86 (9.21) p<0.001† Y 7.53 (9.21) 13.80 (13.66) 0.022 N 
18 2.40 (1.68) 3.63 (4.05) p<0.001† Y 2.73 (2.63) 6.67 (5.83) 0.021† N 
Mean ROS (dB)         
Fixation 8.56 (5.91) 10.20 (5.71) 0.026 N 8.36 (7.32) 11.64 (6.72) 0.056 N 
Central 5° 9.63 (4.83) 11.18 (4.48) 0.003 N 9.27 (6.46) 12.34 (5.17) 0.013 N 
Central 16° 11.03 (4.49) 12.11 (4.00) 0.005† N 10.32 (5.51) 12.55 (4.42) 0.017† N 
Optical Coherence Tomography        
MFT (µm) 233 (59) 205 (40) 0.001† Y 275 (64) 208 (25) 0.002 Y 
MFV (µm) 0.18 (0.05) 0.16 (0.03) p<0.001† Y 0.22 (0.05) 0.16 (0.02) 0.002† Y 
Subjective visual function        
Rasch-scaled LFVFS -1.70 (1.41) -1.86 (1.61) 0.222† N -2.21 (1.85) -2.38 (1.77) 0.414 N 
Rasch-scaled NVS -2.21 (1.32) -2.49 (1.48) 0.210† N -2.48 (1.28) -3.10 (1.28) 0.041† N 
Abbreviations: Bon.=significant following Bonferroni correction?; Y=yes; N=no; CDVA=corrected distance visual acuity; reading speed (at best baseline LogRad 
value); wpm=words per minute; mean reading speed (for range of LogRad values); CS=contrast sensitivity; mesopic=under mesopic conditions; cpd=cycles per 
degree; photopic=under photopic conditions; GD=glare disability; ROS=retinotopic ocular sensitivity; dB=decibel; OCT=optical coherence tomography; MFT=mean 
foveal thickness; MFV=mean foveal volume; NVS=near vision score. 
*all tests were performed on log-transformed data 
†non-parametric tests were used as data was not normally distributed. 
123 
 
 
For the study group (n=43), a statistically significant improvement over time 
was observed for the following parameters: reading acuity (p=0.03); mean reading 
speed (p<0.01); reading speed at best baseline reading acuity (p=0.019); mesopic CS, at 
all spatial frequencies (p<0.01 for all values); photopic CS at 3, 6, 12 and 18 cpd 
(p<0.01, for all); mesopic GD, at all spatial frequencies (p<0.01, for all); photopic GD 
at 3, 6, 12 and 18 cpd (p<0.01, for all); ROS at fixation (p=0.026) and within the central 
5 and central 16 degrees of fixation (p<0.01) (Figure 5.4); MFT and MFV (p<0.01, for 
both). Of note, there was no significant change in CDVA in the study group (Figure 5.5) 
or subgroup (p>0.05, for all).  
 
 
 
Figure 5.4 Box plot values for measures of  mean retinotopic ocular sensitivity at 
baseline and exit study visits at fixation, within the central 5 degrees of fixation and 
within the central 16 degrees of fixation, for the entire study group (paired t test: p= 
0.026, p=0.003 and p=0.005, respectively). 
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Figure 5.5 Corrected distance visual acuity (CDVA) at baseline and at exit study visits 
in the study group. 
 
Possible correlations were investigated between baseline data and observed 
changes in MFT over the course of the study period for the study group and subgroup to 
investigate prognostic indicators for change in MFT. Significant associations are given 
in Table 5.3. All other parameters were non-significant (p>0.05, for all). Figure 5.6 
graphically represents the relationship between baseline ROS (within the central 5°) and 
change in MFT. 
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Table 5.3 Statistically significant correlations between baseline psychophysical 
measures of visual function and change in mean foveal thickness (baseline to exit) for 
the study group and subgroup. 
 Entire study group Sig. after 
Bonferroni? 
Subgroup  Sig. after 
Bonferroni? 
Variable r p   r p   
CDVA 0.353* 0.020 No - - - 
LogRad - - - -0.762** 0.001 Yes 
LogCSmesopic_3cpd - - - 0.644* 0.013 No 
LogCSmesopic_6cpd - - - 0.716** 0.004 No 
LogGDmesopic_1.5cpd - - - 0.639* 0.014 No 
LogGDmesopic_3cpd - - - 0.685* 0.007 No 
LogGDphotopic_6cpd - - - 0.735** 0.003 No 
ROS fixation 0.494** 0.001 Yes 0.808** <0.001 Yes 
ROS central 5° 0.472** 0.002 Yes 0.708** 0.005 No 
ROS central 16° 0.370* 0.017 No 0.623* 0.017 No 
Abbreviations: CDVA=corrected-distance visual acuity; LogRad=log reading acuity; CS=contrast 
sensitivity; cpd=cycles per degree; GD=glare disability; ROS=retinotopic ocular sensitivity 
ROS=retinotopic ocular sensitivity; -=not significant 
*correlation significant at the 0.05 level (2 tailed) 
**correlation significant at the 0.01 level (2 tailed) 
 
 
Figure 5.6 Relationship between change in mean foveal thickness (MFT) and baseline 
measures of retinotopic ocular sensitivity (ROS) within the central 5° of fixation. 
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An analysis was performed to investigate the relationship between observed 
changes in MFT and observed changes in other parameters for the entire study group 
and subgroup, and statistically significant findings are displayed in Table 5.4. Figure 5.7 
graphically represents the relationship between change in ROS (within the central 5°) 
and change in MFT, and Figure 5.8 displays the relationship between change in CDVA 
and change in MFT (following the removal of three outliers). 
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Table 5.4 Significant correlations between observed changes in mean foveal thickness 
and observed changes in other parameters for the entire study group and subgroup. 
Variable Entire group Sig. after 
Bonferroni? 
Subgroup Sig. after 
Bonferroni? 
 r p  r p  
CDVA† -0.311* 0.042 No -0.569* 0.027 No 
LogGDmesopic_1.5cpd -0.334* 0.031 No - - - 
LogGDmesopic_3cpd -0.344* 0.026 No - - - 
LogGDmesopic_18cpd -0.348* 0.024 No - - - 
ROS fixation -0.411** 0.008 No - - - 
ROS central 5° -0.592** <0.001 Yes -0.611* 0.020 No 
ROS central 16° -0.536** <0.001 Yes -0.554* 0.040 No 
Abbreviations: CDVA=corrected-distance visual acuity; CS=contrast sensitivity; 
mesopic/photopic=under mesopic/photopic conditions; cpd=cycles per degree; GD=glare disability; 
ROS=retinotopic ocular sensitivity; MFV=mean foveal thickness. 
*correlation significant at the 0.05 level (2 tailed) 
**correlation significant at the 0.01 level (2 tailed) 
†becomes non-significant with the removal of 3 outliers (r=-0.271; p=0.091); an outlier was defined as 
having a change in CDVA of more than 2 standard deviations from the mean. 
 
 
Figure 5.7 Relationship between change in mean foveal thickness (MFT) and change in 
retinotopic ocular sensitivity (ROS) within the central 5° of fixation 
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Figure 5.8 Relationship between change in mean foveal thickness (MFT) and change in 
corrected distance visual acuity (CDVA) (following the removal of three outliers). 
 
Analysis was then performed to investigate the relationship between observed 
changes in Rasch-scaled LFVFS and NVS over the study period, and observed changes 
in other parameters (psychophysical and measures of retinal thickness), and statistically 
significant correlations are given in Table 5.5. Of note, there was no significant 
correlation between observed changes in LFVFS and observed changes in CDVA (r=-
0.278; p=0.082).  
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Table 5.5 Statistically significant correlations between observed changes in Rasch-
scaled LFVFS and NVS, and observed changes in psychophysical measures over the 
study period for the entire study group and subgroup. 
Variable Entire group 
Sig. after 
Bonferroni? 
Subgroup  
Sig. after 
Bonferroni? 
LFVFS r p  r p  
Reading acuity - - - 0.537 0.039 No 
LogCSphotopic_3cpd -0.400* 0.012 No - - - 
LogCSphotopic_6cpd -0.407* 0.010 No - - - 
LogGDphotopic_6cpd -0.380* 0.017 No - - - 
ROS fixation -0.392* 0.015 No - - - 
NVS r p  r p  
CDVA -0.372* 0.018 No -0.653** 0.008 No 
Reading acuity - - - 0.706** 0.003 No 
LogCSphotopic_3cpd -0.324* 0.044 No - - - 
ROS fixation -0.464** 0.003 No -0.754** 0.002 Yes 
ROS central 5° - - - -0.663** 0.010 No 
Abbreviations: LFVFS=long-form visual function score; reading acuity=best LogRad value; CS=contrast 
sensitivity: photopic=under photopic conditions; cpd=cycles per degree; GD=glare disability; 
ROS=retinotopic ocular sensitivity; CDVA=corrected distance visual acuity. 
*correlation significant at the 0.05 level (2 tailed) 
** correlation significant at the 0.01 level (2 tailed) 
 
Thirty-seven patients met the criteria for the supplementary questionnaire 
analysis; 24 (65%) indicated an overall improvement, 9 (24%) noted no change and 4 
(11%) reported deterioration in their vision, over the course of the study. Analysis of 
variance was then used to investigate the relationship between study eyes that were self-
reported by participants as exhibiting an “improvement”, “no change” or “deterioration” 
with respect to changes in parameters of visual function and macular thickness over the 
course of the study period. Significant relationships were identified between changes in 
mesopic CS (and GD) at 6 cpd and self-reported improvement in visual function in the 
study eye (p=0.030 and p=0.043, respectively), but for no other parameter of visual 
function (p >0.05 for all). 
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5.4 Discussion  
This study investigated visual function, and its response to treatment, through a range of 
psychophysical tests, in patients with nv-AMD undergoing serial intravitreal injections 
of ranibizumab, and explored whether alternative measures of visual function are more 
appropriate than, or complimentary to, CDVA in reflecting the patient’s visual 
experience. In addition, I investigated if any such alternative parameters were more 
sensitive to changes in retinal thickness than CDVA and whether or not they were of 
prognostic value. 
 Values for MFT and MFV decreased in response to treatment, between first and 
final visits, consistent with previous studies (see example Figure 5.11).
153, 344, 367
  In this 
analysis, CDVA did not change significantly for the study group or subgroup, between 
baseline and exit visits. Parameters of visual function that did improve for the study 
group and subgroup, however, included: reading acuity and reading speed, CS under 
mesopic and photopic conditions, GD under mesopic and photopic conditions, and 
ROS. The study eyes in subgroup exhibited an additional and statistically significant 
improvement in the Rasch-scaled NVS. Interestingly, this observed improvement in 
Rasch-scaled NVS within this subgroup was significantly associated with an observed 
improvement in reading acuity (LogRAD), over the course of the study period. 
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Figure 5.9 OCT macular scans at A) baseline with presence of intraretinal fluid and 
intraretinal cysts and, B) at exit, representing normal macular architecture. 
 
Mean CDVA did not improve significantly over the course of the study for the 
group or subgroup. This finding may be attributable to our inclusion criteria and to the 
short period of follow-up in this study. Studies have shown that poor baseline CDVA is 
associated with a greater benefit of treatment in terms of this outcome measure,
342, 343
  
and these observations are consistent with the findings of another study, which reported 
no significant improvement in CDVA in patients with nv-AMD in patients where 
baseline CDVA was 6/12 (logMAR 0.3) or better.
368
  Given that, in the current study, 
all study eyes had baseline CDVA of logMAR 0.7 or better (indeed, 42 of the 43 eyes 
had baseline CDVA of logMAR 0.6 or better), and given the ceiling effect previously 
discussed, it is perhaps unsurprising that no statistically significant improvement in 
CDVA was observed in our study, especially in light of the short period of follow-up. In 
addition, improvements in CDVA may not have been observed due to the fact that a 
proportion of the subjects in our study were already undergoing anti-VEGF therapy at 
the study onset. 
It has been shown that CS may be an important measure of visual function in 
patients with subfoveal CNV due to AMD, providing additional information that cannot 
be obtained from visual acuity.
175
  Studies have suggested that, when compared with 
132 
 
visual acuity, CS better measures the ability to perform tasks accurately and efficiently, 
as well as the ability to discriminate between objects
177
  and judge distances.
178
  Also, 
GD is a clinically important problem in AMD, and impacts adversely on mobility 
performance.
369
   Interestingly, Sandberg et al have proposed that a slow recovery from 
glare may be an independent risk factor for the development of CNV.
370
  In this study, 
all measures of CS and GD for all spatial frequencies improved significantly over the 
course of the study period and only two of the twenty parameters measured did not 
reach statistical significance (for the entire study group). It is also interesting to note, 
when testing CS under photopic conditions, 81% and 96% of study eyes could not see 
any target at either 12 or 18 cpd, respectively, at baseline, and these proportions 
decreased by exit visit (to 75% and 84%, respectively). 
A progressive improvement in ROS in response to ranibizumab therapy for nv-
AMD, as far as 24 months following the initiation of treatment and in spite 
of stabilisation of VA after six months, has been previously demonstrated.
7
  In the 
current study, ROS, within the central 5 degrees and within the central 16 degrees, 
improved significantly for the study group and subgroup, whereas ROS at fixation 
improved significantly only when the entire study group was analysed. Microperimetry 
has also proved useful in monitoring response to other modes of treatment, such as 
verteporfin therapy.
371
  
For the study group and subgroup, a significant improvement in reading speed 
was observed between baseline and exit visits over the course of the study, but this 
observed improvement did not correlate with a change in CDVA. Such a disparity has 
been previously observed by Frennesson et al, who suggested that a change in CDVA 
does not necessarily relate to a change in near vision.
372
  However, it should be stated 
that, in the current study, the repetitive nature of the test (every month), and the 
consequential patient familiarity with the test texts (despite comprehensive patient 
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training at baseline) may have contributed to the observed improvement in reading 
speed over the course of the study period. 
PHP values (TA and TII) exhibited no change over the course of the study 
period, nor did observed changes in these PHP values correlate with observed changes 
in MFT or LFVFS. A study by Das et al did report a significant association between TA 
(of distortion recorded) and reduction in subretinal fluid following anti-VEGF 
therapy.
351
  It has failed, however, at least according to the results of the current study, 
to exhibit significant change in study eyes with nv-AMD which are undergoing 
successful serial monthly intravitreal ranibizumab therapy. Indeed, self-reported 
improvement in visual function over the course of the study period was not associated 
with changes in PHP. These findings may be due to the fact this test was designed 
specifically to detect recent-onset CNV and distinguish it from intermediate AMD,
213
  
and only 15 (of 43) subjects in this study could be classified as having recent-onset 
CNV. The PHP, then, may not have been sensitive enough to detect a change in subjects 
with nv-AMD who were already undergoing serial intravitreal anti-VEGF therapy, 
particularly when one considers that the greatest visual benefit (in response therapy) 
occurs within the first three months of treatment.
150, 343
    
Measurements of subjective visual difficulty did not change over time, either 
when graded according to NEI guidelines, or when questionnaire scores were subjected 
to Rasch analysis for the study group or subgroup (with the exception of improvement 
in the NVS for study eyes in subgroup).  This finding is at odds with previous reports, 
where subjectively perceived visual improvement following anti-VEGF therapy has 
been detected using validated questionnaires.
363, 373
  Possible reasons for this finding 
may include the relatively short duration of the current study, given that treatment for 
this condition may last for years; only subjects with relatively good CDVA were 
assessed, who are likely to be less symptomatic compared to subjects with poor CDVA, 
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thus reducing the scope of potential visual improvement amongst the current study’s 
recruits. Also, the confounding effect of the status of the fellow eye on overall visual 
experience could be influential in respect of this aspect of our investigation. Further, 
and particularly at baseline, it may be difficult for a patient to have yet gauged, much 
less quantified, the impact of his/her condition on aspects of their daily quality of life 
(e.g. playing golf, night driving). In the current study, this latter point may be 
particularly important, as an intravitreal injection of ranibizumab was administered 
within one week of diagnosis for all study eyes. Also, decision-to-treat, in cases of nv-
AMD, and in contrast with more insidious conditions such as cataract, is not made 
solely on the basis of patient symptoms, and may even be recommended when the 
patient is asymptomatic, thus rendering the usefulness of a questionnaire such as the 
NEI VFQ questionable for this purpose. Finally, it should be emphasised that 
stabilisation of visual function can be deemed to be a successful outcome of intravitreal 
anti-VEGF therapy in cases of nv-AMD. Although the NEI VFQ did not exhibit 
improvement over the course of the study period for the study group or subgroup, it is 
important to note that deterioration was not observed either for the study group or 
subgroup, deterioration being the expected outcome of the natural history of nv-AMD. 
Of note, 66% of patients reported an overall improvement in vision over the 
course of the study, when using a supplementary questionnaire. Bearing in mind this 
was not a validated questionnaire and had no means of quantifying the level of 
improvement or deterioration experienced by the patient, it could be considered, at least 
in the context of this study, and because of its within-subject and temporal comparative 
nature, to represent a truer reflection of patient experience. The results of this particular 
analysis suggest that subjectively perceived improvement in visual function in cases of 
nv-AMD undergoing intravitreal anti-VEGF therapy has a closer association with CS 
and GD at medium spatial frequencies, than with CDVA.  
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Of note, and although the study group or subgroup did not exhibit significant 
change in terms of CDVA or LFVFS over the course of the study, some subjects did 
exhibit change in the above parameters, thus facilitating analysis of relationships 
between such changes and other outcome measures. These relationships are discussed 
with full appreciation of the fact that correlations, while identifying relationships 
between variables, may or may not represent causal relationships. 
 Given the importance of OCT in the diagnosis and decision-to-treat/decision-to-
discontinue treatment in cases of nv-AMD, the relationship between observed changes 
in MFT and observed changes in the psychophysical parameters over the course of the 
study period was analysed.  Although there was a significant correlation between 
observed changes in MFT and observed changes in CDVA (which, notably, became 
non-significant with the removal of outliers) and also with observed changes in GD 
under mesopic conditions at low and high spatial frequencies, the strongest such 
association was with observed change in ROS, both at fixation, but more robustly, 
within the central 5 and 16 degrees of fixation. Changes in microperimetry have also 
been shown to reflect changes in macular thickness for other eye conditions, such as 
diabetic macular oedema.
206, 374
  Microperimetry examines the light differential 
threshold at the retina, and in this respect differs from VA, a measure of the angular 
resolution limits of the eye at high contrast. The advantage of ROS is that it is 
retinotopic, a function which allows it to probe visual function more deeply than would 
CDVA. Intuitively, therefore, one would expect that measures of ROS are more 
appropriate than CDVA when attempting to correlate function and morphological 
changes at the macula for conditions such as AMD. On the basis of this rationale, and 
on the basis of the findings of the current study, I believe that ophthalmologists should 
consider incorporating measures of ROS into the routine assessment and monitoring of 
patients with AMD.  
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For the entire study group, significant correlations were detected between 
changes in patient-reported experience for the entire study group and changes in CS 
(under photopic conditions at 3 and 6 cpd), GD (under photopic conditions) at 6 cpd, 
and ROS at fixation, but not with CDVA. In other words, such measures of visual 
function appear to better reflect changes in subjectively perceived visual function than 
does CDVA. These results should be interpreted with full appreciation of the fact that 
they were not significant at the 1% level, in the absence of correction for multiple 
testing. Of note, change in CDVA was associated with change in the NVS.  
 The psychophysical prognostic indicators for reduction in macular thickness for 
the entire study group following treatment were CDVA and ROS, ROS displaying 
significance at the 1% level. Analysis on study eyes in subgroup demonstrated further 
parameters of potential prognostic value, including: reading acuity, CS and GD under 
mesopic conditions at 3 cpd, CS and CS and GD under photopic conditions at 6 cpd. In 
other words, a greater reduction in MFT over the course of the study period was 
associated with worse measures of these aspects of visual function at baseline, a finding 
that is unsurprising as these measures of visual function will be grossly and adversely 
affected where MFT is greater, thus allowing for a more substantial reduction in MFT 
(and a parallel improvement in these parameters) over time. However, it should be 
noted that this finding will have been affected in the current study by confounding 
attributable to the fact that CDVA of logMAR 0.7 or better was an inclusion criterion. 
While CDVA does not appear to be either the most robust or most sensitive outcome 
measure in patients undergoing intravitreal anti-VEGF therapy for nv-AMD, this study 
has shown that it does have some prognostic value for eyes undergoing such treatment 
for this condition, at least where baseline acuity is relatively good (logMAR 0.7, or 
better). 
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In an attempt to achieve best outcomes without overtreating patients with nv-
AMD, the posology for intravitreal ranibizumab for this condition has recently been 
revised 
(http://www.medicines.ie/medicine/11837/SPC/Lucentis+10mg+ml+Solution+for+Injec
tion/#POSOLOGY). This revision of posology was informed by the evolving body of 
literature since the publication of the phase III MARINA and ANCHOR trials, where 
monthly injections were given for a period of two years. In brief, it is now 
recommended that monthly injections are given until best CDVA is achieved and 
maintained for three consecutive injections, when interruption of treatment is 
recommended with monthly monitoring. Where deterioration in CDVA, attributable to 
activity of nv-AMD, is observed, recommencement of treatment is recommended under 
the same regime. In light of this revised posology, however, the results of our study 
strongly suggest that CS-guided or ROS-guided re-treatments are likely to be more 
sensitive indicators of functional deterioration, and would, therefore, prompt 
recommencement of treatment at an earlier stage than would a deterioration in CDVA, 
thereby reducing the risk of irrecoverable loss of visual function prior to re-treatment.
375
  
  
5.5 Conclusion 
This study has demonstrated improvements in many parameters of visual function in 
eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections. Outcome 
measures other than CDVA, such as CS, GD and ROS, should not only be considered in 
the design of studies investigating nv-AMD, but also in treatment and retreatment 
strategies for patients with the condition, at least in eyes where baseline CDVA is 
logMAR 0.7 or better. 
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Chapter 6.  Supplementation with three different macular carotenoid 
formulations in subjects with early age-related macular degeneration. 
 
6.1 Study rationale, aims and objectives 
Although anti-VEGF therapy has resulted in better outcomes for patients with nv-
AMD,
376
  this treatment is cumbersome to the patient and to the healthcare provider, 
often requiring many months/years of monthly intravitreal injections. In addition, there 
is, as yet, no effective treatment for atrophic AMD, which has similarly detrimental 
effects on a patient’s quality of life.21  
 Investigators interested in exploring ways of preventing or delaying the onset of 
AMD, or at least retarding its progression, have directed their attention towards the 
possible protective role of MP, and its constituent components: L, Z and MZ. There is 
also a strong rationale to suggest that MP can enhance visual performance in subjects 
with the condition.  
  While L and Z can be obtained from many foods,
377
  MZ is not present in a 
conventional western diet, although it has been identified in certain types of seafood.
378
  
However, it should be noted that there is a paucity of studies conducted to test foods for 
the presence of MZ, and further study in this area is needed. Interestingly, MZ has been 
found, albeit in trace amounts, in serum of subjects who have not been supplemented 
with this carotenoid.
379
  Certain properties of MZ render this carotenoid of particular 
interest to those exploring ways of preventing or delaying the onset of AMD, or 
ameliorating the course of the condition, or studying the contribution MP makes to 
visual performance and experience (in subjects with and without ocular disease), and 
these include: MZ is generated from L in the primate retina;
380
  it is the dominant 
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carotenoid at the epicentre of the macula (Figure 6.1);
381
 MZ accounts for about one 
third of total MP;
253
  it appears to be the most powerful antioxidant of the macular 
carotenoids in the presence of the xanthophyll binding proteins;
382
 the presence of all 
three macular carotenoids is required if MP is to maximally exert its antioxidant 
effects;
319
 the presence of MZ facilitates a wider range of pre-receptoral blue light 
filtration by MP.
317, 318
   
 
 
 
Figure 6.1 The ratio between MZ and Z concentrations (pink line) and the ratio 
between L and Z concentrations (turquoise line), at the macula (image courtesy of Prof. 
Richard Bone). 
 
 Interestingly, an atypical central dip in the spatial profile of MP, characterised 
by the lack of a central peak in MPOD, is associated with risk for AMD.
321
   It is 
reasonable to hypothesise that such atypical profiles may be attributable, at least in part, 
to an inability to convert retinal L to retinal MZ, and a consequential lack of MP at the 
site of dominance of this carotenoid (i.e. at the foveal centre). Interestingly, 
supplementation with a formulation containing MZ has the ability, to rebuild MP 
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centrally and confer a typical central peak on its spatial profile.
322, 379
 It has also been 
shown that, in normal healthy subjects, a formulation containing all three macular 
carotenoids (including MZ) has the greatest impact, in terms of enhancing visual 
performance, as measured by CS (both in the presence and absence of glare), when 
compared to placebo or when compared to a formulation that contains only L (and 
lesser amounts of Z). 
 While the role of MZ for visual performance in normal subjects has been 
explored,
170
  no trial to date has yet investigated the impact of a supplement containing 
MZ on visual performance (or disease progression), in subjects with early AMD. In 
addition, the majority of clinical trials that have focused on visual outcomes following 
macular carotenoid supplementation have focused, for the most part, on CDVA. 
Evidence suggests that other psychophysical measures of visual performance should be 
considered when attempting to quantify visual changes in response to supplementation. 
Further, no trial has yet investigated the impact of a supplement containing MZ on the 
progression of AMD.  
 MOST AMD (a sister trial to MOST Vision, discussed in section 4.5.3.2) was 
designed to investigate the effect of three different macular carotenoid formulations 
(one of which contains all three macular carotenoids [L, Z and MZ]), on MP 
enhancement, on visual performance (taking into consideration a range of 
psychophysical measures) and on disease progression, in subjects with early AMD 
(MOST Vision assessed normal subjects). 
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6.2 Methods 
6.2.1 Study design 
This study was conducted at the Institute of Vision Research and Institute of Eye 
Surgery, Waterford, Ireland.  Early AMD was defined as the presence of drusen and 
pigmentary changes and the absence of any signs of late AMD (GA or nv-AMD). 
Recruitment was mediated through the Institute of Eye Surgery (ophthalmology clinic) 
and Institute of Vision Research, through advertisement in local media and through 
leaflet, poster and flyer distribution to optometrist practices locally and nationally. 
Inclusion criteria were: early AMD in at least one eye (confirmed by an ophthalmologist 
at a screening clinic and subject to subsequent corroboration by an accredited reading 
centre); CDVA of ≥ 6/12 (logMAR 0.3) in the study eye. Exclusion criteria were: a 
recent history (within three months of baseline visit) of macular carotenoid 
supplementation; diabetes mellitus; any visually consequential ocular co-morbidity. 
Ethics approval was granted by the Waterford Regional Hospital Ethics Committee 
(Appendix 5), and written and informed consent was secured from each subject 
(Appendix 6). The research was conducted in accordance with the principles of the 
Declaration of Helsinki. All subjects were naive to the tests involved (with the 
exception of CDVA). 
This study, titled the Meso-zeaxanthin Ocular Supplementation Trial [MOST]:  
(trial registration number: ISRCTN60816411) is a randomised single-blind clinical trial 
of oral supplementation with one of three different macular carotenoid formulations. 
The supplements were prepared in a soft-gel capsule. Subjects were randomly assigned 
to one of three supplementation groups, as follows: Group 1: 20mg of L and 2mg of Z 
(Ultra Lutein™; supplied by Nature’s Plus, Europe); Group 2: 10mg of MZ, 10mg of L 
and 2mg of Z (Macushield™; supplied by MacuVision, Europe); Group 3: 17 mg MZ, 3 
mg of L and 2mg of Z (supplied by Industrial Organica, Mexico). Study subjects were 
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required to consume one tablet per day with a meal. Compliance was monitored by 
tablet counting at each study visit and encouraged by regular phone calls. Study visits 
were carried out at baseline, six and 12 months. 
 
Visual acuity, and CS and GD using the FVA™ were carried out as outlined in Chapter 
6 (sections 6.1.2 and 6.1.3, respectively). Of note, the unavailability of the FVA™ at the 
study outset resulted in a reduced number of complete (baseline and 12 month) datasets 
for measurements using this device (n=39).   
 
ROS was carried out as described in Chapter 6 (section 6.1.4), the exception being the 
number of retinal loci tested and the extent of the visual field that was examined. This 
change in method was as follows: The central 12 degrees were examined, using a total 
of 29 stimuli. ROS was calculated for the following three areas: within the central 4 
degrees of fixation (using an average of 13 stimuli), within the central 8 degrees of 
fixation (average of 21 stimuli), and within the central 12 degrees of fixation (average 
of 29 stimuli). 
 
6.2.2 Contrast sensitivity by letter chart 
CS was measured (in the study eye only) at five separate spatial frequencies (letter 
sizes) using the logMAR chart provided by Test Chart 2000 PRO® at a test distance of 
4m and at a constant room illuminance of 870 lux (photopic conditions), using distance 
spectacle correction, if required. 
Contrast of a letter is defined as follows (Weber contrast): 
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where I  represents the luminance of the character and Ib represents the luminance of 
the background.  
Each patient was asked to identify (ETDRS) letters, presented in one isolated 
row (spatial frequency) at a time. For each spatial frequency tested, the contrast of the 
letters was reduced systematically using the software’s contrast adjustment function 
(calibrated prior to commencement of the study using a light meter) until the contrast 
threshold of the patient was reached i.e. the patient could not distinguish any more 
letters. The software’s letter randomisation program selected five random letters each 
time a different contrast was tested. The patients were encouraged to take their time 
whilst trying to identify the letters (for adaptation purposes), particularly approaching 
their threshold contrast level, and to blink regularly. 
The average of three different readings was taken for the lowest contrast at 
which letters were legible to the patient, in a similar manner to that used in CDVA 
testing. The percentage contrast level (of the target), CS, and logCS for each spatial 
frequency (row of letters) were recorded. Table 6.1 shows the contrast levels tested and 
their corresponding CS and logCS values. Any missed or any  additional correctly 
identified letters i.e. on a subsequent line, were each assigned a (logCS) value of -0.03 
and +0.03, respectively, and the total was added to the final logCS score. 
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Table 6.1 Contrast levels tested using letter chart, and corresponding CS and logCS 
values. 
% Contrast CS* logCS 
100 1.00 0.00 
71.0 1.41 0.15 
50.1 2.00 0.30 
35.5 2.82 0.45 
25.1 3.98 0.60 
17.8 5.62 0.75 
12.6 7.94 0.90 
8.9 11.24 1.05 
6.3 15.87 1.20 
4.5 22.22 1.35 
3.2 31.62 1.50 
2.2 44.67 1.65 
1.6 62.50 1.80 
1.1 89.13 1.95 
0.8 125.00 2.10 
0.6 178.57 2.25 
 Abbreviations: CS=contrast sensitivity 
*CS=100 divided by % contrast 
 
 Five different letter sizes (spatial frequencies) were tested, each having the 
following angular subtense in cycles per degree (cpd): 6/120 (1.2cpd), 6/60 (2.4cpd), 
6/24 (6cpd), 6/15 (9.6cpd) and 6/9.5 (15.2cpd). It should be noted that letters, by nature, 
can contain many different spatial frequencies, so it is not possible to assign a precise 
spatial frequency to a particular letter. However, it has been suggested that the most 
important frequency for letter identification is two cycles per letter width.
383
  Take the 
letter F, for example; it contains approximately two cycles (two dark bands and two 
white bands). The spatial frequencies cited above represent those calculated on this 
basis (see Appendix 7).   
6.2.3 Macular pigment optical density 
Each subject’s MP spatial profile was obtained using the Macular Densitometer™, a 
device that has been slightly modified from that developed and described by Wooten et 
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al.
384
  The device uses heterochromatic flicker photometry (HFP) to obtain a measure of 
MPOD at five retinal eccentricities. 
 HFP is based on the principle that MP (a yellow pigment), located anterior to the 
photoreceptor layer in the retina, absorbs incident blue light before it reaches the 
photoreceptors. MP’s peak absorption is at approximately 460nm. The test requires the 
subject to make iso-luminance matches between two flickering lights, which alternate 
between a wavelength band absorbed by MP (blue) and one that is not (green). The 
radiance of the blue light (absorbed by MP) is adjusted until the subject’s perception of 
flicker is minimised or eliminated. The higher the individual MP level at a particular 
retinal eccentricity, the more blue light that will be required to match the luminance of 
the green light to minimise the flicker (Figure 6.2). The log ratio of the amount of blue 
light absorbed centrally, where MP peaks, to that absorbed at a peripheral retinal locus 
(in this case, 7°) where MP is optically undetectable, gives a measure of the individual’s 
MPOD.  
 
Figure 6.2 Principle of heterochromatic flicker photometry. At the fovea, more blue 
light (large blue arrow) is required to match the luminance of the green light than at the 
parafovea (reference point), as MP (indicated in yellow) is concentrated at the fovea and 
is optically undetectable at the parafovea (reference point). (Image courtesy of the 
MPRG, Waterford) 
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Typically, there is an inter-individual range of alternation rates where flicker is 
not perceived and this range is called the null zone. Customised HFP (cHFP)
385
  was 
designed to accommodate for these differences in flicker sensitivity amongst 
individuals, which are known to vary with age and disease.
386, 387
  If a fixed flicker 
frequency is used, a subject with low flicker sensitivity (i.e., low critical flicker fusion 
frequency) will most likely experience a large null flicker zone. On the other hand, a 
subject with a high critical flicker frequency may not be able to eliminate flicker from 
the test target, which would make the task difficult to complete. Therefore, predicted 
optimal flicker frequency rates for the targets at each eccentricity (determined using an 
age-guided algorithim; see Table 6.2) were used to customise the test for each subject to 
facilitate accurate subject performance and reduce measurement error (see also 
publication by Connolly et al
379
 ).  
 
Table 6.2 Age-guided optimal flicker frequencies for Densitometer™ targets. 
Age* OFF for each retinal eccentricity 
 0.25° 0.5°, 1°, 1.75° 7° 
18-20 18 19 13 
21-20 18 19 12 
31-40 17 18 11 
41-50 15 16 10 
51-60 13 14 9 
61-70 12 13 8 
71-80 11 12 7 
81+ 10 11 6 
OFF = optimal flicker frequency; 
*years 
 
The spatial profile of MP was measured at four different retinal eccentricities: 
0.25°, 0.5°, 1°, and 1.75°, with a reference point at 7°. The targets and fixation points 
used for each retinal eccentricity measured are displayed in Figure 6.3 and were as 
follows: the 0.25° and 0.5° eccentricities were measured using a 0.5° and 1° diameter 
disc, respectively, with a 5min black fixation point at the centre; the 1° and 1.75° 
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eccentricities were measured using a 20’ wide annuli with mean radii corresponding to 
those eccentricities used with a centrally fixated 5min black fixation point. Values at the 
reference point were obtained using a 2° diameter disc located 7° nasal to a 5min red 
fixation point. 
 
Figure 6.3 Stimuli and fixation points for each of the five targets of the Macular 
Densitometer™. (Image courtesy of the MPRG, Waterford) 
 
Room lights were dimmed for the recording of MPOD (room illuminance was 
1.5 lux). The “bracketing method” previously described by Connolly et al was 
employed for the measurement of MPOD in this study, as it has been found to be more 
suitable for assessing older subjects than the original “method of adjustment”.379  These 
two methods are described as follows:  
 
The Method of Adjustment: The radiance button is set (by the examiner) to either the 
lowest or highest blue light intensity. The subject then pushes one of the (two) radiance 
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control buttons, which alters the blue/green ratio, until the beginning of the null flicker 
zone is reached. They are encouraged to continue holding down the button until the end 
of the null flicker zone is reached. The subject then uses the other radiance control 
button to go back through the zone of no flicker, and then to continue to go back and 
forth through this zone in smaller increments until they feel they have identified the 
centre of this zone (i.e., their null flicker point). The radiance value at this point is 
recorded. The examiner then offsets the radiance button randomly and the test is 
repeated four additional times, as above. The entire procedure is then repeated for the 
remaining eccentricities. MPOD is calculated using the log ratio of the measurement 
radiance values with respect to the reference radiance values (obtained at 7°), using an 
appropriate MPOD calculator provided by Macular Metrics (Providence, Rhode Island, 
USA).  
If the subject cannot identify a null flicker zone, the flicker frequency is 
typically increased the by two Hz. Similarly, if the subject reports a very wide null 
zone, the flicker frequency is reduced by two Hz. Further such adjustments are made if 
required. 
 
The Bracketing Method: The examiner sets the radiance button all the way to lowest 
blue light intensity. The examiner then pushes the radiance button, increasing the 
blue/green ratio until the subject reports no flicker. This radiance value is recorded and 
this procedure repeated an additional four times. The examiner then sets the radiance 
button all the way to highest blue light intensity and the procedure is repeated, as above. 
For any given retinal eccentricity, a total of ten radiance values are obtained; five 
approaching from the lowest blue light intensity and five approaching from highest blue 
light intensity. The same procedure is repeated for the remaining eccentricities. MPOD 
is calculated using, in this case, a bracketing procedure MPOD calculator.  
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All subjects were trained how to perform the HFP task at their first study visit. 
MPOD data was not recorded until subjects demonstrated a high level of understanding 
of the task. Reliability and reproducibility of MPOD measurements obtained using the 
Macular Metrics Densitometer™ have previously been reported.388, 389  
 
6.2.4 Blood extraction 
Non-fasting blood samples were collected at baseline and 12 months by standard 
venepuncture techniques for the purposes of assessing the safety (using pathology 
analysis) of macular carotenoid supplementation, in particular, MZ, as it is currently the 
least explored macular carotenoid. The blood was collected in two plastic collection 
tubes as follows: Tube 1 (glucose) contained sodium fluoride, and tube 2 (hematology) 
contained the anticoagulant dipotassium ethylene diamine tetra-acetic acid (K2EDTA). 
All collection tubes were labelled with the subject’s number, visit number and date and 
were inverted a minimum of eight times to ensure appropriate mixing of the blood with 
each additive in the tubes. 
 
6.2.5 Clinical pathology analysis 
Clinical pathology analysis was performed on all subjects at baseline and at 12 months, 
to test for any change in renal and liver function, lipid profile, hematologic profile, and 
markers of inflammation, following supplementation with the macular carotenoids. 
 The serum tube was centrifuged within two hours of collection, and a 1mL 
sample was aliquotted into a clean, labelled, plastic tube that was then transported with 
the other two tubes to Biomnis Ireland (Dublin, Ireland; Irish National Accreditation 
Board certified), for independent analysis. Serum levels of the following parameters 
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were measured at baseline and at 12 months: sodium; potassium; chloride; urea; 
creatinine; bilirubin; alanine aminotransferase (ALT); alkaline phosphatase (ALP); 
aspartate aminotransferase (AST); gamma-glutamyl transferase (GGT); total protein; 
albumin; globulin; calcium; magnesium; phosphate; uric acid; cholesterol-HDL (high 
density lipoprotein); cholesterol-LDL; cholesterol-total; triglycerides; glucose; full 
blood count + 5-part Diff; C-reactive protein (CRP) - high sensitivity (hsCRP). 
 Analysis at Biomnis Laboratories was conducted using one of two integrated 
diagnostic immunoassay systems (Abbott Architect ci8200; Abbott Labs, Abbott Park, 
IL, or Advia 120; Siemens Healthcare Diagnostics, Deerfield, IL), as appropriate. The 
reference ranges for this study were obtained from the insert kits for the instrumentation 
used by Biomnis Laboratories. Exceptions were the reference ranges for lipids (HDL, 
LDL, total cholesterol and triglycerides), which were obtained from the European 
Guidelines on Cardiovascular Disease Prevention,
390
 and for glucose, which were 
obtained from the World Health Organisation.
391
  
 
6.2.6 L/Z diet screener 
A subject’s weekly intake of carotenoid rich foods (eggs, broccoli, corn, dark leafy 
vegetables) was inputted into the L/Z screener (courtesy of Dr. Elizabeth Johnson, Tufts 
University, Boston, USA) to give a carotenoid-based diet score. The screener was used 
for control purposes, i.e. to ensure that there was no difference between 
supplementation groups at baseline with respect to dietary intake of the carotenoids. In 
the excel-based screener, values are weighted for frequency of intake of the food and for 
bioavailability of L and Z within these foods. A ranking score reflecting the relative 
intakes was generated. Evaluation of the L/Z screener against the Willet food frequency 
questionnaire yielded a positive correlation that was strongly significant (p<0.01).
322
   
The range of scores on the L/Z screener is 0 to 75. After adding foods with known 
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concentrations of the L and Z into the screener, the following estimates were made: a 
low dietary carotenoid intake score ranges from 0-15 (≤2mg/day); a medium dietary 
carotenoid intake score ranges from 16-30 (3-13mg/day); and a high dietary carotenoid 
intake score ranges from 31-75 (>13mg/day). 
 
6.2.7 Subjective visual function (VFNq30)  
An adapted version of the (Visual Function in Normals Questionnaire), a non-validated 
questionnaire designed to assess subjective visual function in normal subjects, was used 
in this study (Appendix 8), in an attempt to investigate the subjective response, if any, 
to supplementation with the macular carotenoids. The design was loosely based on a 
previously validated visual activities questionnaire.
392
  The questionnaire allowed the 
subject to quantify their visual performance using three separate metrics: situational 
analysis (SA), which required the subject to rate their visual performance in specified 
daily life situations; comparative analysis (CAn), which required the subject to compare 
their perceived visual performance to that of their peers/family/friends; subjective 
satisfaction score (SSS), which required the subject to provide an overall estimate of 
their perceived quality of vision. Each of the three metrics described was computed to 
give a performance score for four different functional aspects of vision: acuity/spatial 
vision, glare disability, light/dark adaptation and daily visual tasks. 
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6.2.8 Stereo fundus imaging and grading 
6.2.8.1 Imaging 
Two sets of 30° stereoscopic colour photographs, centred on the disc, centred on the 
macula, and a non-stereoscopic colour fundus photograph centred temporal to, but 
including, the fovea, were obtained. This was followed by the acquisition of a single 
anterior segment image centred on the pupil of each eye. All images were anonymised 
and sent to the Ocular Epidemiology Reading Centre at the University of Wisconsin, 
USA, for grading. 
6.2.8.2 AMD lesion grading (procedure described by Klein et al)
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Early AMD is characterised by retinal drusen and pigmentary abnormalities (increased 
retinal pigment and RPE depigmentation). Late AMD is characterised by areas of GA or 
signs of CNV. AMD grading involves measuring different characteristics of each (e.g. 
size, type and area of drusen and area of pigmentary abnormalities).  
Each photo was fitted with a grid consisting of three concentric circles (central, 
inner and outer subfields) and four radial lines so that the fovea is contained within the 
centre circle (Figure 6.4). The radius of the innermost circle corresponds to 500µm in 
the fundus of an average eye and the radii of the middle and outer circles to 1500µm 
and 3000µm, respectively. This grid divides the photo into nine separate subfields 
(centre circle + four inner subfields + four outer subfields). Three sets of open circles of 
differing sizes were used to estimate the size of drusen, the area involving drusen and 
the area involving pigmentary changes (Figure 6.5) Circles, C0, C1 and C2 have 
diameters corresponding to 63µm, 125µm and 250µm, respectively. Drusen area was 
quantified using the circles C1, I1 and O1, which represent 1.6% of the area of the 
central, inner, and outer subfields, respectively, and by C2, I2 and O2, which represent 
6.3% of the area of the same subfields. 
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Figure 6.4 Grid used to define subfields at the macula. 
 
 
 
Figure 6.5 Grid used to estimate drusen size, drusen area and area of pigmentary 
changes. 
 
Overall findings were reported on an 11-step AREDS AMD-severity scale (see 
Appendix 9) The levels of increasing severity in the 11-step AREDS scale were defined 
by drusen area, increased pigment, RPE depigmentation and the late AMD lesions 
(signs of nv-AMD or GA). For the purposes of this study, a change of two or more steps 
along the AREDS severity scale was defined as being clinically significant.
394
  Fundus 
photographs were graded at baseline and at 12-month study visits. 
 
6.2.9 Statistical analysis 
Descriptive statistics were calculated for the entire group and for each supplementation 
group, for all measured variables, including demographic, ocular, psychophysical and 
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morphological data, as well as data on subjective visual functioning. Statistical analysis 
was performed using the software package PASW Statistics 18.0 (IBM Corp., Somers, 
NY, USA). Power and sample size calculations were performed using PASS 2008 
(NCSS, LLC. Kaysville, Utah, USA). 
 Baseline differences between treatment groups e.g. in measures of visual 
performance, age, gender etc. were assessed using analysis of variance and contingency 
table analysis, as appropriate. Baseline and 12-month visit measures were compared 
using the paired-samples t test. One-way ANOVA was used to test for statistically 
significant differences between the three groups. Pearson correlations were used to 
investigate the relationship between MPOD and a range of psychophysical measures, at 
baseline. Change in AMD severity grade between the three intervention groups was 
assessed using the Pearson chi-square test for contingency tables. 
 Following dropouts and exclusions, data from 52 subjects remained for 
longitudinal analysis. A sample of this size has power of 0.85 for detecting a correlation 
of 0.4 and power of 0.97 for detecting a change of half of one standard deviation on a 
paired t test, assuming a 5% level of significance and a two-tailed test. For a 
contingency table analysis designed to detect changes of two or more steps on the AMD 
severity scale, the power of a sample of this size is 0.78 for detecting a large effect size 
(W=0.5 using Cohen’s classification).395  
 
6.3 Results 
6.3.1 Baseline data  
Seventy-nine eyes (of 79 subjects) were recruited into the study. Following recruitment 
and a baseline visit, a total of 12 subjects were excluded following image grading (at the 
University of Wisconsin); five were excluded on the basis of not having AMD and a 
further seven were excluded on the basis of signs of late AMD. Following these 
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exclusions, 67 eyes (of 67 subjects) remained for analysis. Twenty-three subjects were 
recruited to Group 1, 25 to Group 2 and 19 to Group 3. Positive and statistically 
significant relationships between MPOD and visual function, at baseline, are presented 
in Table 6.3 (see also Figure 6.6 for the graphical representation of the relationships 
between letter CS 2.4 cpd and MPOD at 0.25° eccentricity). 
Table 6.3. The relationship between MPOD (at 0.25° eccentricity) and psychophysical 
parameters of visual function, at baseline. 
Variable r p 
CDVA 0.282 0.022 
Letter CS at 2.4cpd 0.295 0.017 
Letter CS at 15.2cpd 0.300 0.015 
CS ms 3cpd 0.313 0.025 
CS pt 3cpd 0.345 0.013 
GD pt 3cpd 0.281 0.045 
GD pt 6cpd 0.286 0.042 
GD pt 12cpd 0.277 0.049 
Letter CS at 1.2cpd 0.105 0.404 
Letter CS at 6.0cpd 0.205 0.102 
Letter CS at 9.6cpd 0.235 0.059 
CS ms 1.5cpd 0.267 0.059 
CS ms 6cpd 0.141 0.323 
CS ms 12cpd 0.096 0.505 
CS ms 18cpd 0.028 0.843 
CS pt 1.5cpd 0.230 0.104 
CS pt 6cpd 0.237 0.094 
CS pt 12cpd 0.106 0.460 
CS pt 18cpd -0.003 0.984 
GD ms 1.5cpd 0.069 0.631 
GD ms 3cpd 0.223 0.115 
GD ms 6cpd 0.249 0.078 
GD ms 12cpd 0.125 0.383 
GD ms 18cpd 0.036 0.802 
GD pt 1.5cpd 0.177 0.214 
GD pt 18cpd 0.169 0.235 
ROS central 4° 0.134 0.287 
ROS central 8° 0.158 0.209 
ROS central 12° 0.096 0.444 
Diet 0.081 0.524 
Abbreviations: CDVA=corrected distance visual acuity; CS=contrast sensitivity; cpd=cycles per degree; 
ms=under mesopic conditions; pt=under photopic conditions; GD=glare disability; ROS=retinopic ocular 
sensitivity. 
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Figure 6.6 The relationship between MPOD at 0.25° and letter CS at 2.4 cpd (6/60) at 
baseline.  
 
Abbreviations: MPOD=macular pigment optical density; CS=contrast sensitivity; cpd=cycles per degree.  
 
Of the 67 subjects, eight subjects discontinued for personal reasons, three were 
not available to attend for the 12-month visit, two discontinued for health reasons 
(deemed to be unrelated to intervention), one had cataract surgery on the study eye prior 
to the 12-month visit, and one patient developed nv-AMD and did not re-attend, leaving 
52 subjects with complete datasets for the 12-month analyses; 17 in Group 1, 21 in 
Group 2, and 14 in Group 3. Baseline demographic, lifestyle, anthropometric, and visual 
data for the remaining 52 subjects are presented in Table 6.4. Of note, there was no 
significant difference between the groups with respect to any baseline data variables 
(with the exceptional of one questionnaire variable [daily situation analysis]; p=0.046), 
nor with respect to AMD grade (p=0.994; Table 6.5). 
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Table 6.4 Baseline demographic, lifestyle, anthropometric and visual data. 
 Entire group Group 1 Group 2 Group 3 Sig. 
Gender n (%) n (%) n (%) n (%)  
Male 18 (35%) 5 (29%) 8 (38%) 5 (36%) 0.851 
Female 34 (65%) 12 (71%) 13 (62%) 9 (64%)  
Eye      
Right 33 (63%) 9 (53%) 14 (67%) 10 (71%) 0.525 
Left 19 (37%) 8 (47%) 7 (33%) 4 (29%)  
Smoking status      
Current 4 (8%) 2 (12%) 2 (10%) 0 (0%) 0.224 
Past 25 (48%) 8 (47%) 7 (33%) 10 (71%)  
Never 23 (44%) 7 (41%) 12 (57%) 4 (29%)  
Education      
Primary 10 (19%) 3 (18%) 2 (10%) 5 (36%) 0.270 
Secondary 23 (44%) 6 (35%) 12 (57%) 5 (36%)  
Third level 19 (37%) 8 (47%) 7 (33%) 4 (28%)  
Variable 
mean ±(sd) 
(n=52) 
mean ±(sd) 
(n=17) 
mean ±(sd) 
(n=21) 
mean ±(sd) 
(n=14) 
Age  66 (8) 65 (7) 64 (9) 70 (8) 0.117 
BMI (kg/m
2
) 26.1 (5.5) 25.5 (4.1) 27.1 (3.6) 25.2 (8.6) 0.562 
CDVA (study eye)  99 (7) 99 (7) 99 (8) 98 (6) 0.868 
CDVA (non-study eye) 95 (10) 96 (9) 96 (12) 94 (8) 0.834 
Macular Pigment Optical Density     
0.25° eccentricity 0.50 (0.25) 0.50 (0.25) 0.50 (0.24) 0.47 (0.21) 0.925 
0.5° eccentricity 0.39 (0.22) 0.38 (0.27) 0.41 (0.22) 0.36 (0.19) 0.797 
1.0° eccentricity 0.26 (0.15) 0.27 (0.18) 0.27 (0.13) 0.24 (0.17) 0.851 
1.75° eccentricity 0.14 (0.11) 0.16 (0.11) 0.15 (0.11) 0.11 (0.12) 0.554 
Letter CS (photopic conditions)     
1.2 cpd  68.3 (46.4) 73.0 (49.1) 61.2 (41.3) 73.2 (52.3) 0.674 
2.4 cpd  57.1 (41.2) 59.7 (45.3) 56.8 (40.5) 54.3 (41.4) 0.938 
6.0 cpd  25.6 (14.8) 29.0 (14.9) 24.3 (14.0) 23.6 (16.0) 0.530 
9.6 cpd 13.7 (8.6) 16.0 (9.1) 12.3 (7.3) 12.9 (9.7) 0.399 
15.2 cpd 6.5 (4.9) 7.1 (4.5) 6.2 (4.8) 6.4 (5.7) 0.827 
FVA CS (mesopic conditions) (n=39)*     
Frequency (cpd)      
1.5  47.8 (28.1) 45.6 (29.8) 46.3 (24.5) 44.6 (30.4) 0.885 
3 57.1 (36.4) 47.1 (26.5) 58.6 (33.0) 58.0 (44.9) 0.905 
6 25.9 (18.1) 21.0 (17.1) 25.9 (17.5) 24.3 (20.4) 0.762 
12 6.0 (4.2) 4.8 (2.1) 5.6 (3.9) 6.9 (5.4) 0.380 
18 2.6 (2.0) 3.1 (3.0) 2.1 (0.5) 2.4 (1.2) 0.483 
FVA CS (photopic conditions) (n=39)*     
Frequency (cpd)      
1.5 36.0 (23.0) 34.9 (24.3) 41.1 (22.0) 31.8 (21.4) 0.657 
3 63.3 (29.8) 56.6 (27.3) 66.1 (33.6) 65.4 (27.5) 0.492 
6 45.5 (32.0) 40.3 (25.0) 45.1 (32.1) 41.7 (36.4) 0.965 
12 15.2 (13.6) 13.4 (11.0) 14.8 (14.3) 15.2 (13.7) 0.993 
18 7.2 (7.6) 6.4 (6.3) 5.8 (5.5) 8.5 (9.8) 0.691 
FVA GD (mesopic conditions) (n=39)*     
Frequency (cpd)      
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1.5 37.3 (27.0) 39.9 (25.2) 37.5 (28.8) 26.8 (24.1) 0.285 
3 48.6 (37.9) 54.07 (43.5) 42.4 (26.8) 40.4 (40.3) 0.491 
6 20.4 (16.0) 18.0 (17.3) 19.8 (14.3) 18.6 (15.9) 0.832 
12 5.9 (3.7) 5.1 (3.0) 5.1 (3.1) 6.9 (4.3) 0.228 
18 2.3 (1.1) 2.4 (1.6) 2.2 (0.7) 2.1 (0.5) 0.904 
FVA GD (photopic conditions) (n=39)*     
Frequency (cpd)      
1.5 39.8 (22.8) 45.9 (26.9) 36.8 (16.1) 37.9 (23.4) 0.280 
3 65.0 (27.1) 58.1 (28.0) 67.2 (31.2) 59.0 (22.1) 0.786 
6 51.5 (35.3) 45.3 (27.5) 52.3 (40.5) 45.5 (38.7) 0.946 
12 16.1 (14.3) 16.2 (16.7) 12.9 (11.0) 15.8 (14.2) 0.876 
18 7.9 (8.0) 7.7 (9.5) 4.8 (4.1) 9.4 (8.8) 0.410 
ROS      
Central 4° 18.0 (2.2) 18.3 (1.9) 18.4 (1.7) 17.1 (2.9) 0.194 
Central 8° 18.3 (1.8) 18.5 (1.5) 18.5 (1.6) 17.6 (2.5) 0.345 
Central 12° 18.0 (2.2) 18.4 (1.7) 18.2 (2.1) 17.2 (2.7) 0.303 
     
Subjective vision questionnaire (n=49)*     
Glare SA  59 (20) 59 (20) 63 (21) 54 (19) 0.465 
Glare CAn  55 (18) 50 (19) 58 (19) 55 (15) 0.425 
Glare SSS  61 (25) 55 (27) 67 (25) 58 (24) 0.384 
Acuity SA  66 (20) 69 (20) 68 (20) 61 (19) 0.501 
Acuity CAn  56 (15) 58 (16) 57 (13) 52 (15) 0.593 
Acuity SSS  68 (20) 66 (22) 72 (21) 63 (18) 0.499 
Light SA  66 (17) 66 (20) 70 (17) 60 (11) 0.295 
Light CAn 56 (14) 55 (17) 58 (11) 54 (13) 0.662 
Light SSS  67 (19) 69 (17) 70 (21) 60 (17) 0.303 
Daily SA  77 (15) 75 (13) 83 (14) 71 (16) 0.046 
Daily CAn  58 (12) 55 (12) 60 (13) 58 (13) 0.489 
Daily SSS  70 (15) 66 (14) 75 (16) 66 (13) 0.123 
Diet score (n=50) 18.7 (11.2) 17.3 (10.9) 21.9 (12.7) 16.0 (8.4) 0.267 
Abbreviations: BMI=body mass index; CDVA=corrected distance visual acuity; CS=contrast sensitivity; 
cpd=cycles per degree; GD=glare disability; FVA=functional vision analyzer; ROS=retinotopic ocular 
sensitivity; SA=situational analysis; CAn=comparative analysis; SSS=subjective satisfaction score. 
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
* n≠52 (for entire study groups) due to either a) the absence of the test in question at study outset, b) the 
patient had difficulty/could not perform the test, or c) the data was unreliable. 
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Table 6.5 AMD-severity grading for entire group and intervention subgroups at 
baseline. 
Grade Entire group (n=52) Group 1 (n=17) Group 2 (n=21) Group 3 (n=14) Sig. 
1-2 9 (17.3%) 3 (17.6%) 4 (19.0%) 2 (14.3%) 0.994 
3-4 22 (42.3%) 8 (47.1%) 8 (38.1%) 6 (42.9%)  
5-6 13 (25.0%) 4 (23.5%) 5 (23.8%) 4 (28.6%)  
7-8 8 (15.4%) 2 (11.8%) 4 (19.0%) 2 (14.3%)  
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
 
6.3.2 Longitudinal data 
Values for MPOD at each eccentricity, at baseline and 12 months, and their 
corresponding p values with respect to change over time, are summarised in Table 6.6. 
Of note, there were no statistically significant differences between the three 
supplementation groups with respect to change in MPOD, at any eccentricity (p>0.5, for 
all; determined using one-way ANOVA). 
 
Table 6.6 Mean (±sd) MPOD at baseline and twelve months. 
 Group 1 Group 2 Group 3 
Eccentricity Baseline 12 months p Baseline 12 months p Baseline 12 months p 
0.25° 0.50 ±0.25 0.59 ±0.30 0.077 0.50 ±0.25 0.60 ±0.21 0.005 0.46 ±0.21 0.59 ±0.20 0.010 
0.5° 0.38 ±0.27 0.47 ±0.27 0.055 0.42 ±0.22 0.50 ±0.19 0.005 0.36 ±0.19 0.46 ±0.21 0.020 
1° 0.27 ±0.18 0.34 ±0.16 0.083 0.27 ±0.13 0.34 ±0.17 0.005 0.24 ±0.17 0.33 ±0.16 0.019 
1.75° 0.16 ±0.11 0.21 ±0.09 0.018 0.14 ±0.11 0.22 ±0.12 0.002 0.11 ±0.12 0.19 ±0.10 0.006 
Abbreviations: MPOD=macular pigment optical density; n=number of subjects  
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
 
 Mean values (at baseline and 12 months) for parameters measured in the study, 
and their respective p values in relation to change over time, are displayed in Table 6.7. 
Letter CS values at baseline and at 12 months, for the three intervention groups, for 
each spatial frequency, is displayed in Figure 6.7. One-way ANOVA (and subsequent 
post-hoc analysis) showed statistically significant differences between Groups 1 and 3 
with respect to change in letter CS at 6.0, 9.6 and 15.2 cpd, and between Groups 2 and 3 
for letter CS at 6.0 cpd (p<0.05, for all). There were no significant differences between 
groups for the remaining visual performance parameters (p>0.5, for all).
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Table 6.7 Mean (±sd) values for measures of visual function and subjective visual experience, at 
baseline and at 12 months. 
 Group 1  Group 2  Group 3  
 Baseline  12 months p Baseline  12 months p Baseline  12 months p 
CDVA (SE) 99 (7) 98 (6) 0.408 99 (8) 98 (5) 0.554 98 (6) 98 (7) 0.799 
CDVA (nSE) 96 (9) 95 (9) 0.486 96 (12) 95 (11) 0.675 94 (8) 97 (4) 0.201 
Letter CS (photopic)         
1.2 73.0 (49.1) 91.8 (48.5) 0.021* 61.2 (41.3) 91.9 (53.6) 0.014* 73.2 (52.3) 92.2 (55.0) 0.081* 
2.4 59.7 (45.3) 86.7 (54.2) 0.006* 56.8 (40.5) 77.8 (51.6) 0.008* 54.3 (41.4) 86.2 (52.1) 0.002* 
6.0 29.0 (14.9) 38.1 (26.7) 0.098* 24.3 (14.0) 30.9 (18.8) 0.058* 23.6 (16.0) 42.2 (25.9) 0.002* 
9.6 16.0 (9.1) 16.4 (9.0) 0.939* 12.3 (7.3) 17.5 (12.3) 0.066* 12.9 (9.7) 20.1 (11.9) 0.016* 
15.2 7.1 (4.5) 7.8 (5.5) 0.408* 6.2 (4.8) 7.8 (6.4) 0.189* 6.4 (5.7) 8.7 (5.8) 0.005* 
CS (mesopic)†          
Frequency (cpd)          
1.5 45.6 (29.8) 69.6 (28.2) 0.007* 46.3 (24.5) 65.5 (30.1) 0.047* 44.6 (30.4) 61.6 (29.0) 0.292* 
3 47.1 (26.5) 73.9 (63.3) 0.007* 58.6 (33.0) 73.2 (38.0) 0.058* 58.0 (44.9) 90.9 (47.2) 0.175* 
6 21.0 (17.1) 44.2 (91.8) 0.521* 25.9 (17.5) 38.5 (38.7) 0.278* 24.3 (20.4) 46.6 (38.6) 0.123* 
12 4.8 (2.1) 13.9 (30.8) 0.109* 5.6 (3.9) 7.2 (4.2) 0.137* 6.9 (5.4) 11.3 (12.0) 0.498* 
18 3.1 (3.0) 2.1 (0.5) 0.207* 2.1 (0.5) 3.2 (5.1) 0.317* 2.4 (1.2) 3.0 (2.8) 0.655* 
CS (photopic)†          
Frequency (cpd)          
1.5 34.9 (24.3) 47.7 (23.5) 0.007* 41.1 (22.0) 47.3 (26.3) 0.241* 31.8 (21.4) 48.9 (27.0) 0.023* 
3 56.6 (27.3) 75.0 (19.9) 0.002* 66.1 (33.6) 80.2 (32.6) 0.108* 65.4 (27.5) 78.0 (34.9) 0.169* 
6 40.3 (25.0) 48.4 (33.5) 0.310* 45.1 (32.1) 63.5 (49.1) 0.064* 41.7 (36.4) 55.9 (39.8) 0.192* 
12 13.4 (11.0) 13.1 (11.6) 0.709* 14.8 (14.3) 28.5 (34.0) 0.118* 15.2 (13.7) 26.6 (28.7) 0.314* 
18 6.4 (6.3) 5.6 (6.5) 0.498* 5.8 (5.5) 8.0 (9.5) 0.687* 8.5 (9.8) 10.6 (12.3) 0.866* 
GD (mesopic)†          
Frequency (cpd)          
1.5 39.9 (25.2) 40.9 (23.5) 0.753* 37.5 (28.8) 42.9 (27.5) 0.289* 26.8 (24.1) 48.3 (33.1) 0.021* 
3 54.07 (43.5) 47.9 (24.1) 0.439* 42.4 (26.8) 63.3 (35.9) 0.010* 40.4 (40.3) 52.9 (35.9) 0.161* 
6 18.0 (17.3) 14.8 (13.0) 0.564* 19.8 (14.3) 27.6 (31.2) 0.553* 18.6 (15.9) 27.3 (29.8) 0.345* 
12 5.1 (3.0) 5.6 (2.7) 0.273* 5.1 (3.1) 13.9 (28.9) 0.144* 6.9 (4.3) 5.8 (5.0) 0.115* 
18 2.4 (1.6) 2.0 (0.0) 0.336* 2.2 (0.7) 5.7 (15.3) 0.655* 2.1 (0.5) 2.7 (2.7) 0.317* 
GD (photopic)†          
Frequency (cpd)          
1.5 45.9 (26.9) 64.1 (30.1) 0.006* 36.8 (16.1) 61.8 (27.9) 0.002* 37.9 (23.4) 64.6 (34.0) 0.058* 
3 58.1 (28.0) 89.1 (42.2) 0.002* 67.2 (31.2) 99.7 (37.7) 0.006* 59.0 (22.1) 85.4 (40.3) 0.330* 
6 45.3 (27.5) 58.8 (50.3) 0.000* 52.3 (40.5) 69.1 (78.7) 0.012* 45.5 (38.7) 68.6 (49.5) 0.120* 
12 16.2 (16.7) 16.8 (20.6) 0.953* 12.9 (11.0) 18.7 (16.8) 0.169* 15.8 (14.2) 20.5 (22.7) 0.320* 
18 7.7 (9.5) 8.8 (11.9) 0.674* 4.8 (4.1) 13.4 (21.9) 0.071* 9.4 (8.8) 10.6 (11.8) 0.993* 
Retinotopic ocular sensitivity         
Central 4° 18.3 (1.9) 18.5 (1.5) 0.271 18.4 (1.8) 18.3 (2.3) 0.640 17.5 (2.7) 17.7 (3.0) 0.718 
Central 8° 18.5 (1.5) 18.7 (1.3) 0.510 18.5 (1.7) 18.4 (2.1) 0.850 18.0 (2.3) 18.0 (2.7) 0.928 
Central 12° 18.4 (1.7) 18.5 (1.4) 0.442 18.1(2.2) 18.3 (2.1) 0.673 17.5 (2.6) 17.2 (3.2) 0.611 
Questionnaire          
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Glare SA  59 (21) 58 (17) 0.513 65 (20) 69 (25) 0.512 54 (19) 56 (15) 0.723 
Glare CAn  51 (19) 50 (15) 0.655 60 (18) 60 (19) 1.000 55 (15) 51 (16) 0.257 
Glare SSS  55 (28) 62 (21) 0.268 69 (23) 69 (18) 1.000 58 (24) 58 (20) 1.000 
Acuity SA  70 (20) 70 (22) 0.880 68 (21) 73 (16) 0.130 61 (19) 71 (13) 0.041 
Acuity CAn  59 (17) 53 (10) 0.157 57 (14) 60 (13) 0.180 52 (15) 54 (13) 0.753 
Acuity SSS  66 (23) 70 (20) 0.373 73 (21) 70 (17) 0.450 63 (18) 68 (16) 0.549 
Light SA  65 (21) 59 (18) 0.047 70 (18) 74 (15) 0.216 60 (11) 68 (11) 0.037 
Light CAn 56 (18) 54 (9) 0.705 58 (12) 59 (16) 0.790 53 (13) 57 (8) 0.504 
Light SSS  69 (17) 68 (19) 0.634 73 (19) 69 (18) 0.479 60 (17) 70 (10) 0.139 
Daily SA  75 (14) 73 (15) 0.706 83 (15) 82 (19) 0.706 71 (16) 77 (12) 0.144 
Daily CAn  56 (12) 57 (11) 0.655 60 (13) 62 (9) 0.527 58 (13) 58 (16) 1.000 
Daily SSS  66 (15) 73 (16) 0.043 76 (16) 72 (14) 0.191 66 (13) 73 (9) 0.108 
Diet score 17.3 (10.9) 23.3 (11.3) 0.044 20.6 (11.7) 26.7 (16.1) 0.020 15.3 (8.5) 27.5 (11.2) 0.006 
Abbreviations: CDVA=corrected distance visual acuity; SE=study eye; nSE=non-study eye; CS=contrast 
sensitivity; cpd=cycles per degree; GD=glare disability; SA=situational analysis; CAn=comparative analysis; 
SSS=subjective satisfaction score 
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
†as measured by the Functional Vision Analyzer™; n=13 for Group 1, n=14 for Group 2, n=12 for Group 3. 
*the statistical tests were based on log-transformed data.  
Note: The p values reported are for the paired t test (or the corresponding non-parametric test when the data 
distribution was non-normal).
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Figure 6.7 Letter CS at baseline and at 12 months, for each group. 
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
 
 
163 
 
 The proportion of subjects in each intervention group exhibiting a change in 
severity scale grade of two or more, considered clinically meaningful for the purpose of 
this study,
394
  is given in Table 6.8. A change in the negative direction (i.e. -1, -2) 
indicates a progression along the AMD severity scale, whereas positive integers indicate 
regression (improvement). Between baseline and 12 months, there was no statistically 
significant difference between treatment groups with respect to change in AMD severity 
scale (p=0.455, Pearson chi-square test).  
 In brief, 79% of subjects exhibited no clinically meaningful change in AMD 
severity grade between baseline and 12 months, with approximately 11% exhibiting 
deterioration and 9% exhibiting an improvement.  
 
Table 6.8 Change in AMD grade (11-step scale) between baseline and 12 months.  
Group n -2 -1 0 +1 +2 +3 Sig. 
1 17 1 (5.9%) 1 (5.9%) 10 (58.8%) 3 (17.6%) 1 (5.9%) 1 (5.9%) 0.455 
2 21 3 (14.3%) 2 (9.5%) 11 (52.4%) 3 (14.3%) 2 (9.5%) 0  
3 14 2 (14.3%) 5 (35.7%) 4 (28.6%) 2 (14.3%) 1 (7.1%) 0  
Total 52 (100%) 6 (11.5%) 8 (15.4%) 25 (48.1%) 8 (15.4%) 4 (7.7%) 1 (1.9%)  
Abbreviations: n=number of subjects; negative value indicates disease progression; a positive value indicates 
disease regression; 0=no change in grade 
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
 
 Clinical pathology analysis results are reported in Table 6.9. Of note, two 
variables in Group 1, two variables in Group 2 and two variables in Group 3 
demonstrated statistically significant changes from baseline (in both positive and 
negative directions). All variables, however, remained within their respective and 
normal reference ranges. 
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Table 6.9 Clinical pathology variables following supplementation with the macular carotenoids assessed at baseline and at 12 months for each of the 
three intervention groups.  
Pathology variable Function of test Reference Range (Unit) 
Group 1 (n=9)*  Group 2 (n=20)*  Group 3 (n=12)*  
Baseline 12 months p Baseline 12 months p Baseline 12 months p 
Sodium  Renal profile 135-145 (mmol/L) 139±3 138±3 0.312 141±3 138±2 0.001 136±3 137±4 0.371 
Potassium  Renal profile 3.3-5.3 (mmol/L) 4.6±0.3 4.7±0.2 0.366 4.6±0.4 4.7±0.4 0.475 4.7±0.3 4.8±0.2 0.709 
Chloride  Renal profile 98-107 (mmol/L) 104±2 106±2 0.073 104±3 104±3 0.922 103±4 103±4 0.612 
Urea  Renal profile 2.5-7.7 (mmol/L) 7.2±2.4 6.5±1.4 0.174 6.1±1.1 6.6±1.5 0.073 6.7±1.5 6.0±1.7 0.053 
Creatinine   Renal profile 40-90 (μmol/L) 81±13 74±10 0.086 78±14 77±15 0.299 76±19 75±17 0.681 
Total protein  Liver profile 64-83 (g/L) 69±3 68±3 0.499 71±4 70±3 0.415 70±5 70±5 0.558 
Albumin  Liver profile 37-52 (g/L) 41±2 40±3 0.444 43±2 42±2 0.134 41±2 42±2 0.410 
Globulins  Liver profile 21-36 (g/L) 28±4 28±3 1.000 28±4 29±3 0.737 29±5 28±4 0.272 
Total bilirubin   Liver profile 3.4-21.0 (μmol/L) 6.2±2.0 7.8±2.2 0.050 9.1±4.7 9.9±5.3 0.293 8.0±3.6 10.1±4.0 0.001 
AAT   Liver profile 0-55 IU/L 23±8 21±8 0.426 22±6 22±6 0.752 19±3 20±5 0.279 
ASA   Liver profile 5-36 IU/L 24±3 24±4 0.782 22±4 22±4 0.903 21±3 22±4 0.083 
Alkaline phosphate  Liver profile 40-150 IU/L 79±27 87±31 0.013 78±20 79±20 0.501 76±11 82±17 0.114 
GGT Liver profile 9-36 IU/L 39±40 40±41 0.668 27±11 28±14 0.395 27±16 32±23 0.075 
Cholesterol total  Lipid profile <5.0 (mmol/L) 5.2±1.0 5.2±1.1 0.708 4.7±1.3 4.5±0.9 0.231 4.8±1.0 4.8±0.9 1.000 
Triglycerides  Lipid profile 0.60-1.70 (mmol/L) 1.47±0.61 1.34±0.66 0.185 1.44±0.49 1.39±0.60 0.700 1.51±1.31 1.29±0.82 0.236 
HDL  Lipid profile 1.00-1.55 (mmol/L) 1.51±0.37 1.43±0.31 0.063 1.31±0.33 1.24±0.28 0.044 1.46±0.47 1.46±0.51 0.942 
Direct LDL  Lipid profile <3.0 (mmol/L) 3.1±1.0 3.2±1.0 0.419 2.8±1.1 2.7±0.8 0.317 2.8±0.9 2.7±0.9 0.671 
Calcium  Bone profile 2.10-2.60 (mmol/L) 2.31±0.10 2.32±0.14 0.661 2.35±0.07 2.35±0.07 0.825 2.31±0.06 2.40±0.11 0.005 
Phosphate  Bone profile 0.80-1.56 (mmol/L) 1.13±0.17 1.20±0.24 0.292 1.17±0.17 1.19±0.19 0.672 1.07±0.25 1.10±0.21 0.414 
Magnesium  Bone profile 0.65-1.10 (mmol/L) 0.99±0.05 0.94±0.09 0.159 0.97±0.08 0.98±0.06 0.573 0.93±0.12 0.94±0.08 0.599 
Uric Acid  Bone profile 155-394 (μmol/L) 290±54 280±62 0.579 315±65 312±66 0.724 305±65 322±89 0.260 
Glucose  Bone profile 3.1-6.1 (mmol/L) 5.3±0.7 5.3±1.2 0.910 5.0±0.6 5.0±0.7 0.867 5.0±0.9 5.1±0.7 0.273 
HSRP 
Inflammation 
marker 
<5.0 (mg/L) 1.2±0.5 1.6±1.0 0.097 2.2±2.4 2.3±2.1 0.864 4.0±5.1 4.3±6.7 0.728 
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Full blood count            
White cell count Haematology 3.88-10.49 (10e9/L) 6.54±2.00 5.88±1.03 0.331 6.74±1.53 6.81±1.78 0.830 6.13±1.56 5.95±1.10 0.661 
Red cell count Haematology 3.73-5.02 (10e12/L) 4.51±0.42 4.36±0.33 0.367 4.50±0.41 4.47±0.39 0.377 4.44±0.45 4.46±0.45 0.858 
Haemoglobin Haematology 11.3-15.2 (g/dL) 13.6±1.1 13.6±0.9 0.622 13.7±1.1 13.7±1.2 0.596 13.6±1.2 13.6±1.1 0.969 
Haematocrit Haematology 0.323-0.462 (L/L) 0.407±0.032 0.405±0.020 0.769 0.413±0.031 0.413±0.031 0.939 0.409±0.031 0.412±0.031 0.779 
MCV Haematology 83.1-99.1 (fL) 90.5±3.1 93.1±5.1 0.222 92.0±4.0 92.6±4.0 0.414 92.4±3.7 92.6±3.7 0.778 
MCH Haematology 28.3-33.9 (pg) 30.1±1.2 31.3±1.8 0.134 30.4±1.3 30.8±1.2 0.167 30.7±1.2 30.5±1.4 0.632 
MCHC Haematology 32.1-36.6 (g/dL) 33.3±1.0 33.6±0.8 0.357 33.1±0.8 33.3±1.2 0.523 33.2±1.1 33.0±1.0 0.468 
Platelets Haematology 164-382 (10e9/L) 332±249 249±123 0.196 258±88 250±118 0.527 244±46 254±61 0.369 
Differential white cell count           
Neutrophils Haematology 1.91-7.16 (10e9/L) 3.80±1.27 3.44±0.82 0.423 4.09±1.20 4.23±1.38 0.580 3.92±1.23 3.84±1.21 0.809 
Lymphocytes Haematology 1.01-3.13 (10e9/L) 1.82±0.54 1.66±0.39 0.309 1.81±0.43 1.70±0.42 0.128 1.42±0.36 1.38±0.39 0.704 
Monocytes Haematology 0.19-0.68 (10e9/L) 0.47±0.18 0.40±0.13 0.322 0.43±0.11 0.45±0.16 0.495 0.41±0.12 0.35±0.09 0.132 
Eosinophils Haematology 0.05-0.51 (10e9/L) 0.22±0.05 0.18±0.06 0.195 0.18±0.09 0.23±0.13 0.055 0.17±0.10 0.17±0.08 1.000 
Basophils Haematology 0.02-0.15 (10e9/L) 0.05±0.03 0.05±0.02 0.505 0.05±0.02 0.07±0.04 0.063 0.04±0.02 0.06±0.03 0.042 
Large unstained cells Haematology 0.00-0.30 (10e9/L) 0.17±0.07 0.14±0.03 0.222 0.18±0.07 0.16±0.05 0.122 0.16±0.05 0.14±0.02 0.177 
Abbreviations: AAT=alanine aminotransferase; ASA= aspartate aminotransferase; GGT=gamma  glytamyl transpeptidase; HDL=high density lipoprotein; LDL=low density 
lipoprotein; HSCP=high sensitive reactive protein; MCV=mean corpuscular volume; MCH=mean corpuscular haemoglobin; MCHC=mean corpuscular haemoglobin concentration 
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
*total n≠52 as data on pathology analysis was not available for all subjects at both baseline and 12 months
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6.3.3 A subsidiary six-month analysis  
While the study’s primary end-point was 12 months, it was felt that the six-month data, 
when viewed separately, may be of interest in terms of changes in measures of MPOD 
and visual performance, particularly if one wants to consider the possible differences in 
response time to the supplements. Repeated measures that would include baseline, 6 and 
12 month data were not sufficiently powered due to the change in the composition of 
the study cohort between baseline and 12 months (primarily due to dropouts). 
 Twenty-one subjects from Group 1, 22 subjects from Group 2, and 15 subjects 
from Group 3 were eligible for this analysis i.e. had datasets at baseline and six months. 
There were no significant differences between groups with respect to any variable at 
baseline (p>0.05, for all). Values for MPOD at each eccentricity, at baseline and six 
months, are summarized in Table 6.10. Of note, there were statistically significant 
increases in MPOD at all eccentricities for each of the three groups (with the exception 
of 0.5° in Group 3).  
Table 6.11 reports those parameters of visual performance that changed 
significantly between baseline and six months. In brief, two variables in Group 1, nine 
variables in Group 2, and two variables in Group 3, improved significantly between 
baseline and six months. Of note, mean CDVA reduced significantly between baseline 
and six months in Group 1. 
 
Table 6.10 Mean (±sd) MPOD at baseline and six months. 
 Group 1 Group 2 Group 3 
Eccentricity Baseline 6 months p Baseline 6 months p Baseline 6 months p 
0.25° 0.47 ±0.25 0.58 ±0.27 0.001 0.50 ±0.24 0.63 ±0.20 <0.001 0.46 ±0.20 0.55 ±0.21 0.028 
0.5° 0.36 ±0.25 0.46 ±0.23 0.004 0.42 ±0.21 0.52 ±0.19 0.002 0.36 ±0.16 0.42 ±0.17 0.089 
1° 0.25 ±0.17 0.35 ±0.17 0.001 0.28 ±0.13 0.38 ±0.15 <0.001 0.23 ±0.15 0.30 ±0.12 0.023 
1.75° 0.15 ±0.11 0.21 ±0.12 0.010 0.15 ±0.11 0.23 ±0.11 0.004 0.11 ±0.10 0.19 ±0.10 0.006 
Abbreviations: MPOD=macular pigment optical density; n=number of subjects 
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
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Table 6.11 Visual performance parameters which displayed significant changes 
between baseline and 6 months (for each study group). 
Variable Baseline Mean (±sd) 6 months Mean (±sd) p 
Group 1    
CDVA (SE) 99 (7) 96 (7) 0.019* 
GD pt 1.5cpd 40.29 (26.51) 47.94 (24.61) 0.013 
GD pt 3cpd 53.94 (25.67) 79.29 (40.91) 0.019 
Group 2    
Letter CS 1.2cpd 59.09 (38.71) 85.50 (48.71) 0.018 
Letter CS 9.6cpd 12.32 (6.75) 22.59 (20.70) 0.018 
CS ms 3cpd 57.72 (33.79) 71.50 (42.39) 0.012 
CS pt 3cpd 62.78 (31.06) 80.78 (33.70) 0.026 
CS pt 18cpd 5.33 (5.39) 10.70 (12.55) 0.029 
GD ms 3cpd 39.61 (26.81) 52.00 (37.06) 0.031 
GD pt 1.5cpd 34.83 (16.81) 42.14 (20.85) 0.005 
GD pt 3cpd 60.44 (30.20) 79.94 (36.11) 0.009 
Group 3    
CS ms 6cpd 22.07 (21.22) 30.33 (33.61) 0.026 
GD ms 6cpd 16.60 (15.91) 27.80 (34.91) 0.035 
Abbreviations: CDVA=corrected distance visual acuity; SE=study eye; GD=glare disability; pt=under 
photopic conditions; cpd=cycles per degree; CS=contrast sensitivity; ms=under mesopic conditions. 
*p value relates to a significant decrease in visual acuity 
Group 1: 20mg L, 2mg Z; Group 2: 10mg MZ, 10mg L, 2mg Z; Group 3: 17 mg MZ, 3 mg L, 2mg Z 
Note: CS and GD p values are based on log-transformed data. 
 
6.4 Discussion  
MOST AMD is a randomised single-blind clinical trial comparing the effect of 
supplementation with three different macular carotenoid formulations on MPOD, visual 
performance and AMD grade, over a period of twelve months, in subjects with early 
AMD. 
 This study found a positive and statistically significant correlation, at baseline, 
between MPOD and measures of visual function, including CDVA, letter CS, grating 
CS under mesopic and photopic conditions at low spatial frequencies and GD under 
photopic conditions at low and mid-range spatial frequencies. In other words, and in the 
absence of supplementation, high MPOD is associated with better vision. Our findings 
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are consistent with those of another study, which found a significant and positive 
association between MPOD and both CDVA and CS (under mesopic and photopic 
conditions at intermediate spatial frequencies) in subjects without disease.
29
  It has been 
shown that, in subjects with atrophic AMD, lower MP levels are associated with poorer 
CS function (the minimum amount of contrast needed to detect visual stimuli at a range 
of spatial frequencies) for low spatial frequencies, although that observation did not 
reach statistical significance.
34
   
 In the current study, MPOD was significantly greater at one year than at baseline 
at all eccentricities for subjects supplemented with all three macular carotenoids (Group 
2) and for subjects supplemented with high doses of MZ (17mg; Group 3). Although the 
observed augmentation in mean MPOD at 12 months did not reach statistical 
significance for subjects supplemented with high doses of L (20mg; Group 1), except at 
1.75 ° eccentricity, it should be noted that the increases observed for this group at other 
eccentricities were not dissimilar in magnitude to those observed for Groups 2 and 3 
(standard deviations in Group 1 were, however, larger). In addition, there was no 
statistically significant difference between groups with respect to change in MPOD over 
the study period.Of note, the L/Z diet score increased significantly between baseline and 
12 months, for all three groups, which may have also been a contributing factor in the 
observed increase in MPOD. 
 The significant rise in MPOD across the spatial profile when all three macular 
carotenoids (Group 2) are included in the formulation or when supplemented with 17mg 
of MZ and small amounts of L and Z (Group 3), and especially the augmentation of MP 
centrally, is neither surprising nor counter-intuitive, given the known distribution of 
MP’s individual constituent carotenoids. The inclusion of MZ in the formulation is 
likely to result in augmentation of MP centrally (demonstrated in Groups 2 and 3 here), 
169 
 
as this is the site of dominance of this carotenoid. The inclusion of L in the formulation 
(as in all groups) will result in MP augmentation at the more peripheral site of that 
carotenoid’s natural dominance (1.75°), attested to by the significance of the 
augmentation of MP at this locus in the high L group (Group 1). These observations are 
also consistent with recently published findings,
322
  which revealed that 
supplementation with a formulation containing MZ can (re)generate the typical central 
peak of MP at the foveal centre in subjects who lack such a central peak at baseline. 
Interestingly, and in addition, that study showed that subjects supplementing with all 
three macular carotenoids exhibited augmentation in MPOD across their spatial profiles. 
Indeed, this atypical profile (the lack of a central peak, sometimes referred to a “central 
dip”), is of particular interest, as such atypical profiles, putatively attributable to an 
inability to convert retinal L to retinal MZ, are associated with increased risk of 
AMD.
321
  It would appear, therefore, that supplementation with all three macular 
carotenoids results in the greatest augmentation of MPOD across its spatial profile, 
thereby putatively affording the greatest protection against the (photo-) oxidative 
processes known to be important in the pathogenesis of AMD. Interestingly, in vitro 
work has concluded that the antioxidant capacity of the macular carotenoids is 
maximised when all three macular carotenoids are present.
396
  
 In this study, supplementation with the macular carotenoids resulted in the 
demonstrable improvements in CS in subjects with early AMD, but the inclusion of MZ 
in the formulation was required to achieve improvements at low and high spatial 
frequencies. Again, it is unsurprising that CS would improve following augmentation of 
MP, especially as such augmentation was demonstrated centrally, given the 
consequential enhancement of pre-receptoral filtration of blue light and attenuation of 
CA and light scatter. This is particularly important for subjects with AMD, as CS is an 
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important measure of visual function in patients afflicted with the condition. Studies 
have shown that, when compared with VA, CS better relates to the ability to perform 
tasks accurately and efficiently, to discriminate between objects
177
  and to judge 
distances.
178
  A statistically significant improvement (decrease) in contrast acuity 
thresholds (comparable with the reciprocal of CS) has been shown in normal subjects 
supplemented with L under mesopic conditions.
186
  Furthermore, the observation that 
supplementation with high doses of L (in the absence of MZ) resulted in improved CS 
at low spatial frequencies only (and no observed change in mean CS at high spatial 
frequencies) is consistent with the fact that visual function at low spatial frequencies 
will be mediated by slightly eccentric retinal loci. Of note, concentrations of L are 
higher in the peripheral macula, compared to the fovea.
397
  
Previous studies have investigated the impact of macular carotenoid 
supplementation on CS in subjects with AMD, with the majority of studies reporting 
improvements in CS following supplementation (with L and Z),
34, 169, 280, 292, 293
  
although no study to date has tested a formulation containing MZ. A recent study has 
shown significant increases in CS at low spatial frequencies following supplementation 
with either 10mg L, 20mg L, or 10mg L and 10mg Z (combined), in subjects with early 
AMD, over a 48-week study period. 
398
  Although significant improvements were found 
in CS for higher spatial frequencies (by 48 weeks), the magnitude of the differences 
were less than those found at the lower spatial frequencies (across all intervention 
groups). Of interest, the authors report no improvement in CS at 18 cpd in any of the 
groups. This relatively poorer response at higher spatial frequencies could be 
attributable to the absence of MZ in their formulation. These findings are in agreement 
with those reported in the current study, which found demonstrable improvements in CS 
at high spatial frequencies, but only amongst subjects who were supplemented with a 
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formulation containing MZ, and not amongst subjects supplementing with high doses of 
L alone. 
 There were observed improvements across all three groups, between baseline 
and 12 months, in mean CS and GD values measured using the FVA™ for the majority 
of spatial frequencies tested, although not all reached statistical significance, nor was 
the distribution of the significant parameters consistent. This may have been due, at 
least in part, to the reduced number of datasets collected for this particular device (n= 
39). It is interesting to note, however, that mean increases in CS and GD of at least 20% 
(from baseline to 12 months) were seen in 10 (of 20) variables in Group 1, in 19 
variables in Group 2 and in 17 variables in Group 3. This does seem to suggest that 
subjects taking a carotenoid formulation that includes MZ are more likely to have 
improvements in CS and GD, compared to a formulation which does not contain this 
carotenoid. These results, although speculative, do correlate with the findings of a 
recent study in normals.
170
  
 MP’s capacity to filter short wavelength (blue) light at a pre-receptoral level 
render it capable, in theory at least, of reducing the effect of a number of optical 
aberrations. CA is the most important aberration affecting visual quality
399
  and 
primarily relates to the defocus of short wavelength light (up to 1.2 dioptres compared 
to mid wavelength light [550nm]),
400
  the attenuation of which is achieved by the pre-
receptoral absorption of blue light.
401
  In 1866, Max Schultze was the first to propose 
the theory that the absorption of short wavelength light by MP, before it was incident 
upon  the underlying photoreceptors, would reduce CA, putatively improving VA,
402
  
and this theory has been extended to include CS at a range of spatial frequencies.
403, 404
  
The impact of CA on CS is well documented; improvements have been reported in CS 
and CDVA when both chromatic and monochromatic aberrations are minimised.
405
  A 
172 
 
study investigated CS in three different groups of pseudophakic subjects, each group 
having an intra-ocular lens (IOL) implant of differing Abbe number (the lower the Abbe 
number, the greater the CA produced). There was no difference in CS between the three 
groups when CS was measured under 549nm monochromatic light, whereas there were 
statistically significant differences in CS between groups when CS was measured under 
broadband white light; the group with the IOL of lower Abbe number had poorer CS 
under white light compared with the group with the IOL of higher Abbe number. These 
observations suggest that CA (in this case, caused by IOLs) can degrade the quality of 
the retinal image, as measured by CS.
406
  
 The impact of light scatter on CS and visibility has been eloquently described by 
Wooten and Hammond
33
  in a review where they explore the effects of scatter by air 
particles, in particular scatter caused by haze aerosols (a dispersed system of small 
particles suspended in a gas,
190
  the most common component of the atmosphere), on 
visibility i.e. “how far one can see and how well details can be resolved.”  Light scatter 
is wavelength-dependent for small particles (e.g. 0.2µm), such as those found in haze 
aerosols. As light passes through the atmosphere, shorter wavelengths are more prone to 
scatter than longer wavelengths. The scattering of short-wavelength light creates a 
bluish veiling luminance, often termed “blue haze”, which, when superimposed on the 
retinal image, reduces the contrast of targets being observed. The authors propose that 
having MPOD of e.g. 0.5 OD units (compared with having MPOD of zero OD units) 
can attenuate the veiling luminance of a short-wavelength dominant background by 
17%, thereby increasing the visibility and discriminability of objects in natural viewing 
conditions. 
 Results of the subsidiary six-month analysis has shown that, over this time 
period, all three groups had comparable increases in MPOD at all eccentricities 
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following supplementation with the macular carotenoids. Statistically significant 
improvements in vision in this initial six-month period favoured Group 2, where there 
were a total of nine separate parameters of visual performance exhibiting improvements 
during this period, compared with two parameters in both Groups 1 and 3. These 
findings suggest that, within a six-month supplementation period, a formulation 
containing all three macular carotenoids potentially has the greatest impact on visual 
performance. This finding is supported by a similar study in normal subjects, which has 
shown that supplementation with a preparation containing all three macular carotenoids 
(L, Z and MZ) results in demonstrable improvements in visual performance, 
improvements that are not observed amongst subjects supplementing with L and Z 
alone (i.e. in the absence of MZ).
170
  
 These supplementary six-month findings, however, should only be interpreted in 
conjunction with the 12-month results with full appreciation of the fact that it is not a 
comparison of like with like. The apparent inconsistencies between these six-month 
findings and those reported for 12 months (previously discussed), can be deemed 
attributable to differences in the cohort composition at each of these time points. For 
example, not only were there were dropouts between six and 12 months (n=6), there 
were an additional 11 subjects who had a 12-month visit who did not attend for a six-
month visit.  It is not, therefore, possible to compare the changes observed at six months 
with those observed at 12 months as the same subjects are not being analysed at each of 
these time points. This is the most likely reason for the inconsistencies observed here. 
 There was no statistically significant change over time (either at six or 12 
months) in measures of ROS in this study. This may be in part due to the relatively high 
mean ROS scores at baseline (18.1 dB on average; maximum score achievable is 20dB, 
thus creating a ceiling effect), the small numbers in the study and the relatively short 
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follow-up (12 months). Only one study (prior to the current one) has investigated the 
impact of macular carotenoid supplementation on ROS in subjects with early AMD. 
This study reports a mean±sd improvement of 7.3%±13.2% in mean ROS following 
supplementation with L for six months (20mg for first three months and 10mg for the 
remaining three months), although the observed improvements did not reach statistical 
significance. Of note, the authors did report a significant correlation between the 
increase in MPOD and the increase in ROS over the study period.
35
  ROS has been 
shown to be an effective gauge of macular function compared to, for example, 
CDVA.
204
   However, the (albeit limited) evidence to date suggests that microperimetry 
may not be capable of detecting functional improvements following macular carotenoid 
supplementation, at least not within a 12 month time frame and with a relatively small 
study population and with the protocol employed. Further study over a longer period 
(particularly considering the chronic nature of the condition) and with a larger cohort of 
subjects is warranted. Again, it should be noted that deterioration in ROS was also not 
observed for any of the supplementation groups, which is important considering the 
natural degenerative course of the condition. It is interesting to note that ROS was the 
primary outcome measure affected by intravitreal ranibizumab in cases of nv-AMD (see 
Chapter 5) and, therefore, may be more appropriate for appreciation of change in later 
stages of the condition. 
Another study
407
  has demonstrated improvements in retinal function (measured 
using the multifocal elecroretinogram [mfERG]),
81
 following supplementation with the 
macular carotenoids, in patients with early AMD over a 48-week study period.  Retinal 
function was assessed for six separate concentric rings of retinal eccentricity, ring 1 
being closest to fixation. Following 48 weeks of supplementation with either 10mg L, 
20mg L, or 10mg L and 10mg Z (combined), the authors reported statistically 
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significant increases in the mfERG densities within ring 1 for all intervention groups, 
with no observed changes in the placebo group. Furthermore, increases in MP were 
associated with increases in mfERG densities in the central retina (rings 1 and 2, but not 
in rings 3-6). Their findings are consistent with those of a previous study that reported 
significant improvements in mfERG densities in the central retina amongst early AMD 
patients receiving supplementation (10mg L and 1mg Z, in combination with co-
antioxidants) compared to placebo.
408
  In brief, these studies, therefore, provide 
objective evidence that supplementation with the macular carotenoids benefits visual 
function, and are consistent with the findings of the current study.   
 This study has shown that, from a morphological perspective, AMD remains 
stable for at least 12 months following supplementation with the macular carotenoids 
(regardless of intervention type). However, the findings presented here must be 
interpreted with full appreciation of the study’s weaknesses, namely the small numbers 
of subjects involved, the study’s short duration, and the absence of a placebo group. For 
purposes of discussion, it is reasonable to compare our findings to the placebo group in 
the recently published CARMA, which was a randomised, double blind, placebo 
controlled clinical trial of L (12mg) and Z (0.6mg) supplementation with co-
antioxidants versus placebo in patients with early AMD.
294
  The study population of 
CARMA is comparable with that of the current study, in terms of inclusion and 
exclusion criteria, methodology of AMD grading, and demographic and geographic 
considerations.
294
  In CARMA, at 12 months, 47.4% of eyes in the placebo arm 
(108/228 eyes) exhibited any degree of progression (an increase in grade of one or more 
increments) compared with 41.7% of eyes in the active arm (96/230 eyes). While there 
were a slightly higher proportion of eyes in the placebo arm that progressed when 
compared to the active arm, the authors report no statistically significant difference 
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between these event rates (i.e. no intervention effect). Interestingly, however, in the 
current study, only 27% of subjects (all of whom were supplementing with the macular 
carotenoids) showed progression by one or more steps at 12 months (data on file). 
 Clinical pathology analysis has confirmed that, in subjects with early AMD, all 
variables remained with their respective normal reference ranges following 
supplementation with any of the three carotenoid formulations over a 12-month period, 
contributing further to the evidence concerning the safety of these supplements. These 
results follow on from those of a recent report, which found no adverse clinical 
implications in young healthy subjects following six months of supplementation with a 
formulation containing MZ (10.6mg), Z (1.2mg) and L (5.9mg).
409
  
 
6.5 Conclusion 
MP can be augmented, and CS enhanced, in subjects with early AMD who receive 
supplemental macular carotenoids. A formulation containing MZ appears to offer 
advantages over a formulation that does not contain MZ, in terms of improvements in 
psychophysical function and in terms of MP augmentation across its spatial profile, the 
latter putatively affording greater protection against (photo-)oxidative injury. However, 
the results of the current study should prompt and inform a well-designed, placebo-
controlled clinical trial (ideally of longer duration) of supplementation with L, Z and 
MZ in subjects with AMD, where outcome measures should include visual function and 
disease progression.  
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Chapter 7. The relationship between augmentation of central MP and 
visual performance, in subjects with low MP at baseline 
 
7.1 Study rationale, aims and objectives 
It is important to consider baseline MPOD in any sample when investigating the impact 
of supplementation on MPOD augmentation and/or visual performance. MPOD values 
can range from 0.0 to over 1.0 OD units,
235
 and are related to a range of variables, such 
as ethnicity, iris colour and diet.
410-412
  It has been shown that MPOD response to 
supplementation is related to baseline MPOD levels.
323, 413
   
Whilst studies have commented on the response of MP to macular carotenoid 
supplementation amongst subjects with low MP, the impact of macular carotenoid 
supplementation on visual performance in this specific group of subjects has not been 
investigated.  
The lack of a central peak (commonly referred to as a “central dip”) in the 
MPOD spatial profile has generated interest in recent years. A study has found this 
variation in MPOD spatial profile amongst 12% of its study population.
321
   
The purpose of these subsidiary analyses of MOST was to investigate the 
relationship between central MPOD and visual performance, in early AMD subjects, 
who present (at baseline) with differing levels of central MPOD. In addition, I explored 
MPOD response and change in visual performance following supplementation in 
subjects with a central dip in MPOD spatial profile at baseline. 
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7.2 Methods  
Subjects recruited for MOST AMD (Chapter 6) were further divided into tertiles based 
on their baseline MPOD at 0.25° (note: MPOD was not reassessed), as follows: highest 
tertile = MPOD ≥0.54; middle tertile = MPOD >0.32 and <0.54; lowest tertile = MPOD 
≤ 0.32. These three groups were analysed with respect to change in central MP and with 
respect to change in vision following supplementation. 
An atypical central dip MPOD spatial profile was defined as MPOD at 0.25° not 
exceeding MPOD at 0.5° eccentricity by more than 0.04 OD units (previously 
described
322
 ), which is divergent from the more common spatial profile of a central 
peak that declines from the foveal centre. Four of the five central dip subjects were also 
in the low baseline MPOD tertile and these may, therefore, be considered a subgroup of 
the low MP tertile group. 
 The three groups (low, medium and high baseline MP) were compared, with 
respect to observed changes in MPOD and letter CS, using one-way ANOVA. 
 
Methods of MPOD measurement and visual performance assessment are described in 
Chapter 6.  
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7.3 Results 
The relationship between baseline MPOD and response to supplementation, in terms of 
change in MPOD and letter CS, is given in Table 7.1.  
 
Table 7.1 Comparing change in MPOD and letter CS between low, mid-range and high 
baseline MPOD groups. 
  MP group
1
 Change
2
 Sig. 
MPOD at 0.25° 
 Low 0.22 (0.13) 
<0.001  Med 0.01 (0.15) 
 High 0.08 (0.13) 
Letter CS at 1.2cpd 
Low 33.4 (59.2) 
0.435 Med 10.7 (31.7) 
High 29.9 (42.1) 
Letter CS at 2.4cpd 
Low 41.2 (44.0) 
0.186 Med 32.2 (32.8) 
High 14.6 (29.2) 
Letter CS at 6.0cpd 
Low 17.7 (19.4) 
0.176 Med 9.0 (16.7) 
High 8.7 (15.0) 
Letter CS at 9.6cpd 
Low 8.7 (9.9) 
0.211 Med 3.1 (9.1) 
High 2.8 (6.2) 
Letter CS at 15.2cpd 
Low 3.4 (3.5) 
0.062 Med 0.8 (3.9) 
High 1.1 (4.1) 
Abbreviations: MPOD=macular pigment optical density; MP=macular pigment; CS=contrast sensitivity; 
cpd=cycles per degree; GD=glare disability; ms=mesopic conditions. 
1
MP group = tertile groups according to MPOD at 0.25° eccentricity: high=top tertile; med=middle 
tertile; low=bottom tertile. The low groups consisted of 15 subjects with baseline MPOD ≤ 0.32 and the 
high MPOD group had 22 subjects with baseline MPOD ≥ 0.54, leaving 15 subjects in the medium tertile. 
2
Change=mean change between baseline and 12 months.  
 
 Considering the increasing interest in MPOD spatial profiles,321, 322, 414, 415  
change in MPOD and change in measures of visual function was explored, in subjects 
who presented with a central dip at baseline. Five subjects had an atypical MPOD 
spatial profile at baseline. Four of these patients were in Group 2 and one was in Group 
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3. MPOD spatial profiles (at 0.25° and 0.50° eccentricity) at baseline and at twelve 
months following supplementation, for each of the five subjects, are displayed in Table 
7.2. The atypical MPOD spatial profile was no longer present at 12 months in four of 
the five cases (the remaining subject exhibited an increase in MPOD at both 0.25° and 
at 0.50°, but the central dip was not, as such, rebuilt). 
 
Table 7.2 Central MPOD values at baseline and twelve months in subjects with an 
atypical profile at baseline. 
Subject Group Baseline 12 months 
  MPOD 0.25 MPOD 0.5 MPOD 0.25 MPOD 0.5 
MZAMD001 2 0.22 0.26 0.28 0.37 
MZAMD006 2 0.31 0.31 0.39 0.32 
MZAMD039 3 0.21 0.20 0.55 0.37 
MZAMD042 2 0.19 0.33 0.44 0.31 
MZP2006 2 0.55 0.54 0.60 0.55 
Abbreviations: MPOD=macular pigment optical density 
 
 In this group of subjects (n=5), the change in MPOD at 0.25° correlated 
significantly with a change in letter CS at all spatial frequencies (Table 7.3; see Figure 
7.1 for graphical representations of these relationships), but with no other parameter of 
visual function (p >0.05; data not shown). In contrast, these relationships (between 
change in MPOD and change in letter CS) were not significant amongst subjects with 
typical MP spatial profiles at baseline (r < 0.1; p > 0.05, for all). 
 
Table 7.3 Significant associations between change in MPOD (at 0.25° eccentricity) and 
change in other parameters, in patients with an atypical MPOD profile at baseline. 
Variable r p 
CS 1.2 cpd 0.960 0.010 
CS 2.4 cpd 0.966 0.008 
CS 6.0 cpd 0.930 0.022 
CS 9.6 cpd 0.922 0.026 
CS 15.2 cpd 0.914 0.030 
Abbreviations: CS=contrast sensitivity; cpd=cycles per degree
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Figure 7.1 The relationship between the change in MPOD at 0.25° and change in letter 
contrast sensitivity at 1.2, 6.0 and 15.2 cpd, respectively. 
Note: values for CS are presented in log form 
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7.4 Discussion 
The extent to which MP augments in response to carotenoid supplementation is related 
to baseline MP levels,
323, 413
  where subjects with relatively low baseline MP are more 
likely to exhibit increases in MP compared to subjects with high baseline MP (perhaps 
due to a ceiling effect; of note, peak MP levels typically range between 0.0 and 1.0 OD 
units,
235
  and are subject to dietary modification
329, 340
 ). This has been confirmed in the 
current study, where there was a statistically significant difference between subjects in 
the lowest baseline MPOD tertile (≤ 0.32 OD units) compared to subjects in the middle 
or highest baseline MPOD tertiles, with respect to change in central MPOD, where the 
greatest augmentation of MP was seen amongst subjects with low baseline MPOD. 
However, the very low p-value reported here (0.01) should be interpreted with caution; 
statistically there is nearly always a negative correlation between X (MPOD at baseline) 
and Y-X (difference in MPOD between baseline and 12 months), which may account, at 
least in part, for this finding.  
 Of interest, the data indicate that subjects with low MPOD at baseline are likely 
to have the greatest improvements in CS following supplementation (with any of the 
three macular carotenoid formulations), albeit not statistically significant in this small 
sample. In other words, MP enrichment and detectable improvements in vision are of 
greatest relevance to subjects who have poor/low MP to begin with. This has important 
implications for any anticipated improvements in vision following supplementation, and 
may account for the variability in the results of studies investigating the impact of 
carotenoid supplementation on MPOD and vision. Interestingly, Wooten and Hammond 
observed, combining data from a number of (USA-based) studies, that 43% of subjects 
in the sample (n=846) had MP levels of <0.2.
33
 This suggests that a significant 
percentage of the (Western) population may not have optimised vision because of low 
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MP, which may have important implications, not only for the current population with 
early AMD and reduced vision, but possibly also for professionals such as pilots, 
sportspeople, drivers and soldiers. Further study in a normal population is warranted, in 
this respect. In such and similar cases, measurement of MP and, where appropriate, a 
carotenoid-rich diet and/or supplements, may be important to consider, even in the 
absence of disease. 
The spatial profile of MP and its variability has been of interest to those 
investigating the role of MP, both for vision and for protection against AMD. Initial 
studies reporting on the distribution of MP describe it declining exponentially with 
increasing retinal eccentricity.
234, 416
  However, variations in its distribution have also 
been reported,
416, 417
  one of which has been coined a “central dip”. A study (previously 
discussed in section 4.5.3.3) showed that, prior to disease onset, the known risk factors 
for AMD (tobacco use, family history of the condition, increasing age) are 
independently associated with a relative lack of MP.
320
 A proportion of that study 
population (12%) exhibited a central dip in their MPOD spatial profile and, 
interestingly, this central dip was associated with tobacco use and increasing age,
321
  
suggesting that such atypical MP spatial profiles may independently represent risk for 
AMD. It has been hypothesised that these central dips in the MP spatial profile are 
attributable to a relative lack of MZ, considering MZ is the dominant carotenoid in the 
foveal centre, and may be the result of an inability among subjects with such spatial 
profiles to convert retinal L to MZ (retinal MZ is formed from retinal L, but not retinal 
Z). Such subjects may require this carotenoid in supplement form in order to achieve a 
typical and desirable spatial profile. 
 Our analysis has found an association between observed changes in central 
MPOD and observed changes in measures of visual performance as measured by letter 
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CS, amongst subjects with a central dip at baseline. The data from this analysis has 
shown normalisation of atypical MPOD spatial profiles (in 80% of cases) following 
supplementation with an MZ-based formulation (I cannot comment on the response of 
central dip profiles to a high L-based supplement using the results of this study). This 
finding has been previously demonstrated in a study designed to investigate the effect of 
supplementation on a group of subjects (normal) that exhibited a central dip in their MP 
spatial profile (see section 5.5.3.3).
322
  The authors concluded that MP spatial profiles 
characterised by central dips, can be normalised following supplementation with a 
formulation containing MZ, but not with a formulation that is lacking this carotenoid (at 
least not in an eight-week period). In addition, augmentation across MP’s spatial profile 
required supplementation with a formulation containing all three macular carotenoids. 
Interestingly, a recent study has shown that “ring-like structures” in MPOD, observed 
using autoflourescence, and which are representative of central dips observed using 
HFP,
415
  were not attenuated following supplementation with 12mg L and 2mg Z (but 
no MZ).
414
    
While the attenuation of central dips has been demonstrated through (MZ) 
supplementation, the implications of this for vision have not yet been investigated. The 
data from this analysis putatively suggest that subjects with atypical spatial profiles, 
such as have been described, are more likely to benefit visually following 
supplementation. While I fully acknowledge the obvious weakness of small numbers in 
this case, the outcome is intriguing and warrants further study. 
It has already been shown that central MP levels are positively related to visual 
performance.
29-33
  However, the extent to which MP augments in response to carotenoid 
supplementation has been shown to be related to baseline MP levels,
323, 413
  where 
subjects with relatively low baseline MP are more likely to exhibit increases in MP 
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compared to subjects with high baseline MP (probably due to a “ceiling effect”). 
Subjects with a central dip may be similar to subjects with low central MP (and normal 
MP spatial profiles) i.e. both having relatively low central MP, a condition which 
facilitates a heightened uptake of these carotenoids at the macula following 
supplementation. In contrast, one would expect a ceiling effect, in terms of MP (and 
possibly vision), amongst subjects with relatively high amounts of MP. Therefore, MP 
augmentation is of particular importance and relevance for subjects with low MP or 
with a central dip in their MPOD profile. As has been previously discussed (Chapter 6), 
Wooten and Hammond observed, combining data from a number of (USA-based) 
studies, that 43% of subjects in the sample (n=846) had MP levels of <0.2. Kirby et al 
reported that 12% of their study sample (normal, healthy individuals; study based in 
Ireland) had a central dip in their MPOD spatial profile.
321
  Considering these 
observations, the results of this study (in additional to the findings reported in section 
6.3.2) suggest that there may be a significant percentage of the (Western) population 
that may not have optimised vision because of low MP or because of an atypical MP 
spatial profile (see Discussion, Chapter 6). This suggests that MPOD measurement 
should be considered in subjects who present with poor CS and/or who present with 
symptoms of glare, even in the absence of disease, the cause of which may be 
attenuated with macular carotenoid supplementation, particularly in cases where 
atypical profiles are observed. 
The obvious weakness of this subsidiary study is the small number of subjects 
involved, which prevent us drawing firm conclusions. Further trials to confirm these 
findings are necessary, amongst subjects with and without AMD. 
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7.5 Conclusion. 
In the current study, subjects with low baseline central MPOD had the greatest increases 
in MPOD and the greatest improvements in CS, when compared with subjects in the 
mid-range or high baseline MPOD categories. Eighty per cent of subjects who presented 
with a central dip at baseline had their MPOD spatial profile normalised following 
supplementation with the macular carotenoids. This normalisation was strongly 
associated with an improvement in CS at each spatial frequency. These findings indicate 
that the optimisation of CS is putatively dependent on central MP levels, which should 
be given due consideration when investigating the impact of macular carotenoid 
supplementation on visual performance.  
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Chapter 8. The relationship between retinal morphology and visual 
performance, in subjects with age-related macular degeneration.  
 
8.1 Study rationale, aims and objectives 
The diagnosis of AMD is currently determined by the clinical appearance of the macula 
i.e. signs of drusen (size, form and number), pigmentary and atrophic changes. A range 
of AMD grading scales exist, which grade a given individual’s risk of progression to 
later, more visually consequential, forms of the condition. Additional measures, such as 
OCT and FFA have provided a further understanding of AMD, facilitating identification 
of the presence of fluid or cysts in, or under, the retina. 
In addition to clinical examination, valid evaluation of the visual consequences 
of AMD is essential, not only for accurate documentation of disease status and 
progression, but also to inform ophthalmologists of the impact of disease severity on 
visual function and on quality of life. CDVA has been used as the primary measure of 
vision to quantify disease severity in cases of AMD (and other ocular conditions), most 
likely because of its ease of use, low cost and familiarity (for both patient and eye care 
practitioner).
14, 157
  There is, however, a general consensus that it is neither a true 
reflection of daily visual experience, nor of disease severity.
418-420
  The limitation of 
CDVA is that it measures the angular resolution limits of the eye at high contrast only, 
the real world presenting a myriad of different visual experiences, affected by things 
such as lighting conditions, colour, colour contrast levels, which cannot be assessed by 
CDVA. It has already been shown that the use of VA charts in isolation can hinder the 
interpretation of patients’ functional visual difficulty in AMD,418  as well as other eye 
conditions such as glaucoma, cataract and diabetic retinopathy.
419, 420
  
188 
 
The purpose of this study was to investigate the relationship between measures 
of visual performance (including CDVA) and MFT in cases of nv-AMD, and between 
measures of visual performance and AMD-severity grade, in cases of early AMD, and 
to explore whether other psychophysical parameters should be considered instead of, or 
in addition to, CDVA, in an attempt to better understand AMD, and its impact on visual 
function, and also in the design of clinical research studies. 
8.2 Methods  
8.2.1 Subjects 
Data collected for the subjects recruited for the studies outlined in Chapters 6 and 7 
were used for this cross-sectional analysis. Forty-seven subjects (with nv-AMD) were 
recruited for Study 1 (VEGF) and were assessed at baseline for measures of visual 
performance and measures of MFT, as outlined in Chapter 5. Sixty-six subjects (with 
early AMD) were recruited for Study 2 (MOST) and were assessed at baseline with 
respect to measures of visual performance and AMD-severity grade, as outlined in 
Chapter 6. The psychophysical and morphological assessments utilised in the respective 
studies are described in Chapters 5 and 6. 
 
8.2.2 Statistical analysis 
Pearson correlations were used to investigate bivariate relationships between measures 
of foveal thickness and measures of visual performance. Multivariate analysis was used 
to investigate the relationship between AMD-severity grade and measures of visual 
performance. 
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     Assuming a 5% level of significance, and a two-tailed test, a sample of 47 has power 
of 0.81 for detecting a correlation of 0.4 and a sample of 66 has power of 0.92 for 
detecting a correlation of 0.4. 
 
8.3 Results 
8.3.1 Study 1  
Data collected from forty-seven subjects (47 eyes) with active nv-AMD were available 
for this cross sectional analysis. Statistically significant moderate correlations were 
found between measures of MFT and measures of ROS at fixation, within the central 5° 
and within the central 16° of fixation (Table 8.1; see Figures 8.1, 8.2 and 8.3 for 
graphical representation of these respective relationships). All other measures of visual 
performance were not significantly correlated with MFT (p>0.05, for all; Table 8.1). Of 
note, CDVA was not significantly correlated with MFT, (r = -0.247; p = 0.094). 
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Table 8.1 The relationship between MFT and measures of visual performance. 
Variable r p 
ROS fixation -0.325 0.029 
ROS central 5° -0.344 0.021 
ROS central 16° -0.298 0.047 
CDVA -0.247 0.094 
logRAD 0.047 0.752 
Reading speed 0.144 0.334 
Mean reading speed 0.088 0.555 
PHP ta -0.005 0.976 
PHP tii -0.047 0.789 
FVA CS (mesopic conditions)   
Frequency (cpd)   
1.5 -0.050 0.742 
3 -0.088 0.559 
6 0.002 0.987 
12 -0.181 0.229 
18 - - 
FVA CS (photopic conditions)    
Frequency (cpd)   
1.5 0.134 0.374 
3 -0.006 0.969 
6 -0.023 0.879 
12 0.024 0.875 
18 -0.019 0.898 
FVA GD (mesopic conditions)   
Frequency (cpd)   
1.5 -0.019 0.900 
3 -0.080 0.597 
6 0.060 0.692 
12 -0.087 0.567 
18 - - 
FVA GD (photopic conditions)   
Frequency (cpd)   
1.5 0.147 0.329 
3 0.176 0.242 
6 0.026 0.865 
12 -0.069 0.650 
18 -0.052 0.733 
Abbreviations: MFT=mean foveal thickness; ROS=retinotopic ocular sensitivity; CDVA=corrected 
distance visual acuity; PHP=preferential hyperacuity perimetry; ta=total area; tii=total integrated 
intensity; FVA=Functional Vision Analyser; CS=contrast sensitivity; cpd=cycles per degree; GD=glare 
disability. 
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Figure 8.1 The relationship between mean foveal thickness (MFT) and retinotopic 
ocular sensitivity (ROS) at fixation in subjects with neovascular age-related macular 
degeneration. 
 
 
 
Figure 8.2 The relationship between mean foveal thickness (MFT) and retinotopic 
ocular sensitivity (ROS) within the central 5° in subjects with neovascular age-related 
macular degeneration. 
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Figure 8.3 The relationship between mean foveal thickness (MFT) and retinotopic 
ocular sensitivity (ROS) within the central 16° in subjects with neovascular age-related 
macular degeneration. 
 
8.3.2 Study 2 
Data collected from 66 subjects (66 eyes) with early AMD were available for analysis. 
The eight early AMD grades were grouped as follows: Group 1 = grades 1 and 2 
(n=12); Group 2 = grades 3 and 4 (n=25); Group 3 = grades 5 and 6 (n=18); Group 4 = 
grades 7 and 8 (n=11). There was an inversely significant relationship between 
measures of ROS and AMD-severity grade (Table 8.2 and Figure 8.4), such that, as 
AMD severity increased, ROS deteriorated. No other parameters of visual function were 
significantly related to AMD severity, including CDVA (p=0.37; Figure 8.5). 
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Table 8.2 The relationship between AMD severity and measures of visual performance 
ROS.  
Variable Group 1 Group 2 Group 3 Group 4 p 
ROS central 4° 18.91 (0.75) 18.64 (1.77) 16.74 (4.01) 16.00 (3.13) 0.010 
ROS central 8° 18.98 (0.62) 18.89 (1.48) 17.43 (2.89) 16.34 (2.68) 0.003 
ROS central 12° 18.79 (0.87) 18.61 (1.60) 17.10 (2.73) 15.89 (2.91) 0.002 
CDVA 98 (8) 100 (6) 96 (9) 99 (5) 0.373 
Letter CS (photopic conditions)    
1.2 cpd  71.5 (44.7) 81.5 (52.4) 47.3 (25.4) 39.7 (22.1) 0.006 
2.4 cpd  58.1 (40.6) 65.2 (43.2) 45.3 (40.3) 40.1 (22.4) 0.126 
6.0 cpd  26.9 (12.7) 29.6 (15.6) 19.9 (13.5) 23.6 (14..4) 0.242 
9.6 cpd 15.5 (8.4) 16.2 (9.2) 10.2 (7.2) 12.3 (6.6) 0.079 
15.2 cpd 6.5 (4.3) 7.6 (4.9) 4.5 (4.3) 6.1 (4.1) 0.064 
FVA CS (mesopic conditions)    
Frequency (cpd)     
1.5 41.4 (21.1) 47.7 (26.9) 40.2 (31.2) 47.4 (33.2) 0.428 
3 50.8 (33.7) 56.8 (37.3) 41.4 (26.9) 60.0 (39.5) 0.395 
6 27.3 (15.4) 24.3 (19.9) 23.1 (18.7) 20.7 (16.1) 0.822 
12 4.6 (2.9) 6.0 (4.5) 6.6 (4.4) 5.1 (2.0) 0.620 
18 2.7 (2.0)  2.7 (2.3) 2.3 (0.7) 2.0 (2.0) 0.760 
FVA CS (photopic conditions)     
Frequency (cpd)     
1.5 29.4 (9.6) 34.7 (21.6) 31.9 (21.2) 45.0 (30.0) 0.618 
3 57.7 (26.0) 59.1 (28.8) 60.0 (32.1) 61.3 (31.7) 0.914 
6 42.9 (27.5) 47.5 (34.9) 37.6 (37.4) 37.6 (23.0) 0.396 
12 12.2 (10.8) 15.1 (15.7) 12.1 (10.1) 11.7 (8.2) 0.946 
18 5.9 (7.3) 7.6 (8.8) 5.4 (4.2) 4.9 (4.0) 0.926 
FVA GD (mesopic conditions)    
Frequency (cpd)     
1.5 48.2 (34.6) 32.8 (22.6) 27.6 (22.8) 27.1 (19.0) 0.391 
3 38.1 (23.8) 51.0 (37.8) 38.4 (40.7) 37.7 (28.8) 0.403 
6 20.2 (16.9) 19.5 (16.5) 16.6 (14.5) 21.7 (16.0) 0.901 
12 6.4 (4.9) 5.8 (3.7) 5.1 (2.2) 4.0 (0) 0.522 
18 2.7 (2.0) 2.2 (0.6) 3.0 (2.7) 2.0 (0) 0.467 
FVA GD (photopic conditions)    
Frequency (cpd)     
1.5 35.7 (17.3) 39.8 (19.6) 36.0 (29.0) 39.4 (29.4) 0.721 
3 66.0 (25.4) 66.6 (27.4) 50.4 (28.8) 65.3 (28.6) 0.113 
6 39.7 (26.1) 53.8 (35.5) 35.6 (36.1) 51.9 (34.0) 0.211 
12 15.4 (18.5) 16.5 (13.8) 10.9 (9.7) 13.9 (10.7) 0.649 
18 7.7 (10.1) 8.4 (8.2) 5.4 (5.7) 7.0 (5.6) 0.733 
Abbreviations: AMD=age-related macular degeneration; ROS=retinotopic ocular sensitivity; 
CDVA=corrected distance visual acuity; CS=contrast sensitivity; cpd=cycles per degree; 
FVA=Functional Vision Analyser; GD=glare disability. 
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Figure 8.4 The relationship between AMD-severity and ROS within the central 16°. 
Abbreviations: AMD=age-related macular degeneration; ROS=retinotopic ocular sensitivity. 
AMD severity group defined as: group 1=grades 1 and 2; group=grades 3 and 4; group 3=grades 5 and 6; 
group 4=grades 7 and 8. 
 
 
 
Figure 8.5 The relationship between AMD-severity and CDVA. Abbreviations: 
CDVA=corrected distance visual acuity; AMD=age-related macular degeneration; AMD severity group 
defined as: group 1=grades 1 and 2; group=grades 3 and 4; group 3=grades 5 and 6; group 4=grades 7 and 
8. 
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Baseline VA and FVA measures were available from a study involving normal 
subjects (n=36)
170
  and were compared with the corresponding data for both the early 
and nv-AMD groups. There was a statistically significant difference in age between the 
three groups and, hence, age was controlled for in these analyses. As the three studies 
had different inclusion criteria for levels of CVDA (6/6, 6/12 and 6/30 for the normal, 
early AMD and nv-AMD studies, respectively), subjects with relatively good CDVA (≥ 
6/9, to allow for comparable numbers in the three groups) were selected and analysed, 
across the three studies. One-way ANOVA was used to test for differences between 
three groups of subjects with respect CS and GD, controlling for age and CDVA (Table 
8.3). 
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Table 8.3 Comparing measures of visual performance for eyes without disease, eyes 
with early AMD and eyes with nv-AMD, all with relatively good CDVA 
Variable Normals (n=36) Early AMD (n=47) Nv-AMD (n=22) p 
Age (years) 51 (15) 67 (8) 71 (11) <0.001 
     
ROS central 5°† - 18.0 (2.2)  11.9 (3.9) <0.001 
ROS central 16°‡ - 17.9 (2.2) 12.7 (3.7) <0.001 
     
FVA CS (mesopic conditions)     
Frequency (cpd)     
1.5 58.9 (25.3) 48.0 (26.7) 24.8 (9.0) <0.001 
3 68.1 (34.5) 56.3 (33.2) 39.1 (20.1) 0.122 
6 48.1 (29.3) 25.9 (17.9) 14.3 (11.5) 0.033 
12 9.5 (8.6) 6.1 (4.0) 4.0 (0) 0.548 
18 2.6 (2.7) 2.6 (1.8) 2.0 (0) 0.157 
FVA CS (photopic conditions)      
Frequency (cpd)     
1.5 47.6 (25.0) 36.0 (21.6) 28.6 (15.4) 0.113 
3 85.8 (32.7) 62.5 (28.0) 44.2 (21.1) 0.017 
6 99.0 (39.6) 46.3 (32.2) 30.5 (20.4) 0.005 
12 37.7 (26.8) 14.3 (12.8) 7.2 (5.6) 0.002 
18 12.5 (11.2) 6.8 (7.1) 3.0 (3.6) 0.211 
FVA GD (mesopic conditions)*     
Frequency (cpd)     
1.5 31.2 (21.3) 35.6 (25.2) 14.7 (8.7) <0.001 
3 41.8 (23.5) 47.4 (34.8) 22.0 (13.3) 0.010 
6 27.4 (21.5) 20.6 (15.8) 9.2 (8.1) 0.036 
12 5.4 (3.1) 5.6 (3.5) 4.2 (0.9) 0.157 
18 2 (0.5) 2.5 (1.7) 2 (0) 0.044 
FVA GD (photopic conditions)*   
Frequency (cpd)     
1.5 54.3 (25.5) 39.6 (23.4) 25.0 (13.9) 0.002 
3 89.4 (28.7) 65.6 (26.5) 44.0 (25.7) <0.001 
6 102.1 (42.1) 50.3 (33.2) 28.2 (22.4) <0.001 
12 33.2 (18.3) 15.5 (13.5) 7.7 (7.9) 0.055 
18 12.9 (8.6) 7.8 (7.8) 2.8 (2.3) 0.230 
Abbreviations: AMD=age-related macular degeneration; nv-neovascular; CDVA=corrected distance 
visual acuity; ROS=retinotopic ocular sensitivity; FVA=Functional Vision Analyser; CS=contrast 
sensitivity; cpd=cycles per degree; GD=glare disability; - = ROS data not available (test not performed in 
this study) 
†central 4° assessed in early AMD subjects 
‡central 12° assessed in early AMD subjects 
Note: Tests were performed on log-transformed data 
*a higher lux glare source was used in the normal study compared to that used in the early and nv-AMD 
studies 
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 Further analysis was performed to test the assumption that early AMD is of little 
visual consequence. Eyes in the normal and early AMD groups, which had CDVA of ≥ 
6/7.5 were included in the analysis, again controlling for age (but not CDVA). The 
results are presented in Table 8.4 
 
Table 8.4 Measures of CS and GD in normal and in early AMD subjects, all with 
CDVA ≥ 6/7.5 
Variable Normals (n=36) Early AMD (n=35) p 
Age (years) 51 (15) 65 (9) <0.001 
CDVA (study eye) 108 (5)  105 (5) <0.001 
    
FVA CS (mesopic conditions)    
Frequency (cpd)    
1.5 58.9 (25.3) 48.6 (27.9) 0.048 
3 68.1 (34.5) 56.2 (30.1) 0.143 
6 48.1 (29.3) 27.0 (18.2) 0.013 
12 9.5 (8.6) 6.5 (4.5) 0.357 
18 2.6 (2.7) 2.7 (2.1) 0.096 
FVA CS (photopic conditions)     
Frequency (cpd)    
1.5 47.6 (25.0) 34.9 (21.0) 0.193 
3 85.8 (32.7) 63.8 (28.2) 0.034 
6 99.0 (39.6) 50.1 (31.5) <0.001 
12 37.7 (26.8) 16.0 (13.9) <0.001 
18 12.5 (11.2) 7.6 (7.8) 0.266 
FVA GD (mesopic conditions)*    
Frequency (cpd)    
1.5 31.2 (21.3) 34.4 (23.4) 0.185 
3 41.8 (23.5) 50.5 (38.1) 0.234 
6 27.4 (21.5) 22.1 (16.0) 0.370 
12 5.4 (3.1) 6.2 (3.9) 0.155 
18 2 (0.5) 2.4 (1.2) 0.046 
FVA GD (photopic conditions)*  
Frequency (cpd)    
1.5 54.3 (25.5) 38.7 (23.8) 0.115 
3 89.4 (28.7) 64.1 (24.5) 0.007 
6 102.1 (42.1) 54.9 (35.3) 0.001 
12 33.2 (18.3) 18.1 (14.3) 0.029 
18 12.9 (8.6) 8.9 (8.3) 0.597 
Abbreviations: AMD=age-related macular degeneration; CDVA=corrected distance visual acuity; 
FVA=Functional Vision Analyser; CS=contrast sensitivity; cpd=cycles per degree; GD=glare disability; 
Note: Tests were performed on log-transformed data 
*a higher lux glare source was used in the normal study compared to that used in the early AMD study 
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8.4 Discussion 
This analysis was designed to investigate the relationship between disease severity 
related features/measures of macular morphology and a number of measures of visual 
function in subjects with AMD. The results of this study have shown that disease 
severity (defined by MFT in cases of nv-AMD, or AMD-severity grade in cases of early 
AMD) is best reflected psychophysically by measures of ROS. This is consistent with 
the hypothesis that CDVA alone is not an appropriate psychophysical test to evaluate 
the visual impact of AMD, in general. This is of clinical importance as CDVA is still 
the most widely used test of visual function for patients with this condition and is often 
the determining measure of disease impact on quality of life.  
The presence of early AMD lesions are associated with a decrease in CDVA of 
up to two letters or fewer when compared with eyes without AMD.
163
  However, the 
test-retest variability of CDVA can be up to as much as two lines of letters on a 
logMAR chart,
164
  indicating that a difference of two letters cannot be reliably 
measured. Late AMD, on the other hand, is associated with a more significant decrease 
in CDVA (approximately seven lines of letters), but only when signs of advanced AMD 
involved the central subfields of the macula.
163
  It has been shown, however, that there 
is no statistical difference in acuity between subjects with nv-AMD and subjects with 
GA.
163
  CDVA is, therefore, unlikely to be a sensitive psychophysical measure to 
quantify disease severity in cases of AMD. A wide acuity range has also been 
demonstrated despite similar areas of atrophy in AMD, although, unsurprisingly, foveal 
involvement was the key predictor of VA.
165
  Another study has shown that for the 
same level of VA, eyes with GA have worse function, particularly for dark-adapted 
vision tests and reading speed, than eyes with drusen.
167
  Similarly, lesion size in 
subfoveal nv-AMD cannot explain the wide variations in VA.
166
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Microperimetry is a thresholding technique that tests light sensitivity 
incrementally at specific retinal loci (VA is testing spatial resolution of targets). The 
fact that ROS is a retinotopic test allows for a finer probing of macular function that that 
achieved by CDVA. Therefore, one might expect that measures of ROS are more 
appropriate than CDVA, particularly for obtaining a morphology-related functional 
assessment, in cases of AMD. 
 
AMD-severity grade and visual performance: Clinical manifestations of AMD are 
typically categorised into a grading scale to determine disease severity and risk of 
progression to later, more visually consequential, stages of the condition. A number of 
grading systems exist which define and classify the signs of AMD from fundus 
photographs.  The most widely used systems are the Wisconsin Age-related 
Maculopathy Grading System,
393
   the International Classification and Grading System
41
  
and the grading scale used  in AREDS.
421
  In this respect, the current analysis has 
involved subjects diagnosed with the early stages of the condition, based on an 11-step 
AREDS grading scale. The levels of increasing severity in the 11-step AREDS scale are 
defined by drusen area, increased pigment, RPE depigmentation and the late AMD 
lesions (signs of nv-AMD [grade 11] or GA [grades 9 and 10]). Our study has shown 
that disease severity, in cases of early AMD across its range of stages (1-8), is best 
reflected by measures of ROS. 
No study, to my knowledge, has reported on the relationship between ROS (or 
CS or GD) with respect to a classified AMD grade, such as the AREDS scale. However, 
a range of studies have looked at the relationship between clinical signs at the macula 
and ROS in cases of AMD. It has been shown that in subjects with early AMD, ROS 
diminishes in areas overlying drusen and/or pigment abnormalities, in the presence of 
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good VA (6/6), and this reduction in sensitivity was greater when both lesions were 
present.
204
  
 Another study reported a significant reduction in ROS in subjects with early 
AMD compared with age-matched controls.
422
  The use of specialised software to 
overlay the microperimetry infrared image onto the OCT retinal image facilitated the 
assessment of ROS over individual druse, which was found to be significantly reduced 
when compared to adjacent retinal ROS values. The integrity of the inner segment/outer 
segment (IS/OS) junction, which has been shown to be a significant predictor of VA in 
macular diseases,
423
  was also observed to correlate significantly with ROS.
422
  In 
addition, and compared with drusen height, diameter, volume, the integrity of the IS/OS 
junction was the strongest predictor of ROS overlying drusen. Other studies have also 
reported on the correlation between the integrity of the IS/OS junction and ROS for a 
range of eye conditions.
424-427
  Although it has been shown that the IS/OS junction is 
related to drusen volume, it is interesting to note that the IS/OS junction is not a feature 
gradable from fundus images (and, therefore, does not contribute to any grading scale, 
such as AREDS), as it can only be detected using OCT.  
It has also been reported that drusen diameter, drusen height, and drusen volume 
do not offer additional predictive value if the IS/OS junction integrity grading is 
known.
422
  Indeed, Sunness et al have reported comparable sensitivity values between 
drusen and non-drusen areas.
428
   Also, Midena et al found that the number of drusen, 
the presence of focal hyperpigmentation, and the presence of RPE atrophy, did not 
influence mean sensitivity values,
180
  suggesting that drusen alone may not account fully 
for functional deficits. However, differences in methodology may account for the 
discrepancies between these results and those previously discussed, particularly since 
the latter studies (Sunness and Midena) utilised traditional, and considerably more 
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limited, perimetry (the Fundus Camera Stimulator and the Humphrey Field Analyzer™, 
respectively). The latter, when compared with microperimetry, does not allow a point to 
point correlation of function and morphology, cannot facilitate real-time fundus 
tracking, nor provide an appreciation of fixation stability. The Fundus Camera 
Stimulator, on the other hand, facilitates visualisation of the posterior pole and retinal 
location of the targets, but unlike microperimtery, does not automatically correct for a 
subject’s eye movements to ensure, for example, that the desired retinal areas are being 
tested. 
Considering the relevance of the IS/OS junction and the fact that it is not 
measurable using traditional fundus imagery, and yet is related to ROS,  ROS (by 
microperimetry) may, then, offer additional, and possibly more useful, information with 
respect to understanding disease severity in AMD than would be provided by a 
classified grading scale in isolation. A limitation of the current study is that OCT 
measurements were not taken on the early AMD cohort so that the IS/OS junction 
could, therefore, not be assessed. 
Other methods of measuring retinal function (although not ROS) have included 
the measurement of rod and cone sensitivities in isolation. Two particular studies are of 
interest, involving subjects with early AMD; Remky et al investigated cone sensitivity 
using short-wavelength automated perimetry,
429
  and Scholl et al reported on both rod 
and cone sensitivity (through a technique called fine matrix mapping in scotopic and 
photopic conditions, respectively).
430
  In both studies, retinal functional loss was 
evident, even in cases of good VA. The fine matrix mapping technique (Scholl et al) 
detected more rod than cone sensitivity decreases, which supports the notion that 
deterioration in the rod system precedes that of the cone system in AMD.
431
  Both 
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studies found that functional deficits correlated with fundus abnormalities (large soft 
drusen and pigmentary RPE changes). 
AMD-grading scales have been developed for purposes of determining disease 
severity, tracking disease progression, and predicting progression to late AMD.
41, 393, 421
  
It is interesting to note that, while the presence of high-risk drusen has been shown to be 
a sensitive indicator of the risk of disease progression (i.e. if someone is going to 
progress, they will be correctly identified), the specificity is relatively low (i.e. if 
someone is not going to progress, there is a high chance that the scale will incorrectly 
predict progression).
432
  Therefore, there are people who are at greater risk of 
progression who are classified (according to grading scales) similarly to those who have 
lower risk; a notable limitation of the clinical grading system. It is important to identify 
the difference, so that subjects who are at greatest risk are those included, for example, 
in trials investigating factors related to disease progression. In fact, a recent publication 
has suggested that clinical vision measures (in combination with gene testing, which 
cannot detect disease) may increase the power of prediction models for AMD.
433
  
Measures of visual performance, such as ROS, could potentially be used as functional 
biomarkers in AMD. Long-term prospective studies are needed in this respect.  
 
Macular thickness and visual performance: The AREDS scale defines the stage of 
AMD, from early (grades 1-8) through to late (9-11), and distinguishes nv-AMD (grade 
11) from GA (grades 9 and 10) but does not subdivide these later stages. In cases of nv-
AMD, one way in which severity can be further quantified morphologically, is through 
measures of OCT. Nv-AMD is characterised by the presence of CNV, which is 
associated with the leakage of fluid (from neovascular vessels) into and/or under the 
neurosensory retina in the macular region, disrupting the normal structure of the 
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photoreceptors and increasing retinal thickness through the presence of fluid/cysts, as 
observed on OCT. Anti-VEGF therapy functions to inhibit the action of VEGF, thereby 
arresting the development of CNV and thus reducing fluid/cysts at the macula, thus 
normalising retinal thickness. Therefore, one of the most important measurable 
morphological features of nv-AMD is retinal thickness at the fovea. Consequently, 
outcome measures that can efficiently quantify morphological as well as functional 
damage (or status) are of critical importance in determining the most effective treatment 
or treatment strategies.  
A range of studies have previously investigated the relationship between OCT 
parameters and visual function in subjects with AMD
205, 425, 434-436
  and other 
pathological conditions of the macula, such as diabetic macular oedema.
207, 437, 438
   A 
recent study found a statistically significant negative correlation between central retinal 
thickness and central ROS in patients with nv-AMD.
436
  Others have also postulated 
that the measurement of ROS may be a more appropriate method to assess central visual 
function than conventional VA, following a study where there were significant 
improvements in ROS (within the central 10° of fixation), significant decreases in 
foveal thickness, but no significant improvements in CDVA, following PDT in subjects 
with nv-AMD.
439
   
In another study, a statistically significant relationship was found between RPE 
lesion area and central ROS (but not CDVA) in patients with nv-AMD undergoing anti-
VEGF therapy, at every study visit (baseline, one week, one, two and three months).
205
  
In that particular study, however, while the authors did not find a correlation between 
measures of retinal thickness (although it decreased significantly) and visual function, 
they did report a correlation between RPE lesion size and ROS. The absence of a 
correlation between retinal thickness and ROS in that case may be due, at least in part, 
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to the relatively small sample size (n=23) for which correlations were performed. 
However, the authors postulate that the condition of the RPE may be more relevant in 
terms of understanding impact on function. 
There was no statistically significant correlation between measures of CS or GD 
and retinal thickness in this study. However, a previous study has reported on the 
inverse relationship between CS and the subretinal fluid in cases of nv-AMD.
440
  The 
latter study involved a larger sample size (n=122), it only included previously untreated 
nv-AMD subjects and also, the retinal outcome measure was the extent of subretinal 
fluid (compared to MFT in the current study, although these are somewhat related). 
These differences in methodology (particularly in sample size) may be the cause of the 
disparity between the results of the two studies.    
Considering the functional criterion for retreatment in cases of nv-AMD is based 
on a change in CDVA (defined as a loss of five letters),
441
  the results of this particular 
analysis, in combination with the results presented in Chapter 5, are of particular 
importance. Treatment strategies that depend on change in a measure as crude and 
insensitive as CDVA, may mean that patients are not treated early enough, timely 
intervention being paramount to successful outcomes.
151, 155
  This hypothesis is 
supported by a recent study, which explored the relationship between macular thickness, 
VA and ROS in patients undergoing intravitreal ranibizumab for nv-AMD. In brief, 
intravitreal ranibizumab was administered if VA or OCT showed signs of active 
disease. Five (of a total of 21) eyes showed no change in VA or OCT findings, and, 
therefore, required no intravitreal injections. In these eyes, mean ROS decreased by 
13% during the study period, indicating that ROS can deteriorate in eyes with stable VA 
and stable retinal thickness.
435
  This is also of relevance to the results reported in 
Chapter 5. 
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This study reports significant differences between normal, early and nv-AMD subjects 
with respect to measures of CS and GD, under both photopic and mesopic conditions, in 
spite of relatively good CDVA (≥6/9). A statistically significant difference in ROS was 
also observed between the early and nv-AMD groups. This further highlights the fact 
that CDVA alone cannot account for visual performance in AMD. Another study has 
reported differences in foveal dark-adapted sensitivity between eyes with GA and eyes 
with early AMD, and VA of 6/7.5 or better.
167
  Also, poor (patient-reported) visual 
function in dim illumination, specifically poor dark adaptation and need for more light 
when reading, has been shown in subjects with GA, despite good VA.
442
    
A number of studies have also reported on psychophysical function in subjects 
with (early and late) AMD, highlighting a range of functional abnormalities associated 
with the condition, including S-cone sensitivity, flicker sensitivity, dark adaptation, 
colour-match area, and photostress recovery time,  which are often either undetected or 
poorly quantified by traditional CDVA measures.
160, 443-445
  The majority of these tests, 
however, have limitations in clinical or even research settings, for one or more of the 
following reasons: time-consuming; reliant on significant operator expertise; necessitate 
expensive equipment; require reasonably high concentration levels on the part of the 
subject, which may be challenging for the population in question (AMD subjects) who 
can present with poor cognitive function and/or other sensory limitations, hindering 
optimal test performance.  
The results of this study have also shown that measures of CS and GD differ 
between normal, early and nv-AMD subjects, when CDVA is relatively good. However, 
in terms of detecting change within the early and nv-AMD categories, respectively, 
measures of ROS displayed the strongest correlations with retinal morphology, most 
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probably due to the fact that ROS is retinotopic, which probes visual function more 
deeply, compared to CS and GD (and CDVA). ROS may be considered a relatively 
familiar test for patients as it resembles (in terms of patient instruction and operation) 
visual field testing, which is commonly used by ophthalmologists/optometrists amongst 
this study population, thus rendering it potentially more patient-friendly. In terms of 
duration, the procedure for measuring ROS according to our protocol lasted 
approximately five minutes per eye. In this respect, I suggest that it be considered as 
measurement of visual function in a clinical setting as well as in the design of studies 
investigating visual function in AMD.  
Additional results, comparing normal and early AMD subjects with respect to 
measures of CS and GD, have shown that, despite good CDVA, measures of CS and 
GD (particularly at low-mid range spatial frequencies) are significantly worse in eyes 
with early AMD compared to normals. Previous studies have shown similar results; for 
example, CS functions have been shown to be depressed in subjects with early AMD, 
compared with age-matched controls, both at the fovea and paracentrally (at two, five, 
and ten degrees from the fovea), demonstrating that sensitivity loss is not confined to 
the fovea (which is the retinal locus assessed primarily assessed by CDVA).
446
   It has 
also been shown that subjects with early AMD have significant loss of CS at low spatial 
frequencies, before the loss of high contrast VA, across a range of eccentricities, 
including at the fovea itself.
447
  The results of the current study contribute to the 
literature that challenges the general assumption that early AMD is of little visual 
consequence, and suggests that CDVA alone cannot account for the impact of the 
condition on visual performance.  ROS data from normal subjects were not available for 
our analysis; however, a significant reduction in ROS in subjects with early AMD 
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compared with age-matched controls has been previously shown in eyes with CDVA of 
≥6/9.422   
 
8.5 Conclusion 
Our study has contributed to the evidence germane to the relationship between disease 
severity and psychophysical function. This study has shown that measures of CS and 
GD differ between normal, early and nv-AMD subjects, in cases of good CDVA. ROS, 
in addition to this, can also reflect macular morphology, in cases of early, and in cases 
of nv-AMD, an outcome that cannot be achieved by conventional CDVA. Measures of 
ROS may, in fact, provide information complementary to morphological assessment, 
further highlighting the need for appropriate functional, as well as structural evaluation 
in patients with this condition. This is important in terms of understanding disease status 
(and its functional impact), monitoring disease progression, and also assessing the 
efficacy of emerging therapies, both in clinical practice and for the purposes of research 
trials. The findings of this study add to those presented in Chapter 5, where it was 
shown that ROS is a useful tool in the monitoring of subjects undergoing intravitreal 
ranibizumab for nv-AMD, and may be usefully incorporated into progression models 
for the condition. 
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Chapter 9. Conclusions and future considerations 
 
This work was designed to investigate visual performance status and its response to 
intervention, in cases of early and in cases of nv-AMD, using a range of psychophysical 
tests beyond conventional CDVA.  
The results reported and the conclusions drawn herein are based on the 
outcomes of, a) a literature review of the evidence pertaining to the macular 
carotenoids, AMD and visual performance, and b) two clinical trials, one which 
investigated visual function in response to ranibizumab treatment in subjects with nv-
AMD, and the other, which has explored MPOD levels, visual function and AMD 
progression following supplementation with three different macular carotenoid 
formulations. The conclusions and the future considerations proposed as a result of the 
outcomes of this work are as follows: 
 
1. The evidence germane to the role of MP for visual performance and its putative 
protective function against AMD has been reviewed. Appraising the totality of currently 
available evidence, it would appear that supplementation with the macular carotenoids 
offers the best means of fortifying the antioxidant defenses of the macula, thus 
putatively reducing the risk of AMD and/or its progression, and of optimising visual 
performance. I hope that this review of the literature will assist eyecare professionals to 
make well-informed decisions with respect to the prevention and/or delay of AMD 
onset and/or its progression (in anticipation of the results of RCTs), in addition to visual 
performance optimisation.  
 
209 
 
2. This study has investigated the impact of three different macular carotenoid 
formulations on the augmentation of MP, on visual performance and on disease 
progression, in subjects with early AMD. This study has shown that MP can be 
augmented, and CS enhanced, in subjects with early AMD who receive supplemental 
macular carotenoids. This is of particular interest considering the progressively 
degenerative nature of AMD. No trial to date has investigated the potential of MZ with 
respect to development or progression of AMD (or on visual performance in subjects 
with the conditions), as it has only recently become available in supplement form. A 
formulation containing MZ appears to offer advantages over a formulation that does not 
contain MZ, in terms of improvements in psychophysical function and in terms of MP 
augmentation across its spatial profile. However, I do believe that a supplement 
containing equal concentrations (1:1:1) of the three carotenoids (L, Z and MZ) warrants 
investigation, both with respect to AMD progression and visual performance.  
The results of this study should prompt and inform a well-designed, placebo-
controlled clinical trial (ideally of longer duration) of supplementation with L, Z and 
MZ in subjects with AMD, where outcome measures should include, MPOD 
augmentation, visual function and disease progression.  
While the rationale suggests that MP is protective against the onset of AMD, 
there have been no published trials that have investigated the potential of macular 
carotenoids in this respect. This would involve recruiting subjects who are not afflicted 
with the condition and evaluating macular health over time with respect to intake of the 
carotenoids (compared to placebo) and with respect to MPOD. Such a trial would need 
to be no less than 15 years in duration following completion of recruitment. Of note, a 
unique observational study is currently underway in Ireland, entitled “The Irish 
Longitudinal Study of Ageing (TILDA),”448 and is investigating health, lifestyles and 
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financial status of circa 8,000 randomly selected people aged 50 years and older. A 
major component of this prospective cohort study is the investigation into the 
relationship between baseline MP levels and the prevalence and incidence of AMD.
449
  
MP measurements and retinal photographs are being obtained at three separate study 
waves: year one, year four and year eight. This study will investigate, for the first time, 
whether baseline MP levels relate to the ultimate risk of developing AMD. However, 
the gold standard interventional trial to investigate the role of macular carotenoids in 
AMD prevention is still warranted. 
 
3. This study has explored the relationship between central MPOD and visual 
performance, amongst early AMD subjects who present (at baseline) with differing 
levels of central MPOD. While recent studies have commented on the response of MP 
to macular carotenoid supplementation amongst subjects with low MP, the impact of 
macular carotenoid supplementation on visual performance in this specific group of 
subjects was never previously investigated. Subjects with low baseline central MPOD 
had the greatest increases in MPOD and the greatest improvements in CS, when 
compared with subjects with medium or high baseline MPOD. The impact of macular 
supplementation on visual performance in subjects with central dips is provocative and 
warrants further study. The findings suggest that the optimisation of CS (and putatively 
visual performance in general) is somewhat dependent on central MP levels. These 
results should prompt further investigation amongst subjects with low MP and/or with 
atypical spatial profiles (with or without disease), in particular to explore the impact of 
macular carotenoid supplementation on visual performance. This may have 
implications, not only for subjects afflicted with AMD, but also for subjects who 
present with symptoms of glare/reduced vision, particularly those who work in 
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professions where optimised vision is particularly important, such as pilots, 
sportspeople, and drivers.  
If MP levels are playing a role in visual performance, this then warrants the 
measurement of MP in clinical practice, particularly in cases where visual symptoms 
cannot be explained by refractive error or disease. The limitation associated with 
reliably measuring MP, presently, is testing duration, which is of particular relevance 
for a clinical setting. For example, MP measurement using the gold standard 
Densitometer™ takes roughly ten minutes per eye. Other devices, such as VisuCam® 
200, which may employ a shorter testing period, are limited by other factors, such as 
one- (rather than dual-) wavelength technology, and the fact that measurement of 
MPOD at a peripheral reference point is not considered. This field still awaits an easy-
to-use, patient friendly device that can reliably measure MPOD, particularly if MP 
measurement is to be incorporated into routine clinical practice. 
In addition, and given the growing interest in MPOD spatial profiles, a device 
that can yield a spatial profile of MP (similar to that provided by the Densitometer™) 
warrants consideration. Currently available commercial devices, such as the 
MacuScope™ and the MPS 900, measure MP at a single retinal locus (often 0.5° 
eccentricity), and cannot, therefore, detect the presence of e.g. a central dip.  
 
4. In eyes with nv-AMD undergoing monthly intravitreal ranibizumab injections, there 
have been demonstrable improvements in a range of parameters of visual function, but 
no significant change in CDVA, despite a reduction in mean MFT. This finding has 
important implications when attempting to understand the effect of this treatment on a 
subject’s visual performance and also, for a clinician’s decision to treat/retreat/cease 
treatment in patients with the condition. This work  suggests that outcome measures 
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other than CDVA, such as CS, GD and ROS, should not only be considered in the 
design of studies investigating nv-AMD, but also in treatment and retreatment strategies 
for patients with the condition, at least in eyes where baseline CDVA is relatively good.  
 
5. This work also challenges the assumption that early AMD is not visually 
consequential and suggests the use of other tests to determine visual performance and 
experience, in subjects with the condition. While CDVA may not be greatly affected by 
early stages of the condition, it is clear that measures such as CS and GD are depressed 
compared to normal subjects and, therefore, should be considered in the diagnosis and 
monitoring of patients with AMD. 
Glare is an appreciable and common complaint amongst subjects, not only with 
eye disease such as AMD, but also amongst those without disease. However, there is 
currently no “true” GD test, which makes it difficult to conclusively comment on the 
effect of glare. What has been reported is a measure of CS in the presence of glare, 
which is not a measure of glare, per se. Devices are limited even in this respect. Further 
investigation into the measurement of glare is warranted. 
 
6. In terms of understanding disease severity using measures of visual function, this 
study has shown that CDVA poorly reflects retinal morphology in cases of early AMD 
and in cases of nv-AMD. ROS, however, appears to be a measure which is more 
reflective of disease severity in these conditions, where it correlates well with AMD-
severity grade (in cases of early AMD) and also with MFT (in cases of nv-AMD). It has 
also been shown that, where CDVA is good, CS and GD differ between normal, early 
and nv-AMD subjects. ROS, in addition, has been shown to be impacted to a different 
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extent depending on whether you have early- or nv-AMD, something that is not 
observed when using conventional CDVA. Measures of ROS may, in fact, provide 
information complementary to morphological assessment, further highlighting the need 
for appropriate functional, as well as structural evaluation in patients with this 
condition. This is important in terms of understanding disease status (and its functional 
impact), monitoring disease progression, and also assessing the efficacy of emerging 
therapies, both in clinical practice and for the purposes of research trials. If a measure 
such as CDVA is a primary outcome measure in an interventional trial, and yet it is 
showing to be incapable of reflecting disease status or detecting changes in visual 
performance over time, we must, therefore, question its use in such circumstances.  
Also, any intervention that endeavours to improve visual function must seek to 
do so from a patient’s perspective, and not just from observing increases on any given 
device/chart. Currently available subjective vision questionnaires have limitations, 
which have been previously discussed. While they may be capable of distinguishing 
between, e.g. early and late AMD, they have not been sensitive enough, at least with 
respect to the current study, to detect change following intervention. There is a need to 
develop a more refined method of determining patient-perceived change in visual 
performance over time. 
 
7. This study has attempted to probe more deeply the functioning of the visual system in 
subjects with AMD. However, the tests used and discussed here may or may not be 
appropriate for other eye conditions, which would warrant further investigation. In 
addition, the visual function measures reported here are by no means exhaustive. Other 
tests and other devices should also be explored. For example, the mfERG has yielded 
interesting results in other studies, where improvements were observed following 
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macular carotenoid supplementation in subjects with early AMD.
407, 408
 The advantage 
of this technique over e.g. ROS, is that it is objective, not requiring a patient response. It 
is, however, relatively cumbersome. Further exploration of this method, and perhaps 
how it relates to measures ROS in subjects with AMD and additionally, its response 
following supplementation with an MZ-based supplement (which has not been 
previously explored), may be interesting. 
In general, this thesis advocates the incorporation of tests, complimentary to CDVA, 
such as CS, GD, and particularly ROS, when attempting to understand disease severity 
in cases of AMD. In terms of monitoring change over time, the results of this study do 
seem to indicate that measures of ROS may be of particular benefit in monitoring 
subjects with nv-AMD, while measures of CS and GD may be more apt in monitoring 
change in subjects with early AMD. These tests should not only be considered in 
clinical practice settings (optometric, ophthalmological) but also when considering 
vision-related research, such that it may provide better insight into the impact on vision 
in AMD and on its response to intervention, particularly when new therapies are being 
investigated. 
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